var title_f22_54_23392="Pseudopapilledema";
var content_f22_54_23392=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudopapilledema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A patient with hyperopia and a small congested optic disc may have the appearance of mild optic disc swelling.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl C Golnik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_54_23392=[""].join("\n");
var outline_f22_54_23392=null;
var title_f22_54_23393="CT scan horseshoe kidney";
var content_f22_54_23393=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomographic scan of horseshoe kidney",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Unenhanced&nbsp;computed tomographic&nbsp;scan of horseshoe kidney with bilateral calculi.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Laurence Baskin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_54_23393=[""].join("\n");
var outline_f22_54_23393=null;
var title_f22_54_23394="Continence mechanisms";
var content_f22_54_23394=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 503px\">",
"   <div class=\"ttl\">",
"    Mechanisms of preserving continence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 483px; height: 419px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anatomy of the anal canal, rectum, and distal colon illustrating the mechanisms for preserving continence.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Whitehead WE, Schuster MM. Gastrointestinal disorders: Behavioral and physiological basis for treatment. Academic, Orlando 1985.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_54_23394=[""].join("\n");
var outline_f22_54_23394=null;
var title_f22_54_23395="EMG myokymia envenomation";
var content_f22_54_23395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F69008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F69008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    EMG in patient with myokymia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 342px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Doublets and triplets with clinical myokymia following rattle snake envenomation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_54_23395=[""].join("\n");
var outline_f22_54_23395=null;
var title_f22_54_23396="Nitrazepam: Patient drug information";
var content_f22_54_23396=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nitrazepam: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/42/21158?source=see_link\">",
"     see \"Nitrazepam: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2934283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Nitrazepam&reg;;",
"     </li>",
"     <li>",
"      Mogadon;",
"     </li>",
"     <li>",
"      Nitrazadon&reg;;",
"     </li>",
"     <li>",
"      Sandoz-Nitrazepam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F11263484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nitrazepam or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3448673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Very bad liver disease, very bad lung disease, myasthenia gravis, or sleep apnea.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for more than 10 days, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10915 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F708DC0240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_54_23396=[""].join("\n");
var outline_f22_54_23396=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934283\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11263484\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013515\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013514\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013519\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013520\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013522\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013517\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013518\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013523\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013524\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/42/21158?source=related_link\">",
"      Nitrazepam: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_54_23397="Doppler cord prolapse3";
var content_f22_54_23397=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Transabdominal ultrasound using colorflow doppler demonstrating the presence of the umbilical cord (funic presentation) just above the cervical canal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_54_23397=[""].join("\n");
var outline_f22_54_23397=null;
var title_f22_54_23398="Calculator: WHO Infant Weight for Length Percentiles (< 24 months)";
var content_f22_54_23398=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"WHOInfantWeightForLength_form\" name=\"WHOInfantWeightForLength_form\" onkeydown=\"clrResults();\" onkeyup=\"WHOInfantWeightForLength_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: WHO Infant Weight for Length Percentiles (&lt; 24 months)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Sex",
"            </span>",
"           </td>",
"           <td align=\"left\" colspan=\"3\">",
"            <span class=\"medCalcFontOne\">",
"             <input checked=\"checked\" name=\"Sex_radio\" onclick=\"WHOInfantWeightForLength_fx();\" type=\"radio\" value=\"Female\"/>",
"             Female",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"left\">",
"            <br/>",
"           </td>",
"           <td align=\"left\" colspan=\"3\">",
"            <span class=\"medCalcFontOne\">",
"             <input name=\"Sex_radio\" onclick=\"WHOInfantWeightForLength_fx();\" type=\"radio\" value=\"Male\"/>",
"             Male",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Length",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Length_param\" onblur=\"WHOInfantWeightForLength_fx(); minMaxCheck();\" onchange=\"WHOInfantWeightForLength_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Length_unit\" onchange=\"WHOInfantWeightForLength_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|cm\">",
"              cm",
"             </option>",
"             <option value=\"2.54|0|in\">",
"              in",
"             </option>",
"             <option value=\"100|0|m\">",
"              m",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Weight",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Weight_param\" onblur=\"WHOInfantWeightForLength_fx(); minMaxCheck();\" onchange=\"WHOInfantWeightForLength_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Weight_unit\" onchange=\"WHOInfantWeightForLength_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|kg\">",
"              kg",
"             </option>",
"             <option value=\"0.45359237|0|lb\">",
"              lb",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Results:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Z Score",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Z_Score_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td align=\"left\">",
"            &nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Percentile",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Percentile_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td align=\"left\">",
"            &nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"WHOInfantWeightForLength_fx();\">",
"             <option>",
"              0",
"             </option>",
"             <option selected=\"selected\">",
"              1",
"             </option>",
"             <option>",
"              2",
"             </option>",
"             <option>",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Weight for Length Percentile Interpretation",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"      <tr id=\"rr1_1\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         Percentile &lt; 2:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Underweight",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr1_2\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         Percentile &gt;= 2 and &lt; 98:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Healthy weight",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr1_3\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         Percentile &gt;= 98:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Overweight",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOneBold\">",
"     Notes",
"    </span>",
"    <ul class=\"medCalcFontOne\">",
"     <li>",
"      This calculator uses measured recumbent",
"      <b>",
"       Length",
"      </b>",
"      for infants and toddlers from birth through 24 months of age.",
"     </li>",
"     <li>",
"      It is not valid for standing height.",
"     </li>",
"     <li>",
"      At the extremes (&gt; 98th percentile or &lt; 2nd percentile), small differences in percentiles represent clinically important differences in weight/height. At these extremes, the z-score is a more precise reflection of how far the measurement deviates from the mean, and is a useful tool for tracking changes.",
"     </li>",
"    </ul>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOneBold\">",
"     Examples",
"    </span>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table border=\"1\" cellpadding=\"3\" class=\"medCalcFontOne\" summary=\"MedCalc 3000 Table\" width=\"40%\">",
"      <tr>",
"       <td align=\"center\" bgcolor=\"#cccccc\">",
"        <b>",
"         Z-score",
"        </b>",
"       </td>",
"       <td align=\"center\" bgcolor=\"#cccccc\">",
"        <b>",
"         Percentile equivalent",
"        </b>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        - 3.0",
"       </td>",
"       <td align=\"center\">",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        - 2.0",
"       </td>",
"       <td align=\"center\">",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        + 2.0",
"       </td>",
"       <td align=\"center\">",
"        97.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        + 3.0",
"       </td>",
"       <td align=\"center\">",
"        99.7",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontRef\">",
"     <b>",
"      References",
"     </b>",
"    </span>",
"    <ol>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Percentile conversion from Z-Score is done by table look-up in the standard Normal Table. Percentiles are provided for Z Scores between -3.09 and 3.09.  Values beyond these extremes return percentiles of 0.1 and 99.9 respectively.",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       LMS Parameters for Boys: Weight-for-length. World Health Organization 2006, Child Growth Standards.",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       LMS Parameters for Boys: Weight-for-length. World Health Organization 2006, Child Growth Standards.",
"      </span>",
"     </li>",
"    </ol>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_54_23398=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"n = new Array;",
"var L = 0;",
"var M = 0;",
"var S = 0;",
"",
"n[0] = 50;",
"n[1] = 50.399;",
"n[2] = 50.798;",
"n[3] = 51.197;",
"n[4] = 51.595;",
"n[5] = 51.994;",
"n[6] = 52.392;",
"n[7] = 52.79;",
"n[8] = 53.188;",
"n[9] = 53.586;",
"n[10] = 53.983;",
"n[11] = 54.38;",
"n[12] = 54.776;",
"n[13] = 55.172;",
"n[14] = 55.567;",
"n[15] = 55.962;",
"n[16] = 56.356;",
"n[17] = 56.749;",
"n[18] = 57.142;",
"n[19] = 57.535;",
"n[20] = 57.926;",
"n[21] = 58.317;",
"n[22] = 58.706;",
"n[23] = 59.095;",
"n[24] = 59.483;",
"n[25] = 59.871;",
"n[26] = 60.257;",
"n[27] = 60.642;",
"n[28] = 61.026;",
"n[29] = 61.409;",
"n[30] = 61.791;",
"n[31] = 62.172;",
"n[32] = 62.552;",
"n[33] = 62.93;",
"n[34] = 63.307;",
"n[35] = 63.683;",
"n[36] = 64.058;",
"n[37] = 64.431;",
"n[38] = 64.803;",
"n[39] = 65.173;",
"n[40] = 65.542;",
"n[41] = 65.91;",
"n[42] = 66.276;",
"n[43] = 66.64;",
"n[44] = 67.003;",
"n[45] = 67.364;",
"n[46] = 67.724;",
"n[47] = 68.082;",
"n[48] = 68.439;",
"n[49] = 68.793;",
"n[50] = 69.146;",
"n[51] = 69.497;",
"n[52] = 69.847;",
"n[53] = 70.194;",
"n[54] = 70.54;",
"n[55] = 70.884;",
"n[56] = 71.226;",
"n[57] = 71.566;",
"n[58] = 71.904;",
"n[59] = 72.24;",
"n[60] = 72.575;",
"n[61] = 72.907;",
"n[62] = 73.237;",
"n[63] = 73.565;",
"n[64] = 73.891;",
"n[65] = 74.215;",
"n[66] = 74.537;",
"n[67] = 74.857;",
"n[68] = 75.175;",
"n[69] = 75.49;",
"n[70] = 75.804;",
"n[71] = 76.115;",
"n[72] = 76.424;",
"n[73] = 76.73;",
"n[74] = 77.035;",
"n[75] = 77.337;",
"n[76] = 77.637;",
"n[77] = 77.935;",
"n[78] = 78.23;",
"n[79] = 78.524;",
"n[80] = 78.814;",
"n[81] = 79.103;",
"n[82] = 79.389;",
"n[83] = 79.673;",
"n[84] = 79.955;",
"n[85] = 80.234;",
"n[86] = 80.511;",
"n[87] = 80.785;",
"n[88] = 81.057;",
"n[89] = 81.327;",
"n[90] = 81.594;",
"n[91] = 81.859;",
"n[92] = 82.121;",
"n[93] = 82.381;",
"n[94] = 82.639;",
"n[95] = 82.894;",
"n[96] = 83.147;",
"n[97] = 83.398;",
"n[98] = 83.646;",
"n[99] = 83.891;",
"n[100] = 84.134;",
"n[101] = 84.375;",
"n[102] = 84.614;",
"n[103] = 84.849;",
"n[104] = 85.083;",
"n[105] = 85.314;",
"n[106] = 85.543;",
"n[107] = 85.769;",
"n[108] = 85.993;",
"n[109] = 86.214;",
"n[110] = 86.433;",
"n[111] = 86.65;",
"n[112] = 86.864;",
"n[113] = 87.076;",
"n[114] = 87.286;",
"n[115] = 87.493;",
"n[116] = 87.698;",
"n[117] = 87.9;",
"n[118] = 88.1;",
"n[119] = 88.298;",
"n[120] = 88.493;",
"n[121] = 88.686;",
"n[122] = 88.877;",
"n[123] = 89.065;",
"n[124] = 89.251;",
"n[125] = 89.435;",
"n[126] = 89.617;",
"n[127] = 89.796;",
"n[128] = 89.973;",
"n[129] = 90.147;",
"n[130] = 90.32;",
"n[131] = 90.49;",
"n[132] = 90.658;",
"n[133] = 90.824;",
"n[134] = 90.988;",
"n[135] = 91.149;",
"n[136] = 91.308;",
"n[137] = 91.466;",
"n[138] = 91.621;",
"n[139] = 91.774;",
"n[140] = 91.924;",
"n[141] = 92.073;",
"n[142] = 92.22;",
"n[143] = 92.364;",
"n[144] = 92.507;",
"n[145] = 92.647;",
"n[146] = 92.785;",
"n[147] = 92.922;",
"n[148] = 93.056;",
"n[149] = 93.189;",
"n[150] = 93.319;",
"n[151] = 93.448;",
"n[152] = 93.574;",
"n[153] = 93.699;",
"n[154] = 93.822;",
"n[155] = 93.943;",
"n[156] = 94.062;",
"n[157] = 94.179;",
"n[158] = 94.295;",
"n[159] = 94.408;",
"n[160] = 94.52;",
"n[161] = 94.63;",
"n[162] = 94.738;",
"n[163] = 94.845;",
"n[164] = 94.95;",
"n[165] = 95.053;",
"n[166] = 95.154;",
"n[167] = 95.254;",
"n[168] = 95.352;",
"n[169] = 95.449;",
"n[170] = 95.543;",
"n[171] = 95.637;",
"n[172] = 95.728;",
"n[173] = 95.818;",
"n[174] = 95.907;",
"n[175] = 95.994;",
"n[176] = 96.08;",
"n[177] = 96.164;",
"n[178] = 96.246;",
"n[179] = 96.327;",
"n[180] = 96.407;",
"n[181] = 96.485;",
"n[182] = 96.562;",
"n[183] = 96.638;",
"n[184] = 96.712;",
"n[185] = 96.784;",
"n[186] = 96.856;",
"n[187] = 96.926;",
"n[188] = 96.995;",
"n[189] = 97.062;",
"n[190] = 97.128;",
"n[191] = 97.193;",
"n[192] = 97.257;",
"n[193] = 97.32;",
"n[194] = 97.381;",
"n[195] = 97.441;",
"n[196] = 97.5;",
"n[197] = 97.558;",
"n[198] = 97.615;",
"n[199] = 97.67;",
"n[200] = 97.725;",
"n[201] = 97.778;",
"n[202] = 97.831;",
"n[203] = 97.882;",
"n[204] = 97.932;",
"n[205] = 97.982;",
"n[206] = 98.03;",
"n[207] = 98.077;",
"n[208] = 98.124;",
"n[209] = 98.169;",
"n[210] = 98.214;",
"n[211] = 98.257;",
"n[212] = 98.3;",
"n[213] = 98.341;",
"n[214] = 98.382;",
"n[215] = 98.422;",
"n[216] = 98.461;",
"n[217] = 98.5;",
"n[218] = 98.537;",
"n[219] = 98.574;",
"n[220] = 98.61;",
"n[221] = 98.645;",
"n[222] = 98.679;",
"n[223] = 98.713;",
"n[224] = 98.745;",
"n[225] = 98.778;",
"n[226] = 98.809;",
"n[227] = 98.84;",
"n[228] = 98.87;",
"n[229] = 98.899;",
"n[230] = 98.928;",
"n[231] = 98.956;",
"n[232] = 98.983;",
"n[233] = 99.01;",
"n[234] = 99.036;",
"n[235] = 99.061;",
"n[236] = 99.086;",
"n[237] = 99.111;",
"n[238] = 99.134;",
"n[239] = 99.158;",
"n[240] = 99.18;",
"n[241] = 99.202;",
"n[242] = 99.224;",
"n[243] = 99.245;",
"n[244] = 99.266;",
"n[245] = 99.286;",
"n[246] = 99.305;",
"n[247] = 99.324;",
"n[248] = 99.343;",
"n[249] = 99.361;",
"n[250] = 99.379;",
"n[251] = 99.396;",
"n[252] = 99.413;",
"n[253] = 99.43;",
"n[254] = 99.446;",
"n[255] = 99.461;",
"n[256] = 99.477;",
"n[257] = 99.492;",
"n[258] = 99.506;",
"n[259] = 99.52;",
"n[260] = 99.534;",
"n[261] = 99.547;",
"n[262] = 99.56;",
"n[263] = 99.573;",
"n[264] = 99.585;",
"n[265] = 99.598;",
"n[266] = 99.609;",
"n[267] = 99.621;",
"n[268] = 99.632;",
"n[269] = 99.643;",
"n[270] = 99.653;",
"n[271] = 99.664;",
"n[272] = 99.674;",
"n[273] = 99.683;",
"n[274] = 99.693;",
"n[275] = 99.702;",
"n[276] = 99.711;",
"n[277] = 99.72;",
"n[278] = 99.728;",
"n[279] = 99.736;",
"n[280] = 99.744;",
"n[281] = 99.752;",
"n[282] = 99.76;",
"n[283] = 99.767;",
"n[284] = 99.774;",
"n[285] = 99.781;",
"n[286] = 99.788;",
"n[287] = 99.795;",
"n[288] = 99.801;",
"n[289] = 99.807;",
"n[290] = 99.813;",
"n[291] = 99.819;",
"n[292] = 99.825;",
"n[293] = 99.831;",
"n[294] = 99.836;",
"n[295] = 99.841;",
"n[296] = 99.846;",
"n[297] = 99.851;",
"n[298] = 99.856;",
"n[299] = 99.861;",
"n[300] = 99.865;",
"n[301] = 99.869;",
"n[302] = 99.874;",
"n[303] = 99.878;",
"n[304] = 99.882;",
"n[305] = 99.886;",
"n[306] = 99.889;",
"n[307] = 99.893;",
"n[308] = 99.896;",
"n[309] = 99.9;",
"",
"function ZtoPercentile(z){",
"with (document.WHOInfantWeightForLength_form){",
"az = Math.abs(z);",
"if (z < -3.09) return 0.1;",
"if (z > 3.09) return 99.9;",
"thispercentile = n[Math.round(az * 100)];",
"if (z >= 0) { return thispercentile }",
"else { return 100 - thispercentile }",
"}}",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function WHOInfantWeightForLength_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.WHOInfantWeightForLength_form){",
"",
"",
"doCalc = true;",
"if (Sex_radio[0].checked){ Sex = 1; }",
"if (Sex_radio[1].checked){ Sex = 2; }",
"if (Length_param.value.indexOf(',') >= 0){ Length_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Length_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Length_unit.options[Length_unit.selectedIndex].value.split('|');",
"Length = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Weight_param.value.indexOf(',') >= 0){ Weight_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Weight_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Weight_unit.options[Weight_unit.selectedIndex].value.split('|');",
"Weight = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"if (Sex == 1){",
"if(Length >= 45.0 && Length < 45.5){L = -0.3833; M = 2.4607; S = 0.09029;};",
"if(Length >= 45.5 && Length < 46){L = -0.3833; M = 2.5457; S = 0.09033;};",
"if(Length >= 46.0 && Length < 46.5){L = -0.3833; M = 2.6306; S = 0.09037;};",
"if(Length >= 46.5 && Length < 47){L = -0.3833; M = 2.7155; S = 0.09040;};",
"if(Length >= 47.0 && Length < 47.5){L = -0.3833; M = 2.8007; S = 0.09044;};",
"if(Length >= 47.5 && Length < 48){L = -0.3833; M = 2.8867; S = 0.09048;};",
"if(Length >= 48.0 && Length < 48.5){L = -0.3833; M = 2.9741; S = 0.09052;};",
"if(Length >= 48.5 && Length < 49){L = -0.3833; M = 3.0636; S = 0.09056;};",
"if(Length >= 49.0 && Length < 49.5){L = -0.3833; M = 3.1560; S = 0.09060;};",
"if(Length >= 49.5 && Length < 50){L = -0.3833; M = 3.2520; S = 0.09064;};",
"if(Length >= 50.0 && Length < 50.5){L = -0.3833; M = 3.3518; S = 0.09068;};",
"if(Length >= 50.5 && Length < 51){L = -0.3833; M = 3.4557; S = 0.09072;};",
"if(Length >= 51.0 && Length < 51.5){L = -0.3833; M = 3.5636; S = 0.09076;};",
"if(Length >= 51.5 && Length < 52){L = -0.3833; M = 3.6754; S = 0.09080;};",
"if(Length >= 52.0 && Length < 52.5){L = -0.3833; M = 3.7911; S = 0.09085;};",
"if(Length >= 52.5 && Length < 53){L = -0.3833; M = 3.9105; S = 0.09089;};",
"if(Length >= 53.0 && Length < 53.5){L = -0.3833; M = 4.0332; S = 0.09093;};",
"if(Length >= 53.5 && Length < 54){L = -0.3833; M = 4.1591; S = 0.09098;};",
"if(Length >= 54.0 && Length < 54.5){L = -0.3833; M = 4.2875; S = 0.09102;};",
"if(Length >= 54.5 && Length < 55){L = -0.3833; M = 4.4179; S = 0.09106;};",
"if(Length >= 55.0 && Length < 55.5){L = -0.3833; M = 4.5498; S = 0.09110;};",
"if(Length >= 55.5 && Length < 56){L = -0.3833; M = 4.6827; S = 0.09114;};",
"if(Length >= 56.0 && Length < 56.5){L = -0.3833; M = 4.8162; S = 0.09118;};",
"if(Length >= 56.5 && Length < 57){L = -0.3833; M = 4.9500; S = 0.09121;};",
"if(Length >= 57.0 && Length < 57.5){L = -0.3833; M = 5.0837; S = 0.09125;};",
"if(Length >= 57.5 && Length < 58){L = -0.3833; M = 5.2173; S = 0.09128;};",
"if(Length >= 58.0 && Length < 58.5){L = -0.3833; M = 5.3507; S = 0.09130;};",
"if(Length >= 58.5 && Length < 59){L = -0.3833; M = 5.4834; S = 0.09132;};",
"if(Length >= 59.0 && Length < 59.5){L = -0.3833; M = 5.6151; S = 0.09134;};",
"if(Length >= 59.5 && Length < 60){L = -0.3833; M = 5.7454; S = 0.09135;};",
"if(Length >= 60.0 && Length < 60.5){L = -0.3833; M = 5.8742; S = 0.09136;};",
"if(Length >= 60.5 && Length < 61){L = -0.3833; M = 6.0014; S = 0.09137;};",
"if(Length >= 61.0 && Length < 61.5){L = -0.3833; M = 6.1270; S = 0.09137;};",
"if(Length >= 61.5 && Length < 62){L = -0.3833; M = 6.2511; S = 0.09136;};",
"if(Length >= 62.0 && Length < 62.5){L = -0.3833; M = 6.3738; S = 0.09135;};",
"if(Length >= 62.5 && Length < 63){L = -0.3833; M = 6.4948; S = 0.09133;};",
"if(Length >= 63.0 && Length < 63.5){L = -0.3833; M = 6.6144; S = 0.09131;};",
"if(Length >= 63.5 && Length < 64){L = -0.3833; M = 6.7328; S = 0.09129;};",
"if(Length >= 64.0 && Length < 64.5){L = -0.3833; M = 6.8501; S = 0.09126;};",
"if(Length >= 64.5 && Length < 65){L = -0.3833; M = 6.9662; S = 0.09123;};",
"if(Length >= 65.0 && Length < 65.5){L = -0.3833; M = 7.0812; S = 0.09119;};",
"if(Length >= 65.5 && Length < 66){L = -0.3833; M = 7.1950; S = 0.09115;};",
"if(Length >= 66.0 && Length < 66.5){L = -0.3833; M = 7.3076; S = 0.09110;};",
"if(Length >= 66.5 && Length < 67){L = -0.3833; M = 7.4189; S = 0.09106;};",
"if(Length >= 67.0 && Length < 67.5){L = -0.3833; M = 7.5288; S = 0.09101;};",
"if(Length >= 67.5 && Length < 68){L = -0.3833; M = 7.6375; S = 0.09096;};",
"if(Length >= 68.0 && Length < 68.5){L = -0.3833; M = 7.7448; S = 0.09090;};",
"if(Length >= 68.5 && Length < 69){L = -0.3833; M = 7.8509; S = 0.09085;};",
"if(Length >= 69.0 && Length < 69.5){L = -0.3833; M = 7.9559; S = 0.09079;};",
"if(Length >= 69.5 && Length < 70){L = -0.3833; M = 8.0599; S = 0.09074;};",
"if(Length >= 70.0 && Length < 70.5){L = -0.3833; M = 8.1630; S = 0.09068;};",
"if(Length >= 70.5 && Length < 71){L = -0.3833; M = 8.2651; S = 0.09062;};",
"if(Length >= 71.0 && Length < 71.5){L = -0.3833; M = 8.3666; S = 0.09056;};",
"if(Length >= 71.5 && Length < 72){L = -0.3833; M = 8.4676; S = 0.09050;};",
"if(Length >= 72.0 && Length < 72.5){L = -0.3833; M = 8.5679; S = 0.09043;};",
"if(Length >= 72.5 && Length < 73){L = -0.3833; M = 8.6674; S = 0.09037;};",
"if(Length >= 73.0 && Length < 73.5){L = -0.3833; M = 8.7661; S = 0.09031;};",
"if(Length >= 73.5 && Length < 74){L = -0.3833; M = 8.8638; S = 0.09025;};",
"if(Length >= 74.0 && Length < 74.5){L = -0.3833; M = 8.9601; S = 0.09018;};",
"if(Length >= 74.5 && Length < 75){L = -0.3833; M = 9.0552; S = 0.09012;};",
"if(Length >= 75.0 && Length < 75.5){L = -0.3833; M = 9.1490; S = 0.09005;};",
"if(Length >= 75.5 && Length < 76){L = -0.3833; M = 9.2418; S = 0.08999;};",
"if(Length >= 76.0 && Length < 76.5){L = -0.3833; M = 9.3337; S = 0.08992;};",
"if(Length >= 76.5 && Length < 77){L = -0.3833; M = 9.4252; S = 0.08985;};",
"if(Length >= 77.0 && Length < 77.5){L = -0.3833; M = 9.5166; S = 0.08979;};",
"if(Length >= 77.5 && Length < 78){L = -0.3833; M = 9.6086; S = 0.08972;};",
"if(Length >= 78.0 && Length < 78.5){L = -0.3833; M = 9.7015; S = 0.08965;};",
"if(Length >= 78.5 && Length < 79){L = -0.3833; M = 9.7957; S = 0.08959;};",
"if(Length >= 79.0 && Length < 79.5){L = -0.3833; M = 9.8915; S = 0.08952;};",
"if(Length >= 79.5 && Length < 80){L = -0.3833; M = 9.9892; S = 0.08946;};",
"if(Length >= 80.0 && Length < 80.5){L = -0.3833; M = 10.0891; S = 0.08940;};",
"if(Length >= 80.5 && Length < 81){L = -0.3833; M = 10.1916; S = 0.08934;};",
"if(Length >= 81.0 && Length < 81.5){L = -0.3833; M = 10.2965; S = 0.08928;};",
"if(Length >= 81.5 && Length < 82){L = -0.3833; M = 10.4041; S = 0.08923;};",
"if(Length >= 82.0 && Length < 82.5){L = -0.3833; M = 10.5140; S = 0.08918;};",
"if(Length >= 82.5 && Length < 83){L = -0.3833; M = 10.6263; S = 0.08914;};",
"if(Length >= 83.0 && Length < 83.5){L = -0.3833; M = 10.7410; S = 0.08910;};",
"if(Length >= 83.5 && Length < 84){L = -0.3833; M = 10.8578; S = 0.08906;};",
"if(Length >= 84.0 && Length < 84.5){L = -0.3833; M = 10.9767; S = 0.08903;};",
"if(Length >= 84.5 && Length < 85){L = -0.3833; M = 11.0974; S = 0.08900;};",
"if(Length >= 85.0 && Length < 85.5){L = -0.3833; M = 11.2198; S = 0.08898;};",
"if(Length >= 85.5 && Length < 86){L = -0.3833; M = 11.3435; S = 0.08897;};",
"if(Length >= 86.0 && Length < 86.5){L = -0.3833; M = 11.4684; S = 0.08895;};",
"if(Length >= 86.5 && Length < 87){L = -0.3833; M = 11.5940; S = 0.08895;};",
"if(Length >= 87.0 && Length < 87.5){L = -0.3833; M = 11.7201; S = 0.08895;};",
"if(Length >= 87.5 && Length < 88){L = -0.3833; M = 11.8461; S = 0.08895;};",
"if(Length >= 88.0 && Length < 88.5){L = -0.3833; M = 11.9720; S = 0.08896;};",
"if(Length >= 88.5 && Length < 89){L = -0.3833; M = 12.0976; S = 0.08898;};",
"if(Length >= 89.0 && Length < 89.5){L = -0.3833; M = 12.2229; S = 0.08900;};",
"if(Length >= 89.5 && Length < 90){L = -0.3833; M = 12.3477; S = 0.08903;};",
"if(Length >= 90.0 && Length < 90.5){L = -0.3833; M = 12.4723; S = 0.08906;};",
"if(Length >= 90.5 && Length < 91){L = -0.3833; M = 12.5965; S = 0.08909;};",
"if(Length >= 91.0 && Length < 91.5){L = -0.3833; M = 12.7205; S = 0.08913;};",
"if(Length >= 91.5 && Length < 92){L = -0.3833; M = 12.8443; S = 0.08918;};",
"if(Length >= 92.0 && Length < 92.5){L = -0.3833; M = 12.9681; S = 0.08923;};",
"if(Length >= 92.5 && Length < 93){L = -0.3833; M = 13.0920; S = 0.08928;};",
"if(Length >= 93.0 && Length < 93.5){L = -0.3833; M = 13.2158; S = 0.08934;};",
"if(Length >= 93.5 && Length < 94){L = -0.3833; M = 13.3399; S = 0.08941;};",
"if(Length >= 94.0 && Length < 94.5){L = -0.3833; M = 13.4643; S = 0.08948;};",
"if(Length >= 94.5 && Length < 95){L = -0.3833; M = 13.5892; S = 0.08955;};",
"if(Length >= 95.0 && Length < 95.5){L = -0.3833; M = 13.7146; S = 0.08963;};",
"if(Length >= 95.5 && Length < 96){L = -0.3833; M = 13.8408; S = 0.08972;};",
"if(Length >= 96.0 && Length < 96.5){L = -0.3833; M = 13.9676; S = 0.08981;};",
"if(Length >= 96.5 && Length < 97){L = -0.3833; M = 14.0953; S = 0.08990;};",
"if(Length >= 97.0 && Length < 97.5){L = -0.3833; M = 14.2239; S = 0.09000;};",
"if(Length >= 97.5 && Length < 98){L = -0.3833; M = 14.3537; S = 0.09010;};",
"if(Length >= 98.0 && Length < 98.5){L = -0.3833; M = 14.4848; S = 0.09021;};",
"if(Length >= 98.5 && Length < 99){L = -0.3833; M = 14.6174; S = 0.09033;};",
"if(Length >= 99.0 && Length < 99.5){L = -0.3833; M = 14.7519; S = 0.09044;};",
"if(Length >= 99.5 && Length < 100){L = -0.3833; M = 14.8882; S = 0.09057;};",
"if(Length >= 100.0 && Length < 100.5){L = -0.3833; M = 15.0267; S = 0.09069;};",
"if(Length >= 100.5 && Length < 101){L = -0.3833; M = 15.1676; S = 0.09083;};",
"if(Length >= 101.0 && Length < 101.5){L = -0.3833; M = 15.3108; S = 0.09096;};",
"if(Length >= 101.5 && Length < 102){L = -0.3833; M = 15.4564; S = 0.09110;};",
"if(Length >= 102.0 && Length < 102.5){L = -0.3833; M = 15.6046; S = 0.09125;};",
"if(Length >= 102.5 && Length < 103){L = -0.3833; M = 15.7553; S = 0.09139;};",
"if(Length >= 103.0 && Length < 103.5){L = -0.3833; M = 15.9087; S = 0.09155;};",
"if(Length >= 103.5 && Length < 104){L = -0.3833; M = 16.0645; S = 0.09170;};",
"if(Length >= 104.0 && Length < 104.5){L = -0.3833; M = 16.2229; S = 0.09186;};",
"if(Length >= 104.5 && Length < 105){L = -0.3833; M = 16.3837; S = 0.09203;};",
"if(Length >= 105.0 && Length < 105.5){L = -0.3833; M = 16.5470; S = 0.09219;};",
"if(Length >= 105.5 && Length < 106){L = -0.3833; M = 16.7129; S = 0.09236;};",
"if(Length >= 106.0 && Length < 106.5){L = -0.3833; M = 16.8814; S = 0.09254;};",
"if(Length >= 106.5 && Length < 107){L = -0.3833; M = 17.0527; S = 0.09271;};",
"if(Length >= 107.0 && Length < 107.5){L = -0.3833; M = 17.2269; S = 0.09289;};",
"if(Length >= 107.5 && Length < 108){L = -0.3833; M = 17.4039; S = 0.09307;};",
"if(Length >= 108.0 && Length < 108.5){L = -0.3833; M = 17.5839; S = 0.09326;};",
"if(Length >= 108.5 && Length < 109){L = -0.3833; M = 17.7668; S = 0.09344;};",
"if(Length >= 109.0 && Length < 109.5){L = -0.3833; M = 17.9526; S = 0.09363;};",
"if(Length >= 109.5 && Length < 110){L = -0.3833; M = 18.1412; S = 0.09382;};",
"if(Length >= 110.0 && Length < 110.5){L = -0.3833; M = 18.3324; S = 0.09401;};",
"}",
"if (Sex == 2){",
"if(Length >= 45.0 && Length < 45.5){L = -0.3521; M = 2.4410; S = 0.09182;};",
"if(Length >= 45.5 && Length < 46){L = -0.3521; M = 2.5244; S = 0.09153;};",
"if(Length >= 46.0 && Length < 46.5){L = -0.3521; M = 2.6077; S = 0.09124;};",
"if(Length >= 46.5 && Length < 47){L = -0.3521; M = 2.6913; S = 0.09094;};",
"if(Length >= 47.0 && Length < 47.5){L = -0.3521; M = 2.7755; S = 0.09065;};",
"if(Length >= 47.5 && Length < 48){L = -0.3521; M = 2.8609; S = 0.09036;};",
"if(Length >= 48.0 && Length < 48.5){L = -0.3521; M = 2.9480; S = 0.09007;};",
"if(Length >= 48.5 && Length < 49){L = -0.3521; M = 3.0377; S = 0.08977;};",
"if(Length >= 49.0 && Length < 49.5){L = -0.3521; M = 3.1308; S = 0.08948;};",
"if(Length >= 49.5 && Length < 50){L = -0.3521; M = 3.2276; S = 0.08919;};",
"if(Length >= 50.0 && Length < 50.5){L = -0.3521; M = 3.3278; S = 0.08890;};",
"if(Length >= 50.5 && Length < 51){L = -0.3521; M = 3.4311; S = 0.08861;};",
"if(Length >= 51.0 && Length < 51.5){L = -0.3521; M = 3.5376; S = 0.08831;};",
"if(Length >= 51.5 && Length < 52){L = -0.3521; M = 3.6477; S = 0.08801;};",
"if(Length >= 52.0 && Length < 52.5){L = -0.3521; M = 3.7620; S = 0.08771;};",
"if(Length >= 52.5 && Length < 53){L = -0.3521; M = 3.8814; S = 0.08741;};",
"if(Length >= 53.0 && Length < 53.5){L = -0.3521; M = 4.0060; S = 0.08711;};",
"if(Length >= 53.5 && Length < 54){L = -0.3521; M = 4.1354; S = 0.08681;};",
"if(Length >= 54.0 && Length < 54.5){L = -0.3521; M = 4.2693; S = 0.08651;};",
"if(Length >= 54.5 && Length < 55){L = -0.3521; M = 4.4066; S = 0.08621;};",
"if(Length >= 55.0 && Length < 55.5){L = -0.3521; M = 4.5467; S = 0.08592;};",
"if(Length >= 55.5 && Length < 56){L = -0.3521; M = 4.6892; S = 0.08563;};",
"if(Length >= 56.0 && Length < 56.5){L = -0.3521; M = 4.8338; S = 0.08535;};",
"if(Length >= 56.5 && Length < 57){L = -0.3521; M = 4.9796; S = 0.08507;};",
"if(Length >= 57.0 && Length < 57.5){L = -0.3521; M = 5.1259; S = 0.08481;};",
"if(Length >= 57.5 && Length < 58){L = -0.3521; M = 5.2721; S = 0.08455;};",
"if(Length >= 58.0 && Length < 58.5){L = -0.3521; M = 5.4180; S = 0.08430;};",
"if(Length >= 58.5 && Length < 59){L = -0.3521; M = 5.5632; S = 0.08406;};",
"if(Length >= 59.0 && Length < 59.5){L = -0.3521; M = 5.7074; S = 0.08383;};",
"if(Length >= 59.5 && Length < 60){L = -0.3521; M = 5.8501; S = 0.08362;};",
"if(Length >= 60.0 && Length < 60.5){L = -0.3521; M = 5.9907; S = 0.08342;};",
"if(Length >= 60.5 && Length < 61){L = -0.3521; M = 6.1284; S = 0.08324;};",
"if(Length >= 61.0 && Length < 61.5){L = -0.3521; M = 6.2632; S = 0.08308;};",
"if(Length >= 61.5 && Length < 62){L = -0.3521; M = 6.3954; S = 0.08292;};",
"if(Length >= 62.0 && Length < 62.5){L = -0.3521; M = 6.5251; S = 0.08279;};",
"if(Length >= 62.5 && Length < 63){L = -0.3521; M = 6.6527; S = 0.08266;};",
"if(Length >= 63.0 && Length < 63.5){L = -0.3521; M = 6.7786; S = 0.08255;};",
"if(Length >= 63.5 && Length < 64){L = -0.3521; M = 6.9028; S = 0.08245;};",
"if(Length >= 64.0 && Length < 64.5){L = -0.3521; M = 7.0255; S = 0.08236;};",
"if(Length >= 64.5 && Length < 65){L = -0.3521; M = 7.1467; S = 0.08229;};",
"if(Length >= 65.0 && Length < 65.5){L = -0.3521; M = 7.2666; S = 0.08223;};",
"if(Length >= 65.5 && Length < 66){L = -0.3521; M = 7.3854; S = 0.08218;};",
"if(Length >= 66.0 && Length < 66.5){L = -0.3521; M = 7.5034; S = 0.08215;};",
"if(Length >= 66.5 && Length < 67){L = -0.3521; M = 7.6206; S = 0.08213;};",
"if(Length >= 67.0 && Length < 67.5){L = -0.3521; M = 7.7370; S = 0.08212;};",
"if(Length >= 67.5 && Length < 68){L = -0.3521; M = 7.8526; S = 0.08212;};",
"if(Length >= 68.0 && Length < 68.5){L = -0.3521; M = 7.9674; S = 0.08214;};",
"if(Length >= 68.5 && Length < 69){L = -0.3521; M = 8.0816; S = 0.08216;};",
"if(Length >= 69.0 && Length < 69.5){L = -0.3521; M = 8.1955; S = 0.08219;};",
"if(Length >= 69.5 && Length < 70){L = -0.3521; M = 8.3092; S = 0.08224;};",
"if(Length >= 70.0 && Length < 70.5){L = -0.3521; M = 8.4227; S = 0.08229;};",
"if(Length >= 70.5 && Length < 71){L = -0.3521; M = 8.5358; S = 0.08235;};",
"if(Length >= 71.0 && Length < 71.5){L = -0.3521; M = 8.6480; S = 0.08241;};",
"if(Length >= 71.5 && Length < 72){L = -0.3521; M = 8.7594; S = 0.08248;};",
"if(Length >= 72.0 && Length < 72.5){L = -0.3521; M = 8.8697; S = 0.08254;};",
"if(Length >= 72.5 && Length < 73){L = -0.3521; M = 8.9788; S = 0.08262;};",
"if(Length >= 73.0 && Length < 73.5){L = -0.3521; M = 9.0865; S = 0.08269;};",
"if(Length >= 73.5 && Length < 74){L = -0.3521; M = 9.1927; S = 0.08276;};",
"if(Length >= 74.0 && Length < 74.5){L = -0.3521; M = 9.2974; S = 0.08283;};",
"if(Length >= 74.5 && Length < 75){L = -0.3521; M = 9.4010; S = 0.08289;};",
"if(Length >= 75.0 && Length < 75.5){L = -0.3521; M = 9.5032; S = 0.08295;};",
"if(Length >= 75.5 && Length < 76){L = -0.3521; M = 9.6041; S = 0.08301;};",
"if(Length >= 76.0 && Length < 76.5){L = -0.3521; M = 9.7033; S = 0.08307;};",
"if(Length >= 76.5 && Length < 77){L = -0.3521; M = 9.8007; S = 0.08311;};",
"if(Length >= 77.0 && Length < 77.5){L = -0.3521; M = 9.8963; S = 0.08314;};",
"if(Length >= 77.5 && Length < 78){L = -0.3521; M = 9.9902; S = 0.08317;};",
"if(Length >= 78.0 && Length < 78.5){L = -0.3521; M = 10.0827; S = 0.08318;};",
"if(Length >= 78.5 && Length < 79){L = -0.3521; M = 10.1741; S = 0.08318;};",
"if(Length >= 79.0 && Length < 79.5){L = -0.3521; M = 10.2649; S = 0.08316;};",
"if(Length >= 79.5 && Length < 80){L = -0.3521; M = 10.3558; S = 0.08313;};",
"if(Length >= 80.0 && Length < 80.5){L = -0.3521; M = 10.4475; S = 0.08308;};",
"if(Length >= 80.5 && Length < 81){L = -0.3521; M = 10.5405; S = 0.08301;};",
"if(Length >= 81.0 && Length < 81.5){L = -0.3521; M = 10.6352; S = 0.08293;};",
"if(Length >= 81.5 && Length < 82){L = -0.3521; M = 10.7322; S = 0.08284;};",
"if(Length >= 82.0 && Length < 82.5){L = -0.3521; M = 10.8321; S = 0.08273;};",
"if(Length >= 82.5 && Length < 83){L = -0.3521; M = 10.9350; S = 0.08260;};",
"if(Length >= 83.0 && Length < 83.5){L = -0.3521; M = 11.0415; S = 0.08246;};",
"if(Length >= 83.5 && Length < 84){L = -0.3521; M = 11.1516; S = 0.08231;};",
"if(Length >= 84.0 && Length < 84.5){L = -0.3521; M = 11.2651; S = 0.08215;};",
"if(Length >= 84.5 && Length < 85){L = -0.3521; M = 11.3817; S = 0.08198;};",
"if(Length >= 85.0 && Length < 85.5){L = -0.3521; M = 11.5007; S = 0.08181;};",
"if(Length >= 85.5 && Length < 86){L = -0.3521; M = 11.6218; S = 0.08163;};",
"if(Length >= 86.0 && Length < 86.5){L = -0.3521; M = 11.7444; S = 0.08145;};",
"if(Length >= 86.5 && Length < 87){L = -0.3521; M = 11.8678; S = 0.08128;};",
"if(Length >= 87.0 && Length < 87.5){L = -0.3521; M = 11.9916; S = 0.08111;};",
"if(Length >= 87.5 && Length < 88){L = -0.3521; M = 12.1152; S = 0.08096;};",
"if(Length >= 88.0 && Length < 88.5){L = -0.3521; M = 12.2382; S = 0.08082;};",
"if(Length >= 88.5 && Length < 89){L = -0.3521; M = 12.3603; S = 0.08069;};",
"if(Length >= 89.0 && Length < 89.5){L = -0.3521; M = 12.4815; S = 0.08058;};",
"if(Length >= 89.5 && Length < 90){L = -0.3521; M = 12.6017; S = 0.08048;};",
"if(Length >= 90.0 && Length < 90.5){L = -0.3521; M = 12.7209; S = 0.08041;};",
"if(Length >= 90.5 && Length < 91){L = -0.3521; M = 12.8392; S = 0.08034;};",
"if(Length >= 91.0 && Length < 91.5){L = -0.3521; M = 12.9569; S = 0.08030;};",
"if(Length >= 91.5 && Length < 92){L = -0.3521; M = 13.0742; S = 0.08026;};",
"if(Length >= 92.0 && Length < 92.5){L = -0.3521; M = 13.1910; S = 0.08025;};",
"if(Length >= 92.5 && Length < 93){L = -0.3521; M = 13.3075; S = 0.08025;};",
"if(Length >= 93.0 && Length < 93.5){L = -0.3521; M = 13.4239; S = 0.08026;};",
"if(Length >= 93.5 && Length < 94){L = -0.3521; M = 13.5404; S = 0.08029;};",
"if(Length >= 94.0 && Length < 94.5){L = -0.3521; M = 13.6572; S = 0.08034;};",
"if(Length >= 94.5 && Length < 95){L = -0.3521; M = 13.7746; S = 0.08040;};",
"if(Length >= 95.0 && Length < 95.5){L = -0.3521; M = 13.8928; S = 0.08047;};",
"if(Length >= 95.5 && Length < 96){L = -0.3521; M = 14.0120; S = 0.08056;};",
"if(Length >= 96.0 && Length < 96.5){L = -0.3521; M = 14.1325; S = 0.08067;};",
"if(Length >= 96.5 && Length < 97){L = -0.3521; M = 14.2544; S = 0.08078;};",
"if(Length >= 97.0 && Length < 97.5){L = -0.3521; M = 14.3782; S = 0.08092;};",
"if(Length >= 97.5 && Length < 98){L = -0.3521; M = 14.5038; S = 0.08106;};",
"if(Length >= 98.0 && Length < 98.5){L = -0.3521; M = 14.6316; S = 0.08122;};",
"if(Length >= 98.5 && Length < 99){L = -0.3521; M = 14.7614; S = 0.08139;};",
"if(Length >= 99.0 && Length < 99.5){L = -0.3521; M = 14.8934; S = 0.08157;};",
"if(Length >= 99.5 && Length < 100){L = -0.3521; M = 15.0275; S = 0.08177;};",
"if(Length >= 100.0 && Length < 100.5){L = -0.3521; M = 15.1637; S = 0.08198;};",
"if(Length >= 100.5 && Length < 101){L = -0.3521; M = 15.3018; S = 0.08220;};",
"if(Length >= 101.0 && Length < 101.5){L = -0.3521; M = 15.4419; S = 0.08243;};",
"if(Length >= 101.5 && Length < 102){L = -0.3521; M = 15.5838; S = 0.08267;};",
"if(Length >= 102.0 && Length < 102.5){L = -0.3521; M = 15.7276; S = 0.08292;};",
"if(Length >= 102.5 && Length < 103){L = -0.3521; M = 15.8732; S = 0.08317;};",
"if(Length >= 103.0 && Length < 103.5){L = -0.3521; M = 16.0206; S = 0.08343;};",
"if(Length >= 103.5 && Length < 104){L = -0.3521; M = 16.1697; S = 0.08370;};",
"if(Length >= 104.0 && Length < 104.5){L = -0.3521; M = 16.3204; S = 0.08397;};",
"if(Length >= 104.5 && Length < 105){L = -0.3521; M = 16.4728; S = 0.08425;};",
"if(Length >= 105.0 && Length < 105.5){L = -0.3521; M = 16.6268; S = 0.08453;};",
"if(Length >= 105.5 && Length < 106){L = -0.3521; M = 16.7826; S = 0.08481;};",
"if(Length >= 106.0 && Length < 106.5){L = -0.3521; M = 16.9401; S = 0.08510;};",
"if(Length >= 106.5 && Length < 107){L = -0.3521; M = 17.0995; S = 0.08539;};",
"if(Length >= 107.0 && Length < 107.5){L = -0.3521; M = 17.2607; S = 0.08568;};",
"if(Length >= 107.5 && Length < 108){L = -0.3521; M = 17.4237; S = 0.08599;};",
"if(Length >= 108.0 && Length < 108.5){L = -0.3521; M = 17.5885; S = 0.08629;};",
"if(Length >= 108.5 && Length < 109){L = -0.3521; M = 17.7553; S = 0.08660;};",
"if(Length >= 109.0 && Length < 109.5){L = -0.3521; M = 17.9242; S = 0.08691;};",
"if(Length >= 109.5 && Length < 110){L = -0.3521; M = 18.0954; S = 0.08723;};",
"if(Length >= 110.0 && Length < 110.5){L = -0.3521; M = 18.2689; S = 0.08755;};",
"}",
"Z_Score =  (power((Weight / M), L) - 1) / (L * S);",
"",
"if (doCalc) Z_Score_param.value = fixDP(Z_Score, dp);",
"",
"",
"",
"Percentile =  ZtoPercentile(Z_Score);",
"",
"if (doCalc) Percentile_param.value = fixDP(Percentile, dp);",
"",
"",
"",
"",
"if (doCalc){",
"",
"rrclr();",
"if (Percentile < 2){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((Percentile >= 2) && (Percentile < 98)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if (Percentile >= 98){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.WHOInfantWeightForLength_form){",
"",
"if (Length_param.value && Length < 45) {",
"Length = 0;",
"Length_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Length is 45 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Length_param.value && Length > 109.99) {",
"Length_param.value = \"\";",
"clrResults();",
"Length = 0;",
"doCalc = false;",
"alert(\"The maximum value for Length is 109.99 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Weight_param.value && Weight < 0.5) {",
"Weight = 0;",
"Weight_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Weight is 0.5 kg.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Weight_param.value && Weight > 100) {",
"Weight_param.value = \"\";",
"clrResults();",
"Weight = 0;",
"doCalc = false;",
"alert(\"The maximum value for Weight is 100 kg.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.WHOInfantWeightForLength_form){",
"",
"Z_Score_param.value = '';",
"Percentile_param.value = '';",
"",
"rrclr();",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"}",
"",
"",
"/* ]]> */"].join("\n");
var outline_f22_54_23398=null;
var title_f22_54_23399="Prenatal screening and diagnosis for fragile X syndrome";
var content_f22_54_23399=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prenatal screening and diagnosis for fragile X syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/54/23399/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/54/23399/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/54/23399/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/54/23399/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/54/23399/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/54/23399/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/54/23399/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fragile X syndrome is the most common inherited cause of intellectual disability [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/1\">",
"     1",
"    </a>",
"    ]. It is caused by expansion of a repetition of the cytosine&ndash;guanine&ndash;guanine trinucleotide segment (CGG) of the fragile X mental retardation 1 (FMR-1) gene, which leads to altered transcription and loss of function of the FMR-1 gene. The FMR-1 fragile site is located on the X chromosome at Xq27.3. Fragile X syndrome results when expansion of the FMR-1 triplet repeat occurs, and both males and females can be affected. Prevalence of the syndrome is 1 in 3600 males and 1 in 4000 to 6000 females [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENOTYPE AND INHERITANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in a region of the X chromosome, known as the fragile X mental retardation-1 (FMR-1) gene, are associated with the characteristic clinical features of fragile X syndrome in both males and females (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical features'",
"    </a>",
"    below). The FMR-1 gene of the X chromosome is typically comprised of a limited number of cytosine-guanine-guanine (CGG) repeats at the 5' end. In the general population, this region is stable, relatively small (less than 40 CGG repeats), and passes from generation to generation without significant alteration. However, during meiosis in oocytes, the region can expand, reaching either intermediate (45 to 54 CGG repeats) or premutation (55 to 200 CGG repeats) lengths.",
"   </p>",
"   <p>",
"    The distinction between an intermediate and premutation length may not be as clear as implied by the precise ranges cited for repeat size. Repeat sizes in the range of 50 to 60, when found in pedigrees ascertained through fragile X individuals with full mutations, are able to undergo expansion, generally into the clearly premutation range, but never into a full mutation. Thus, repeat lengths of 40 to 60 may be best described by their repeat lengths rather than the labels of intermediate and premutation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As repeat size increases, stability decreases and further increases in the number of repeats in the FMR-1 region become likely. Once the premutation reaches expansion to &gt;90 CGG repeats, the likelihood of expansion to a full mutation (ie, over 200 repeats) is at least 80 percent (",
"    <a class=\"graphic graphic_table graphicRef64429 \" href=\"UTD.htm?8/60/9163\">",
"     table 1",
"    </a>",
"    ). Similar expansion of the fragile site does not occur during meiosis in sperm.",
"   </p>",
"   <p>",
"    As premutation expansion is initiated only during meiosis in oocytes, only women with a premutation FMR-1 can pass the full mutation to their offspring as a result of CGG region expansion. Fathers with premutations pass the FMR-1 gene in a stable fashion to all of their daughters (who inherit their father's X chromosome) and to none of their sons (who inherit their father's Y chromosome). However, expansion of the premutation to a full mutation could occur in their daughters' offspring (ie, their grandchildren).",
"   </p>",
"   <p>",
"    In rare situations, contraction from a premutation to normal allele has been documented in mother-to-daughter transmissions and, interestingly, one-third of daughters of fathers with premutations have contraction in the expansion size [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The timing of expansion to a full FMR-1 mutation is variable, although, as discussed above, it typically occurs during maternal meiosis. However, postzygotic mitotic CGG length changes have also been reported. As an example, discordance for CGG repeat number between identical twins is assumed to be due to this mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of adenosine-guanine-guanine (AGG) interspersion is also being studied as a factor in predicting expansion to a full mutation. AGG interspersed in the variable region is theorized to act as a stabilizer for the region; therefore, the presence of fewer AGG interspersions may destabilize the region and allow expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elongation of the FMR1 triplet repeat region accounts for over 99 percent of cases of fragile X syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/8\">",
"     8",
"    </a>",
"    ]. Rare deletions or point mutations within the gene comprise the remaining cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fragile X mental retardation protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;DNA methylation turns off gene activity, thus preventing gene transcription. Elongation of the CGG repeats allows hypermethylation of FMR-1, resulting in impaired transcription and reduced production of the fragile X mental retardation protein (FMRP). This protein has a role in postnatal brain development and dendrite maturation in animal knock-out models [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/9\">",
"     9",
"    </a>",
"    ], and likely plays a role in prenatal and postnatal brain development in humans. Lower levels of FMRP, as assessed by immunochemistry in lymphocytes, appear to have a major impact upon the severity of the fragile X phenotype. Individuals with nearly normal levels of FMRP may have mild or no symptoms, while those with very little or no normal FMRP may have more severe symptoms.",
"   </p>",
"   <p>",
"    Further correlations between FMRP and specific physical, developmental and neuropsychiatric characteristics are emerging and provide insight into the variability of presentation in both males and females. Three major factors that are thought to impact the level of FMRP produced are: the number of CGG repeats (more repeats are associated with lower FMRP levels), cellular mosaicism (FMR1 mutation is present in some cells, but not others), and female sex (females, since they are XX, carry one normal FMR1 gene and one mutated FMR1 gene) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of fragile X syndrome are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34889?source=see_link\">",
"     \"Clinical features and diagnosis of fragile X syndrome in children and adolescents\"",
"    </a>",
"    .) The following is a synopsis of this information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Full mutation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Males",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fragile X syndrome in males has a wide range of behavioral and cognitive manifestations and often subtle physical manifestations, but is never asymptomatic. The syndrome has been diagnosed in up to 3 percent of males with special needs, such as autism, special education, or nonsyndromic intellectual disability [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Behavior &mdash; The behavioral phenotype, which is often present, is characterized by autism spectrum behaviors such as attention",
"      <span class=\"nowrap\">",
"       deficit/hyperactivity,",
"      </span>",
"      expressive delay, tactile defensiveness (ie, having a negative response to touch), perseverative speech (ie, continued repetition of words or phrases), and echolalia (ie, involuntary parrot-like repetition of a word or phrase just spoken by another person), as well as social anxiety and avoidance of eye contact [",
"      <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cognition &mdash; Males with a full mutation generally have moderate to severe mental impairment. Individuals with fragile X syndrome tend to have good memories for pictures and visual patterns, which helps them to learn to recognize letters and words and follow instructions presented as pictures. They are less able to comprehend abstract ideas, organize information, plan ahead, or problem-solve.",
"     </li>",
"     <li>",
"      Seizures &mdash; Ten to 20 percent of males with fragile X syndrome have seizures. Most are simple or complex partial seizures (although other types can also occur). They are relatively easy to control and often spontaneously remit during childhood [",
"      <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/14\">",
"       14",
"      </a>",
"      ]. Seizures are considerably less common amongst women with fragile X syndrome.",
"     </li>",
"     <li>",
"      Physical and anatomic characteristics &mdash; Infants and young boys with fragile X syndrome may have no distinctive physical features. Some boys have very soft, velvety skin, a broad forehead, or a slightly larger head than other children their age. Physical characteristics of the syndrome are more readily identifiable around puberty. As an example, the characteristic elongated face becomes apparent in later teen and adult years, but is subtle in young children. In older boys, adolescents and adults, facial appearance is often described as long and narrow with prognathism (ie, protruding lower jaw) and large ears. Macrocephaly can be present. Most postpubertal males develop macroorchidism. Hyperflexible joints, flat feet, mitral valve prolapse occasionally occur. Height tends to be below average.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Females",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a group, females tend to have fewer and milder abnormalities than males since they inherit two X chromosomes, one of which is inactivated randomly in each cell. However, some females with full fragile X mutation will present with the characteristics of the classic syndrome, whereas others will have an IQ within the normal range. The behavioral spectrum in women can include autistic behaviors. Females with fragile X syndrome are more likely than males to have relatively normal cognitive development, but they may show a learning disability whereby academic achievement in some areas is lower than predicted by IQ alone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/15\">",
"     15",
"    </a>",
"    ]. This may be related to behavioral issues, such as hyperactivity. Approximately 50 percent of females with full mutations of FMR-1 have IQs in the borderline or mentally retarded range [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/16\">",
"     16",
"    </a>",
"    ]. The remaining 50 percent have an IQ in the normal range, although some females with a full mutation may exhibit subtle specific cognitive disabilities (eg, difficulties with mathematics) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/17\">",
"     17",
"    </a>",
"    ]. It is not currently possible to accurately predict the prognosis of fragile X syndrome in females who inherit a full mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Premutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carriers of lower levels of CGG elongation (premutation, &lt;200 CGG repeats) had been thought to be asymptomatic. However, further investigation reveals three potential areas of concern: (1) premature ovarian failure (women), (2) tremor-ataxia syndrome later in life (some men and a few women) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/18\">",
"     18",
"    </a>",
"    ], and (3) an equivocal subtle effect on neurocognitive function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Premature ovarian failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a premutation (61 to 200 CGG repeats) are at increased risk of premature ovarian failure (POF), defined as menopause prior to 40 years of age. Approximately 20 percent of premutation carriers of fragile X experience POF [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7817?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)\", section on 'Fragile X syndrome premutation carriers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Tremor-ataxia syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men older than 50 years of age with a premutation are at risk for a progressive neurodegenerative disorder characterized by ataxia and Parkinsonism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/20\">",
"     20",
"    </a>",
"    ]. A milder presentation may occur in older women with premutations. An estimated one-third of men with premutations of FMR1 are thought to develop fragile X associated",
"    <span class=\"nowrap\">",
"     tremor/ataxia",
"    </span>",
"    syndrome; a lesser number of women are likely to be affected [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29242?source=see_link&amp;anchor=H18#H18\">",
"     \"The spinocerebellar ataxias\", section on 'Fragile X-associated tremor/ataxia syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neuro-cognitive functioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether fragile-X premutations have a subtle effect on cognition is controversial. This issue has been under debate for several years and there is still no clear consensus of opinion. It is therefore likely that any effect, if it exists, is likely to be mild [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intermediate allele",
"    </span>",
"    &nbsp;&mdash;&nbsp;These are thought to have no clinical phenotype. A longitudinal cohort study failed to find any strong evidence of association between FRAXA intermediate alleles and special educational needs, behavioral problems, or cognitive difficulties [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of fragile X syndrome is based on molecular genetic analysis. Molecular analysis of the length of CGG repeats in the FMR-1 region has replaced the older and less reliable technologies of karyotype visualization of the fragile X site following culture in folate deficient media. Most laboratories now utilize a combination of two approaches: (1) Southern blot analysis to measure the degree of methylation and (2) polymerase chain reaction (PCR) to discriminate small differences in the intermediate and premutation sizes at a more refined level.",
"   </p>",
"   <p>",
"    Southern blot analysis has the advantage of methylation determination, but is limited in its ability to distinguish normal from premutation allele sizes. PCR has the advantage of the need for less DNA, more sensitive determination of normal and premutation allele size, and less cost, but is limited in its ability to assess full mutations, as the PCR itself may selectively amplify shorter DNA segments. When combined, however, these technologies are highly specific and sensitive when assessing individuals with phenotypic findings suggestive of fragile X syndrome: over 99 percent of fragile X males have elongation of the fragile site. The same techniques are used for screening for premutation carriers.",
"   </p>",
"   <p>",
"    Diagnosis is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34889?source=see_link\">",
"     \"Clinical features and diagnosis of fragile X syndrome in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Candidates for screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;General population screening is not recommended, other than in the setting of research studies. Instead, a careful assessment of the family history should be performed to identify individuals at sufficient likelihood of premutation or full mutation carrier status to warrant screening. Data from a population of over 14,000 women are helpful in assessing the frequencies of the various expansion categories by risk factors. In general, premutations were identified in",
"    <span class=\"nowrap\">",
"     1/10",
"    </span>",
"    women with premature ovarian failure,",
"    <span class=\"nowrap\">",
"     1/86",
"    </span>",
"    women with a family history of mental",
"    <span class=\"nowrap\">",
"     retardation/developmental",
"    </span>",
"    <span class=\"nowrap\">",
"     delay/autism",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     1/257",
"    </span>",
"    women with an unremarkable family history [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American College of Medical Genetics (ACMG) and the American College of Obstetricians and Gynecologists (ACOG) guidelines for screening for fragile X syndrome are listed in the tables (",
"    <a class=\"graphic graphic_table graphicRef50931 \" href=\"UTD.htm?26/62/27627\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65747 \" href=\"UTD.htm?41/56/42891\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The main criteria are summarized below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals of either sex with intellectual disability, developmental delay, or autism.",
"     </li>",
"     <li>",
"      Individuals seeking reproductive counseling who have a family history of fragile X syndrome or undiagnosed intellectual disability.",
"     </li>",
"     <li>",
"      ACMG: fetuses of carrier mothers (premutation or full mutation, because females with premutations can have offspring with full mutations as a result of expansion). ACOG: fetuses of mothers or fathers with premutations or full mutations (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Prenatal diagnosis'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Young women with elevated levels of follicle-stimulating hormone, especially with a family history of premature ovarian failure, fragile X syndrome, or a relative of either sex with undiagnosed intellectual disability.",
"     </li>",
"     <li>",
"      Individuals with late-onset intention tremor or ataxia, especially with a family history of movement disorders, fragile X, or undiagnosed intellectual disability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several authors have advocated routine screening of preconception and prenatal populations, given the relatively high premutation carrier rate (1 in 113 to 350 women), high test sensitivity, and the implications of intellectual disability in offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/26\">",
"     26",
"    </a>",
"    ]. However, this is not common practice and there are several concerns related to routine",
"    <span class=\"nowrap\">",
"     preconceptional/prenatal",
"    </span>",
"    screening. [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/27\">",
"     27",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The underlying mechanisms which destabilize intermediate alleles and allow expansion to premutations remain unclear. The risk that an intermediate allele expands to a premutation is approximately 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/25\">",
"     25",
"    </a>",
"    ]. The risk that a premutation will expand to a full mutation increases as the number of CGG repeats increases (",
"    <a class=\"graphic graphic_table graphicRef64429 \" href=\"UTD.htm?8/60/9163\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/28\">",
"     28",
"    </a>",
"    ]. Prenatal diagnosis is not recommended for carriers of alleles with &lt;59 repeats, as only one case of expansion to a full mutation in one generation has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional concern is that, in both boys and girls who inherit a full mutation, it is not possible to predict exactly which of the fragile X syndrome characteristics the child will display. In females, the presence of their second X chromosome and the randomness of X inactivation are significant contributors to whether any of the fragile X syndrome features will be present. Likewise, although all male children inheriting the full mutation are expected to have clinical features of the fragile X syndrome, the degree of developmental impairment is variable and can range from developmental delay to moderate intellectual disability. Autism spectrum and associated features also occur, but predicting the prognosis for a specific individual child is not currently possible based on the molecular findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of prenatal diagnosis is to identify fetuses who are likely to have clinical sequelae. We recommend offering prenatal (fetal) diagnosis if a maternal premutation or full mutation is present. Prenatal diagnosis is not indicated for women with intermediate alleles, as their offspring are not at risk of developing a clinically significant full-mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/25\">",
"     25",
"    </a>",
"    ]. As the sperm cells of full mutation males are thought to carry only premutation alleles, risk of expansion is not present and prenatal testing is not typically offered, although at least one exception has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues surrounding father to daughter inheritance of a premutation gene should also be discussed. Men with a premutation will pass this expansion to all of their female offspring, who will therefore be carriers. Carrier females have the potential for bearing children with a full mutation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CVS and amniocentesis &mdash; Molecular diagnostics of fragile X can be applied to fetal DNA, whether obtained from chorionic villus samples (CVS) at 11 to 13 weeks of gestation or amniocytes obtained by amniocentesis at 15 to 16 weeks of gestation. Analysis of cells obtained very early in pregnancy can be assessed for repeat copy number. Examination of parental alleles may provide helpful information to compare with the fetal sample.",
"     </li>",
"     <li>",
"      Preimplantation genetic diagnosis &mdash; Preimplantation genetic diagnosis (PGD) may be another option for women with a premutation fragile X; however, there are several limitations to this approach. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=see_link\">",
"       \"Preimplantation genetic diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The limited amount of DNA obtained from a single cell biopsy prohibits Southern blot analysis and the methylation abnormalities of fragile X detected by the Southern blot analysis may not yet be present in the blastomere stage. Systems incorporating closely linked markers have been developed and may help to circumvent the issue of the variable onset of methylation abnormalities. Direct PCR analysis for the normal allele has been attempted, although PCR for the expanded allele is considered less reliable. An additional concern is that premutation carriers may have impaired ability to sustain adequate follicle development for harvest, in vitro fertilization, and subsequent embryo transfer, all of which are necessary components of PGD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23399/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Interpretation of findings at prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the complexity of this disorder, the results of prenatal testing should be provided to parents in consultation with a genetic counselor. Briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Male fetus with full mutation &mdash; Expression of the full phenotype is expected, including autistic behavior and mild to severe intellectual disability (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Males'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Male fetus with premutation &mdash; Usually asymptomatic, but at some risk for tremor-ataxia syndrome in late adult life (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Tremor-ataxia syndrome'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Female fetus with full mutation &mdash; Up to 50 percent of females with a full fragile X mutation demonstrate learning and behavioral difficulties that are similar to, but usually less severe than, those seen in affected males (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Females'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Female fetus with premutation &mdash; Usually asymptomatic, but at risk for premature ovarian failure and possibly late adult onset neurologic disorder (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Premature ovarian failure'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The National Fragile X Foundation provides information on fragile X on its website (",
"    <a class=\"external\" href=\"file://www.FragileX.org\">",
"     www.FragileX.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF AFFECTED INDIVIDUALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17896?source=see_link\">",
"     \"Management of children and adolescents with fragile X syndrome\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/4/12355?source=see_link\">",
"       \"Patient information: Fragile X syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fragile X syndrome is the most common inherited cause of intellectual disability. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Changes in a region of the X chromosome, known as the fragile X mental retardation-1 (FMR-1) gene, are associated with the characteristic clinical features of fragile X syndrome. This gene is normally comprised of 40 or fewer cytosine-guanine-guanine (CGG) repeats. The premutation consists of 61 to 200 CGG repeats and the full mutation contains over 200 repeats. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genotype and inheritance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elongation of the CGG repeats leads to hypermethylation, impaired translation, and reduced production of the fragile X mental retardation protein (FMRP). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Fragile X mental retardation protein'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fragile X syndrome is associated with a variety of physical, behavioral, and cognitive abnormalities that vary according to the patient's age, sex, and degree of CGG elongation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of fragile X syndrome is based on molecular analysis using both Southern blot analysis and polymerase chain reaction. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals at increased risk of an abnormality of the fragile X mental retardation-1 gene include (1) males or females with intellectual disability, developmental delay, or autism or who have a family history of fragile X syndrome or undiagnosed intellectual disability, (2) fetuses of either sex of mothers with a premutation or a full mutation, (3) young women with elevated levels of follicle-stimulating hormone, especially with a family history of premature ovarian failure, fragile X syndrome, or a relative of either sex with undiagnosed intellectual disability, and (4) individuals with late-onset intention tremor or ataxia, especially with a family history of movement disorders, fragile X, or undiagnosed intellectual disability. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Candidates for screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not offering screening for fragile X syndrome to the general obstetrical population (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Preconception or prenatal screening for the fragile X mental retardation-1 gene should be offered to individuals seeking reproductive counseling who have a family history of fragile X syndrome. Women with a family history of undiagnosed intellectual disability should also be offered carrier screening, although it would be preferable to test the proband directly where this is possible. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Candidates for screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prenatal diagnosis of potentially affected fetuses should be offered in pregnancies in which the mother possesses a premutation or full mutation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Prenatal diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/1\">",
"      Crawford DC, Acu&ntilde;a JM, Sherman SL. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med 2001; 3:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/2\">",
"      American College of Obstetricians and Gynecologists Committee on Genetics. ACOG Committee Opinion No. 469: Carrier screening for fragile X syndrome. Obstet Gynecol 2010; 116:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/3\">",
"      Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. Genet Med 2005; 7:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/4\">",
"      Nolin SL, Lewis FA 3rd, Ye LL, et al. Familial transmission of the FMR1 CGG repeat. Am J Hum Genet 1996; 59:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/5\">",
"      Fisch GS, Snow K, Thibodeau SN, et al. The fragile X premutation in carriers and its effect on mutation size in offspring. Am J Hum Genet 1995; 56:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/6\">",
"      Tiberio G. MZ female twins discordant for X-linked diseases: a review. Acta Genet Med Gemellol (Roma) 1994; 43:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/7\">",
"      Zhong N, Ju W, Pietrofesa J, et al. Fragile X \"gray zone\" alleles: AGG patterns, expansion risks, and associated haplotypes. Am J Med Genet 1996; 64:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/8\">",
"      McConkie-Rosell A, Finucane B, Cronister A, et al. Genetic counseling for fragile x syndrome: updated recommendations of the national society of genetic counselors. J Genet Couns 2005; 14:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/9\">",
"      Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004; 27:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/10\">",
"      Hatton DD, Sideris J, Skinner M, et al. Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am J Med Genet A 2006; 140A:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/11\">",
"      Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev 2004; 10:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/12\">",
"      Mart&iacute;nez R, Bonilla-Henao V, Jim&eacute;nez A, et al. Skewed X inactivation of the normal allele in fully mutated female carriers determines the levels of FMRP in blood and the fragile X phenotype. Mol Diagn 2005; 9:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/13\">",
"      Budimirovic DB, Bukelis I, Cox C, et al. Autism spectrum disorder in Fragile X syndrome: differential contribution of adaptive socialization and social withdrawal. Am J Med Genet A 2006; 140A:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/14\">",
"      Berry-Kravis E. Epilepsy in fragile X syndrome. Dev Med Child Neurol 2002; 44:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/15\">",
"      Keysor CS, Mazzocco MM. A developmental approach to understanding Fragile X syndrome in females. Microsc Res Tech 2002; 57:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/16\">",
"      de Vries BB, Wiegers AM, Smits AP, et al. Mental status of females with an FMR1 gene full mutation. Am J Hum Genet 1996; 58:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/17\">",
"      Cronister A, Hagerman RJ, Wittenberger M, Amiri K. Mental impairment in cytogenetically positive fragile X females. Am J Med Genet 1991; 38:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/18\">",
"      Hagerman PJ, Hagerman RJ. The fragile-X premutation: a maturing perspective. Am J Hum Genet 2004; 74:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/19\">",
"      Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet 2000; 97:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/20\">",
"      Willemsen R, Mientjes E, Oostra BA. FXTAS: a progressive neurologic syndrome associated with Fragile X premutation. Curr Neurol Neurosci Rep 2005; 5:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/21\">",
"      Greco CM, Berman RF, Martin RM, et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 2006; 129:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/22\">",
"      Van Esch H, Matthijs G, Fryns JP. Should we screen for FMR1 premutations in female subjects presenting with ataxia? Ann Neurol 2005; 57:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/23\">",
"      Van Esch H. The Fragile X premutation: new insights and clinical consequences. Eur J Med Genet 2006; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/24\">",
"      Ennis S, Murray A, Youings S, et al. An investigation of FRAXA intermediate allele phenotype in a longitudinal sample. Ann Hum Genet 2006; 70:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/25\">",
"      Cronister A, Teicher J, Rohlfs EM, et al. Prevalence and instability of fragile X alleles: implications for offering fragile X prenatal diagnosis. Obstet Gynecol 2008; 111:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/26\">",
"      Musci TJ, Caughey AB. Cost-effectiveness analysis of prenatal population-based fragile X carrier screening. Am J Obstet Gynecol 2005; 192:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/27\">",
"      Terracciano A, Pomponi MG, Marino GM, et al. Expansion to full mutation of a FMR1 intermediate allele over two generations. Eur J Hum Genet 2004; 12:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/28\">",
"      Nolin SL, Brown WT, Glicksman A, et al. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet 2003; 72:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/29\">",
"      Fernandez-Carvajal I, Lopez Posadas B, Pan R, et al. Expansion of an FMR1 grey-zone allele to a full mutation in two generations. J Mol Diagn 2009; 11:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/30\">",
"      Zeesman S, Zwaigenbaum L, Whelan DT, et al. Paternal transmission of fragile X syndrome. Am J Med Genet A 2004; 129A:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23399/abstract/31\">",
"      Platteau P, Sermon K, Seneca S, et al. Preimplantation genetic diagnosis for fragile Xa syndrome: difficult but not impossible. Hum Reprod 2002; 17:2807.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 437 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9662981F41-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_54_23399=[""].join("\n");
var outline_f22_54_23399=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENOTYPE AND INHERITANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fragile X mental retardation protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Full mutation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Males",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Females",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Premutation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Premature ovarian failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Tremor-ataxia syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neuro-cognitive functioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intermediate allele",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Candidates for screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Interpretation of findings at prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MANAGEMENT OF AFFECTED INDIVIDUALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/437\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/437|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/60/9163\" title=\"table 1\">",
"      CGG repeats mutation status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/62/27627\" title=\"table 2\">",
"      ACMG fragile X screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/56/42891\" title=\"table 3\">",
"      ACOG fragile X screening",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34889?source=related_link\">",
"      Clinical features and diagnosis of fragile X syndrome in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17896?source=related_link\">",
"      Management of children and adolescents with fragile X syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7817?source=related_link\">",
"      Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/4/12355?source=related_link\">",
"      Patient information: Fragile X syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=related_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29242?source=related_link\">",
"      The spinocerebellar ataxias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_54_23400="Photoaging";
var content_f22_54_23400=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Photoaging",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/54/23400/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/54/23400/contributors\">",
"     Anna L Chien, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/54/23400/contributors\">",
"     Sewon Kang, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/54/23400/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/54/23400/contributors\">",
"     Craig A Elmets, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/54/23400/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/54/23400/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/54/23400/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H16665010\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photoaging is premature skin aging resulting from prolonged and repeated exposure to solar radiation. The changes of photodamage are superimposed on the changes caused by chronological aging and are responsible for most of the age-associated features of skin appearance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38282?source=see_link&amp;anchor=H23810980#H23810980\">",
"     \"Normal aging\", section on 'Skin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Salient clinical features of photoaging include fine and coarse wrinkles, dyspigmentation, and loss of elasticity. Photodamage can be partially prevented and reversed with proper sun protection and various prescription medications. Concerns about photoaging are primarily cosmetic. They are influenced by geographical differences, culture, and personal values.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical features, and medical treatment of photoaging will be discussed here. Procedural techniques for the treatment of photoaging, including injection of soft tissue fillers or botulinum toxin, and laser therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27049?source=see_link\">",
"     \"Injectable soft tissue fillers: Overview of clinical use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22778?source=see_link\">",
"     \"Overview of botulinum toxin for cosmetic indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/20/14665?source=see_link\">",
"     \"Botulinum toxin for cosmetic indications: Treatment of specific sites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1610?source=see_link\">",
"     \"Ablative laser resurfacing for skin rejuvenation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42089?source=see_link\">",
"     \"Nonablative skin resurfacing for skin rejuvenation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10962084\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photoaging is responsible for the majority of age-associated cosmetic skin problems in fair skinned populations. In European and North American adult populations with skin prototypes I, II, and III (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 1",
"    </a>",
"    ), the prevalence of photoaging may be as high as 80 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/1\">",
"     1",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Risk factors for photoaging include age, sex, skin prototype, and geographic location. Individuals with fair and less pigmented skin are at increased risk for photodamage and sun-induced skin cancer. The amount of time spent in the sunlight over a lifetime is a key risk factor for photoaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H5#H5\">",
"     \"Risk factors for the development of melanoma\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an Australian study, skin texture changes of moderate to severe photoaging were observed in 72 percent of men and 47 percent of women under the age of 30 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/2\">",
"     2",
"    </a>",
"    ]. The severity of photoaging increases rapidly after the age of 30 and is associated with medium or light skin color, burning and never tanning after exposure to strong sunlight, and prolonged occupational or recreational sun exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In populations with darker skin, wrinkling is not readily apparent until the age of about 50 years and the severity is not as marked as in light-skinned populations of similar age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/4\">",
"     4",
"    </a>",
"    ]. One study found that the onset of wrinkles in Chinese women occurred on average 10 years later than in French women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16665018\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The loss of the structural integrity of the dermal extracellular matrix caused by chronic ultraviolet (UV) exposure is believed to be primarily responsible for the wrinkled appearance of photodamage skin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/6\">",
"     6",
"    </a>",
"    ]. The dermal extracellular matrix is a complex meshwork of several macromolecules, including collagen and elastic fibers, glycoproteins, and glycosaminoglycans which provide strength and resilience to the skin. Type I and III collagens are the most abundant proteins in the dermis and the main target of sun-induced damage.",
"   </p>",
"   <p>",
"    Both UVA and UVB appear to be implicated in the photoaging process, although UVA is emerging as the major contributor to photodamage. UVA radiations (wavelengths 320 to 400 nm) are thought to have a larger role than UVB in photoaging because they are able to penetrate into the dermis deeper than UVB and are at least 10-fold more abundant than UVB in the terrestrial sunlight [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/7\">",
"     7",
"    </a>",
"    ]. Short wave UVB radiations (wavelengths 290 to 320 nm) are mainly absorbed in the epidermis by cellular DNA. They induce direct DNA damage with formation of cyclobutanol pyrimidine dimers, and are responsible for sunburn, inflammation, photo carcinogenesis, and immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Long wavelength radiations in the infrared (IR) range, which represent 50 percent of the total solar energy, may also contribute to photoaging of human skin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms underlying the UV-mediated damage to the skin connective tissue involve the formation of reactive oxygen species (ROS), cell surface receptor-initiated signaling, protein oxidation, and mitochondrial damage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/7,13\">",
"     7,13",
"    </a>",
"    ]. ROS, including superoxide anion,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    , and singlet oxygen, activate cell surface receptors for cytokines and growth factors, including epidermal growth factor (EG), interleukin 1 (IL-1), and tumor necrosis factor (TNF) alpha. ROS also induce the transcription factor activator protein 1 (AP-1) and the nuclear transcription factor NF-ab (",
"    <a class=\"graphic graphic_figure graphicRef78164 \" href=\"UTD.htm?32/26/33190\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    AP-1 upregulate matrix metalloproteinases (MPM), including interstitial collagenase (MMP-1), stromelysin-1 (MMP-3), and 92kDa gelatinase (MMP-9) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The combined actions of MMP-1, 3, and 9 degrade most of type I and III dermal collagen. With repeated sun exposure, the degraded collagen accumulates over time resulting in the clinical and histologic features of photoaging [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. AP-1 also inhibits type I and type III procollagen gene expression in the dermis by binding to the transcriptional complex responsible for procollagen transcription or blocking the activity of transforming growth factor (TGF) beta [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The activation of the nuclear transcription factor NF-ab upregulate the expression of proinflammatory cytokines such as IL-1 beta, TNF-alpha, IL-6, IL-8, and various adhesion molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. These cytokines in turn upregulate AP-1 and further activate the NF-ab pathway, enhancing the response to UV irradiation.",
"   </p>",
"   <p>",
"    Mitochondria are the main endogenous source of ROS, which are produced during the conversion of ADP to ATP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/7\">",
"     7",
"    </a>",
"    ]. Endogenous ROS, particularly singlet oxygen, may induce deletions and rearrangements of mitochondrial DNA (tDNA). The most common mitochondrial mutation is a 4977 base-pair deletion termed &ldquo;common deletion&rdquo;, which is found with high frequency in degenerative diseases and cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. This mutation is increased in photodamage skin and may be induced in dermal fibroblasts by repetitive exposure to UVA radiation. [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5836769\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopic changes in the photodamage skin include epidermal atrophy with thinning of the spinous layer, flattened dermoepidermal junction with loss of rete ridges, decreased collagen content, and deposition of amorphous masses of abnormally thickened, curled, and disintegrated elastic fibers and collagen breakdown products (solar elastosis) (",
"    <a class=\"graphic graphic_picture graphicRef83455 \" href=\"UTD.htm?20/20/20808\">",
"     picture 1",
"    </a>",
"    ). Increased number of atypical melanocytes and atypical epidermal cells may also be seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16665025\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sun-induced cutaneous changes vary among individuals, reflecting intrinsic differences in vulnerability and repair capacity. Sun-induced changes include fine and coarse wrinkles, lentigines, mottled pigmentation, actinic keratoses, telangiectasias, loss of translucency and elasticity, xerotic texture, and sallow color (",
"    <a class=\"graphic graphic_table graphicRef82638 \" href=\"UTD.htm?35/22/36204\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef81287 graphicRef61033 graphicRef68136 graphicRef71483 graphicRef53576 graphicRef66252 \" href=\"UTD.htm?43/30/44522\">",
"     picture 2A-F",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Age, sex, geographic location, and skin type (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 1",
"    </a>",
"    ) are factors influencing the severity of photoaging [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In populations with skin types I or II, atrophic and dysplastic changes (egg, actinic keratoses) with fine wrinkling are common signs of photoaging. In contrast, increased skin thickness, deep wrinkles, and leathery appearance are predominant in individuals with skin type III or IV [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/7\">",
"     7",
"    </a>",
"    ]. Hyperpigmented macules and mottled hyperpigmentation are also common features of photodamage skin (",
"    <a class=\"graphic graphic_picture graphicRef81287 \" href=\"UTD.htm?5/30/5604\">",
"     picture 2A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In individuals with skin types V or VI, the effects of photodamage generally occur 10 to 20 years later and are less severe than those observed in individuals with lighter skin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/30\">",
"     30",
"    </a>",
"    ]. In darker skin, premature aging typically manifests in the midface with prominent nasolabial folds but less wrinkles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11306635\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of photoaging is clinical. Typical skin changes include fine and coarse wrinkles, lentigines, mottled pigmentation, loss of translucency and elasticity, and sallow color (",
"    <a class=\"graphic graphic_picture graphicRef81287 graphicRef61033 graphicRef68136 graphicRef71483 graphicRef53576 graphicRef66252 \" href=\"UTD.htm?43/30/44522\">",
"     picture 2A-F",
"    </a>",
"    ). In clinical practice, photographic scales of photoaging severity may be used for patient evaluation and management decisions (",
"    <a class=\"graphic graphic_picture graphicRef68754 \" href=\"UTD.htm?0/42/681\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In research settings, several invasive and non invasive methods have been used to quantify the photodamage, including histopathology and immunohistochemistry, skin surface topography, ultrasound, or reflectance confocal microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7498788\">",
"    <span class=\"h1\">",
"     OVERVIEW OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photoaging can be partially prevented and improved through a number of modalities such as sun protection, topical prescription medications, cosmeceuticals, and cosmetic procedures. Factors to consider in the management of a patient with photoaging include the severity of skin changes and the patient&rsquo;s concern, expectations, and willingness to accept the costs of treatment.",
"   </p>",
"   <p>",
"    The first step in the management of photoaging involves educating the patient to adopt appropriate sun protection measures, including sun avoidance and regular use of sunscreen and protective clothing. (See",
"    <a class=\"local\" href=\"#H16665039\">",
"     'Photoprotection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Topical retinoids are the mainstay of medical therapy for patients with mild to severe photoaging. (See",
"    <a class=\"local\" href=\"#H11545631\">",
"     'Topical retinoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Photoaging in patients with actinic keratoses may improve in response to treatment with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/34\">",
"     34",
"    </a>",
"    ]. Fluorouracil&rsquo;s mechanism of action involves epidermal injury, wound healing, and remodeling of the dermal matrix, resulting in improved appearance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30968?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of actinic keratosis\", section on 'Topical 5-fluorouracil'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of other substances called cosmeceuticals, which include antioxidants, vitamins, or plant extracts, are incorporated in cosmetic preparations and have been used in conjunction with topical retinoids (",
"    <a class=\"graphic graphic_table graphicRef83291 \" href=\"UTD.htm?26/32/27148\">",
"     table 3",
"    </a>",
"    ). However, there is limited evidence from clinical studies to suggest that they are beneficial or that one particular preparation is better than another. (See",
"    <a class=\"local\" href=\"#H16665053\">",
"     'Cosmeceuticals'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16665039\">",
"    <span class=\"h1\">",
"     PHOTOPROTECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protection from the sun, including sun avoidance and use of sunscreens and protective clothing, is the first line of defense against photoaging.",
"   </p>",
"   <p>",
"    UV irradiation tends to be the strongest at peak hours (10 am to 4 pm), during summer months and at high altitudes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Water, snow, and concrete can reflect up to 90 percent of the UV rays, whereas shade decreases the amount of UV by 50 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Staying away from the sun in the peak hours or seeking shade may considerably reduce sun exposure.",
"   </p>",
"   <p>",
"    Sunscreen is the most widely used method of photoprotection. Regular use of broad spectrum sunscreens, which provide protection against UVA and UVB radiation (",
"    <a class=\"graphic graphic_table graphicRef73127 \" href=\"UTD.htm?6/27/6589\">",
"     table 4",
"    </a>",
"    ), may prevent short and long term skin damage induced by solar radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/39\">",
"     39",
"    </a>",
"    ]. Adequate amounts of sunscreen should be applied daily to achieve proper protection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18073?source=see_link&amp;anchor=H5#H5\">",
"     \"Primary prevention of melanoma\", section on 'Sun protection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clothes, hats, and sunglasses provide uniform and reliable protection against UVB and UVA, are easy to use and less costly than sunscreens [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Factors that increase the UV protection factor (UP) in clothing include synthetic (egg, polyester), tightly woven, or thicker fabric, darker colors, and washing with optical whitening agents or UV absorbing chemicals (egg, Tinos orb FD) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18073?source=see_link&amp;anchor=H5#H5\">",
"     \"Primary prevention of melanoma\", section on 'Sun protection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Strict sun protection may increase the risk for vitamin D deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/45\">",
"     45",
"    </a>",
"    ], but most individuals do not apply sufficient amounts of sunscreen for this to be a significant problem [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/46\">",
"     46",
"    </a>",
"    ]. However, oral vitamin D supplementation is a safe, well-tolerated, and inexpensive alternative to achieve adequate vitamin D levels [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=see_link\">",
"     \"Vitamin D insufficiency and deficiency in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11545631\">",
"    <span class=\"h1\">",
"     TOPICAL RETINOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest topical retinoids (",
"    <a class=\"graphic graphic_table graphicRef70303 \" href=\"UTD.htm?8/9/8347\">",
"     table 5",
"    </a>",
"    ) for patients who desire treatment for photoaging.",
"   </p>",
"   <p>",
"    Retinoids are a class of naturally occurring or synthetic compounds related to retinol (vitamin A). In the body, retinol is naturally converted to derivatives including retinoic acid (the most biologically active form of the vitamin), retinaldehyde, and retinyl esters. Tretinoin (all-trans retinoic acid) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    (a synthetic derivative) are topical retinoids available by prescription for the treatment of photoaging (",
"    <a class=\"graphic graphic_table graphicRef70303 \" href=\"UTD.htm?8/9/8347\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Retinoids exert their effects by binding and activating two groups of receptors belonging to the nuclear hormone receptor superfamily: the retinoid acid receptors (RIRS) and the retinoid X receptors (RIRS), which are ligand-dependent nuclear transcription factors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/48\">",
"     48",
"    </a>",
"    ]. In human skin, topical retinoids increase collagen production, induce epidermal hyperplasia, and decrease keratinocyte and melanocyte atypia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/49-53\">",
"     49-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1104917962\">",
"    <span class=\"h2\">",
"     Pretreatment counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to counsel patients before initiating treatment with topical retinoids (tretinoin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    ). Patients should be informed that local skin irritation can be expected as part of the treatment. Skin irritation, redness, scaling, dryness, burning, stinging, and peeling are common side effects of topical retinoids and often result in patient nonadherence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/54\">",
"     54",
"    </a>",
"    ]. Adverse effects peak during the first two weeks, are more frequent with higher concentrations and decrease with time. Regular application of moisturizers is helpful in reducing irritation from topical retinoids.",
"   </p>",
"   <p>",
"    Treatment with topical retinoids should not be started or continued during pregnancy because retinoids are known teratogens. However, there is no direct evidence that topical retinoids causes congenital malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9275666\">",
"    <span class=\"h2\">",
"     Tretinoin",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1104918044\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who desire treatment for photoaging, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1862?source=see_link\">",
"     topical tretinoin",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef70303 \" href=\"UTD.htm?8/9/8347\">",
"     table 5",
"    </a>",
"    ) as first line therapy. We prefer tretinoin to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    because multiple available concentrations make titration easier and in clinical experience (although not in clinical trials) tretinoin is less irritating. Topical tretinoin can be used for mild to severe photoaging in patients of all skin prototypes. Several weeks or months of treatment typically are required before clinical improvement is appreciated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/49,57\">",
"     49,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of tretinoin for the treatment of photoaging is supported by several randomized trials and a metaanalysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/49,54,57-59\">",
"     49,54,57-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A metaanalysis of 12 randomized trials demonstrated that in individuals with mild to severe photoaging of the face or forearms tretinoin cream in concentrations of 0.02% to 0.1% applied once daily for 16 to 48 weeks was more effective than placebo in the physician-assessed overall improvement of photodamage [",
"      <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/54\">",
"       54",
"      </a>",
"      ]. As an example, the relative risk of overall improvement for tretinoin 0.05% cream versus placebo after 24 weeks was 1.73 (95% CI 1.39 to 2.14).",
"     </li>",
"     <li>",
"      A subsequent trial evaluated the long-term efficacy and safety of daily application of tretinoin 0.05% emollient cream for two years in 204 subjects with moderate to severe photoaging [",
"      <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/59\">",
"       59",
"      </a>",
"      ]. The improvement in all signs of photodamage, overall photodamage severity, and global assessment of clinical response was greater in the active treatment group than in the placebo group. Treatment with tretinoin was not associated with increased keratinocytic or melanocytic atypia (",
"      <a class=\"graphic graphic_picture graphicRef53021 \" href=\"UTD.htm?1/14/1248\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11306985\">",
"    <span class=\"h3\">",
"     Instructions for application",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concentration and frequency of application of tretinoin is titrated based upon the observed skin reaction in individual patients. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tretinoin is initiated at the lowest active dose to minimize adverse effects and increase patient&rsquo;s adherence. Tretinoin 0.020% or 0.025% cream or gel applied every other day, preferably at nighttime, is a common starting regimen. Patients with particularly sensitive skin may start with a twice a week regimen for the first few weeks and increase the frequency of application gradually.",
"     </li>",
"     <li>",
"      Tretinoin concentration and frequency of application may be gradually increased over several weeks as tolerated by the patient, up to a daily application of tretinoin 0.1%. However, higher concentrations may not correlate with increased clinical efficacy. As an example, 0.1% tretinoin is considerably more irritating than 0.025% tretinoin, but may not offer additional benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1862?source=see_link\">",
"       Topical tretinoin",
"      </a>",
"      should be tried for a minimum of four months because benefits may not be appreciated before then [",
"      <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The benefits of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1862?source=see_link\">",
"       topical tretinoin",
"      </a>",
"      are lost upon discontinuation. Although it has only been studied for a duration of two years [",
"      <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/59\">",
"       59",
"      </a>",
"      ], it may be continued indefinitely. A long-term maintenance regimen with a lower concentration or less frequent application may be an alternative to continued use. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9275681\">",
"    <span class=\"h2\">",
"     Tazarotene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef70303 \" href=\"UTD.htm?8/9/8347\">",
"     table 5",
"    </a>",
"    ) is an alternative to tretinoin for patients with mild to severe photoaging who desire treatment. (See",
"    <a class=\"local\" href=\"#H7498788\">",
"     'Overview of management'",
"    </a>",
"    above.) Topical tazarotene gel or cream is available at concentrations of 0.05% or 0.1%.",
"   </p>",
"   <p>",
"    The efficacy of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    is supported by several randomized trials and a metaanalysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/54,57,60\">",
"     54,57,60",
"    </a>",
"    ]. In individuals with mild to severe photoaging of the face, tazarotene 0.05% or 0.1% cream applied daily for 24 weeks was more effective than placebo in the physician-assessed overall improvement of photodamage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/54\">",
"     54",
"    </a>",
"    ]. In one small study, tazarotene 0.05% and 0.1% were as effective as tretinoin 0.05% [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/57\">",
"     57",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Treatment is initiated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    0.05% cream or gel applied twice per week at nighttime. The concentration or frequency of application is gradually increased over several weeks as tolerated (up to 0.1% cream applied once daily).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16665053\">",
"    <span class=\"h1\">",
"     COSMECEUTICALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term cosmeceuticals refers to a heterogeneous category of nonprescription topical products including antioxidants, vitamins, retinoids, hydroxyacids, and plant extracts that may have some activity in the treatment of photoaging (",
"    <a class=\"graphic graphic_table graphicRef83291 \" href=\"UTD.htm?26/32/27148\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/61\">",
"     61",
"    </a>",
"    ]. Cosmeceuticals are not classified as drugs and not subject to rigorous testing or regulation by local regulatory agencies such as the Food and Drug Administration in the United States or the European Medicines Agency.",
"   </p>",
"   <p>",
"    Cosmeceuticals are popular ingredients of a wide range of cosmetic products and are sometimes used in conjunction with topical retinoids to potentially enhance the antiaging benefits. However, there is limited evidence from clinical studies to suggest that they are beneficial or that one particular preparation is better than another",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16665060\">",
"    <span class=\"h1\">",
"     CHEMICAL PEELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical peels involve the application of caustic chemical substances to ablate definite skin layers; the subsequent cutaneous regeneration tightens the skin and evens the color. The decision to use chemical peels in the treatment of photoaging depends upon individual patient values and preferences.",
"   </p>",
"   <p>",
"    Peels are classified by their intended depth of injury or ablation (",
"    <a class=\"graphic graphic_table graphicRef75958 \" href=\"UTD.htm?41/20/42315\">",
"     table 6",
"    </a>",
"    ). Chemical peels result in a thinner, more compact stratum corneum, thicker epidermis, and uniform distribution of melanin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23400/abstract/62\">",
"     62",
"    </a>",
"    ]. Superficial and medium-depth peels may improve mild or moderate photoaging. Deep peels may be used for severe photodamage. Adverse effects are more common with medium-depth and deep peels and include hypo- or hyperpigmentation, infection, and scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1104917722\">",
"    <span class=\"h1\">",
"     OTHER THERAPEUTIC OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other treatments that are commonly used to improve the signs of photoaging include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Injectable botulinum toxin (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22778?source=see_link\">",
"       \"Overview of botulinum toxin for cosmetic indications\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/20/14665?source=see_link\">",
"       \"Botulinum toxin for cosmetic indications: Treatment of specific sites\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Injectable fillers (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27049?source=see_link\">",
"       \"Injectable soft tissue fillers: Overview of clinical use\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Laser therapy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1610?source=see_link\">",
"       \"Ablative laser resurfacing for skin rejuvenation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42089?source=see_link\">",
"       \"Nonablative skin resurfacing for skin rejuvenation\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decision to use these therapies in the treatment of photoaging depends upon individual patient values and preferences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16665067\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Photoaging is premature skin aging resulting from prolonged and repeated exposure to solar radiation. Photoaging is responsible for most of the age-associated changes of the skin. Fair and less pigmented skin is at increased risk of photodamage. (See",
"      <a class=\"local\" href=\"#H16665010\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10962084\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16665018\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical signs of photoaging include wrinkles, lentigines, mottled hyperpigmentation, actinic keratoses, loss of translucency and elasticity, xerotic texture, and sallow color (",
"      <a class=\"graphic graphic_picture graphicRef81287 graphicRef61033 graphicRef68136 graphicRef71483 graphicRef53576 graphicRef66252 \" href=\"UTD.htm?43/30/44522\">",
"       picture 2A-F",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16665025\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Photoaging can be partially prevented and improved through a number of modalities including sun protection and prescription medications. Protection from the sun, including sun avoidance and use of sunscreens and protective clothing, is the first line of defense against photoaging. (See",
"      <a class=\"local\" href=\"#H16665039\">",
"       'Photoprotection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who desire treatment for photoaging, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1862?source=see_link\">",
"       topical tretinoin",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef70303 \" href=\"UTD.htm?8/9/8347\">",
"       table 5",
"      </a>",
"      ) over",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"       tazarotene",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Topical tretinoin can be used for mild to severe photoaging in patients of all skin prototypes. Tretinoin 0.020% or 0.025% cream or gel applied every other day, preferably at nighttime, is a common starting regimen. Tretinoin concentration and frequency of application may be gradually increased over several weeks as tolerated, up to a daily application of tretinoin 0.1%. (See",
"      <a class=\"local\" href=\"#H9275666\">",
"       'Tretinoin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin irritation, redness, and peeling are common adverse effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1862?source=see_link\">",
"       topical tretinoin",
"      </a>",
"      and may be managed by dose titration and regular use of moisturizers. (See",
"      <a class=\"local\" href=\"#H1104917962\">",
"       'Pretreatment counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"       Tazarotene",
"      </a>",
"      0.05% or 0.1% cream or gel may be used as an alternative to tretinoin. Treatment is initiated with 0.05% cream or gel applied twice per week at nighttime. The concentration or frequency of application is gradually increased over several weeks as tolerated (up to 0.1% cream applied once daily). (See",
"      <a class=\"local\" href=\"#H9275681\">",
"       'Tazarotene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Moisturizers containing cosmeceuticals, such as antioxidants, vitamins, or plant extracts, can be used in conjunction with topical retinoids for the treatment of photoaging (",
"      <a class=\"graphic graphic_table graphicRef83291 \" href=\"UTD.htm?26/32/27148\">",
"       table 3",
"      </a>",
"      ). However, there is limited evidence of efficacy from clinical studies to suggest these preparations. (See",
"      <a class=\"local\" href=\"#H16665053\">",
"       'Cosmeceuticals'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/1\">",
"      Maddin S, Lauharanta J, Agache P, et al. Isotretinoin improves the appearance of photodamaged skin: results of a 36-week, multicenter, double-blind, placebo-controlled trial. J Am Acad Dermatol 2000; 42:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/2\">",
"      Green AC. Premature ageing of the skin in a Queensland population. Med J Aust 1991; 155:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/3\">",
"      Green AC, Hughes MC, McBride P, Fourtanier A. Factors associated with premature skin aging (photoaging) before the age of 55: a population-based study. Dermatology 2011; 222:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/4\">",
"      Goh SH. The treatment of visible signs of senescence: the Asian experience. Br J Dermatol 1990; 122 Suppl 35:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/5\">",
"      Nouveau-Richard S, Yang Z, Mac-Mary S, et al. Skin ageing: a comparison between Chinese and European populations. A pilot study. J Dermatol Sci 2005; 40:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/6\">",
"      Talwar HS, Griffiths CE, Fisher GJ, et al. Reduced type I and type III procollagens in photodamaged adult human skin. J Invest Dermatol 1995; 105:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/7\">",
"      Yaar M, Gilchrest BA. Photoageing: mechanism, prevention and therapy. Br J Dermatol 2007; 157:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/8\">",
"      Benjamin CL, Ullrich SE, Kripke ML, Ananthaswamy HN. p53 tumor suppressor gene: a critical molecular target for UV induction and prevention of skin cancer. Photochem Photobiol 2008; 84:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/9\">",
"      Schwarz T. 25 years of UV-induced immunosuppression mediated by T cells-from disregarded T suppressor cells to highly respected regulatory T cells. Photochem Photobiol 2008; 84:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/10\">",
"      Krutmann J, Morita A, Chung JH. Sun exposure: what molecular photodermatology tells us about its good and bad sides. J Invest Dermatol 2012; 132:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/11\">",
"      Schroeder P, Lademann J, Darvin ME, et al. Infrared radiation-induced matrix metalloproteinase in human skin: implications for protection. J Invest Dermatol 2008; 128:2491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/12\">",
"      Schroeder P, Haendeler J, Krutmann J. The role of near infrared radiation in photoaging of the skin. Exp Gerontol 2008; 43:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/13\">",
"      Fisher GJ, Kang S, Varani J, et al. Mechanisms of photoaging and chronological skin aging. Arch Dermatol 2002; 138:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/14\">",
"      Quan T, He T, Voorhees JJ, Fisher GJ. Ultraviolet irradiation blocks cellular responses to transforming growth factor-beta by down-regulating its type-II receptor and inducing Smad7. J Biol Chem 2001; 276:26349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/15\">",
"      Fisher GJ, Voorhees JJ. Molecular mechanisms of photoaging and its prevention by retinoic acid: ultraviolet irradiation induces MAP kinase signal transduction cascades that induce Ap-1-regulated matrix metalloproteinases that degrade human skin in vivo. J Investig Dermatol Symp Proc 1998; 3:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/16\">",
"      Fisher GJ, Datta S, Wang Z, et al. c-Jun-dependent inhibition of cutaneous procollagen transcription following ultraviolet irradiation is reversed by all-trans retinoic acid. J Clin Invest 2000; 106:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/17\">",
"      Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/18\">",
"      Angel P, Szabowski A, Schorpp-Kistner M. Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene 2001; 20:2413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/19\">",
"      Massagu&eacute; J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000; 1:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/20\">",
"      Senftleben U, Karin M. The IKK/NF-kappaB pathway. Crit Care Med 2002; 30:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/21\">",
"      Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/22\">",
"      Shen L, Fang H, Chen T, et al. Evaluating mitochondrial DNA in cancer occurrence and development. Ann N Y Acad Sci 2010; 1201:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/23\">",
"      Park CB, Larsson NG. Mitochondrial DNA mutations in disease and aging. J Cell Biol 2011; 193:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/24\">",
"      Berneburg M, Plettenberg H, Medve-K&ouml;nig K, et al. Induction of the photoaging-associated mitochondrial common deletion in vivo in normal human skin. J Invest Dermatol 2004; 122:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/25\">",
"      Berneburg M, Gattermann N, Stege H, et al. Chronically ultraviolet-exposed human skin shows a higher mutation frequency of mitochondrial DNA as compared to unexposed skin and the hematopoietic system. Photochem Photobiol 1997; 66:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/26\">",
"      Kang S, Fisher GJ, Voorhees JJ. Photoaging and topical tretinoin: therapy, pathogenesis, and prevention. Arch Dermatol 1997; 133:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/27\">",
"      Kligman AM. Early destructive effect of sunlight on human skin. JAMA 1969; 210:2377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/28\">",
"      Malvy Jm, Guinot C, Preziosi P, et al. Epidemiologic determinants of skin photoaging: baseline data of the SU.VI.MAX. cohort. J Am Acad Dermatol 2000; 42:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/29\">",
"      Griffiths CE, Goldfarb MT, Finkel LJ, et al. Topical tretinoin (retinoic acid) treatment of hyperpigmented lesions associated with photoaging in Chinese and Japanese patients: a vehicle-controlled trial. J Am Acad Dermatol 1994; 30:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/30\">",
"      Davis EC, Callender VD. Aesthetic dermatology for aging ethnic skin. Dermatol Surg 2011; 37:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/31\">",
"      Griffiths CE, Wang TS, Hamilton TA, et al. A photonumeric scale for the assessment of cutaneous photodamage. Arch Dermatol 1992; 128:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/32\">",
"      Chung JH. Photoaging in Asians. Photodermatol Photoimmunol Photomed 2003; 19:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/33\">",
"      Baillie L, Askew D, Douglas N, Soyer HP. Strategies for assessing the degree of photodamage to skin: a systematic review of the literature. Br J Dermatol 2011; 165:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/34\">",
"      Sachs DL, Kang S, Hammerberg C, et al. Topical fluorouracil for actinic keratoses and photoaging: a clinical and molecular analysis. Arch Dermatol 2009; 145:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/35\">",
"      Wang SQ, Balagula Y, Osterwalder U. Photoprotection: a review of the current and future technologies. Dermatol Ther 2010; 23:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/36\">",
"      Rigel DS, Rigel EG, Rigel AC. Effects of altitude and latitude on ambient UVB radiation. J Am Acad Dermatol 1999; 40:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/37\">",
"      Kromann N, Wulf HC, Eriksen P, Brodthagen H. Relative ultraviolet spectral intensity of direct solar radiation, sky radiation and surface reflections. Relative contribution of natural sources to the outdoor UV irradiation of man. Photodermatol 1986; 3:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/38\">",
"      Moise AF, Aynsley R. Ambient ultraviolet radiation levels in public shade settings. Int J Biometeorol 1999; 43:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/39\">",
"      Fourtanier A, Moyal D, Seit&eacute; S. Sunscreens containing the broad-spectrum UVA absorber, Mexoryl SX, prevent the cutaneous detrimental effects of UV exposure: a review of clinical study results. Photodermatol Photoimmunol Photomed 2008; 24:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/40\">",
"      Hatch KL, Osterwalder U. Garments as solar ultraviolet radiation screening materials. Dermatol Clin 2006; 24:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/41\">",
"      Wang SQ, Kopf AW, Marx J, et al. Reduction of ultraviolet transmission through cotton T-shirt fabrics with low ultraviolet protection by various laundering methods and dyeing: clinical implications. J Am Acad Dermatol 2001; 44:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/42\">",
"      Davis S, Capjack L, Kerr N, Fedosejevs R. Clothing as protection from ultraviolet radiation: which fabric is most effective? Int J Dermatol 1997; 36:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/43\">",
"      Crews PC, Kachman S, Beter AG. Influences on UVR transmission of undyed woven fabrics. Textile Chemist Colorist 1999; 31:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/44\">",
"      Georgouras KE, Stanford DG, Pailthorpe MT. Sun protective clothing in Australia and the Australian/New Zealand standard: an overview. Australas J Dermatol 1997; 38 Suppl 1:S79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/45\">",
"      Linos E, Keiser E, Kanzler M, et al. Sun protective behaviors and vitamin D levels in the US population: NHANES 2003-2006. Cancer Causes Control 2012; 23:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/46\">",
"      Marks R, Foley PA, Jolley D, et al. The effect of regular sunscreen use on vitamin D levels in an Australian population. Results of a randomized controlled trial. Arch Dermatol 1995; 131:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/47\">",
"      Lim HW, Gilchrest BA, Cooper KD, et al. Sunlight, tanning booths, and vitamin D. J Am Acad Dermatol 2005; 52:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/48\">",
"      Zussman J, Ahdout J, Kim J. Vitamins and photoaging: do scientific data support their use? J Am Acad Dermatol 2010; 63:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/49\">",
"      Cho S, Lowe L, Hamilton TA, et al. Long-term treatment of photoaged human skin with topical retinoic acid improves epidermal cell atypia and thickens the collagen band in papillary dermis. J Am Acad Dermatol 2005; 53:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/50\">",
"      Griffiths CE, Russman AN, Majmudar G, et al. Restoration of collagen formation in photodamaged human skin by tretinoin (retinoic acid). N Engl J Med 1993; 329:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/51\">",
"      Bhawan J, Olsen E, Lufrano L, et al. Histologic evaluation of the long term effects of tretinoin on photodamaged skin. J Dermatol Sci 1996; 11:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/52\">",
"      Kang S, Duell EA, Fisher GJ, et al. Application of retinol to human skin in vivo induces epidermal hyperplasia and cellular retinoid binding proteins characteristic of retinoic acid but without measurable retinoic acid levels or irritation. J Invest Dermatol 1995; 105:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/53\">",
"      Fisher GJ, Datta SC, Talwar HS, et al. Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature 1996; 379:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/54\">",
"      Samuel M, Brooke RC, Hollis S, Griffiths CE. Interventions for photodamaged skin. Cochrane Database Syst Rev 2005; :CD001782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/55\">",
"      Loureiro KD, Kao KK, Jones KL, et al. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A 2005; 136:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/56\">",
"      Shapiro L, Pastuszak A, Curto G, Koren G. Safety of first-trimester exposure to topical tretinoin: prospective cohort study. Lancet 1997; 350:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/57\">",
"      Kang S, Leyden JJ, Lowe NJ, et al. Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24 weeks. Arch Dermatol 2001; 137:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/58\">",
"      Griffiths CE, Kang S, Ellis CN, et al. Two concentrations of topical tretinoin (retinoic acid) cause similar improvement of photoaging but different degrees of irritation. A double-blind, vehicle-controlled comparison of 0.1% and 0.025% tretinoin creams. Arch Dermatol 1995; 131:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/59\">",
"      Kang S, Bergfeld W, Gottlieb AB, et al. Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of photodamaged facial skin: a two-year, randomized, placebo-controlled trial. Am J Clin Dermatol 2005; 6:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/60\">",
"      Kang S, Krueger GG, Tanghetti EA, et al. A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment of photodamage. J Am Acad Dermatol 2005; 52:268.",
"     </a>",
"    </li>",
"    <li>",
"     Kligman AM. Introduction: What is cosmeceuticals. In: Procedures in Cosmetic Dermatology Series: Cosmeceuticals, 1st ed, Draelos ZD (Ed), WB Saunders, Philadelphia 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23400/abstract/62\">",
"      Fabbrocini G, De Padova MP, Tosti A. Chemical peels: what's new and what isn't new but still works well. Facial Plast Surg 2009; 25:329.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15255 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-94DAD92080-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_54_23400=[""].join("\n");
var outline_f22_54_23400=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16665067\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16665010\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10962084\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16665018\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5836769\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16665025\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11306635\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7498788\">",
"      OVERVIEW OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16665039\">",
"      PHOTOPROTECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11545631\">",
"      TOPICAL RETINOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1104917962\">",
"      Pretreatment counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9275666\">",
"      Tretinoin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1104918044\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11306985\">",
"      - Instructions for application",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9275681\">",
"      Tazarotene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16665053\">",
"      COSMECEUTICALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16665060\">",
"      CHEMICAL PEELS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1104917722\">",
"      OTHER THERAPEUTIC OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16665067\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15255\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15255|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/26/33190\" title=\"figure 1\">",
"      Pathogenesis of photoaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15255|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/20/20808\" title=\"picture 1\">",
"      Photoaging histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/30/5604\" title=\"picture 2A\">",
"      Solar lentigines face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/23/11637\" title=\"picture 2B\">",
"      Elastosis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/48/44803\" title=\"picture 2C\">",
"      Elastosis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/35/26165\" title=\"picture 2D\">",
"      Photoaging periocular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/62/7139\" title=\"picture 2E\">",
"      Photoaging arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/41/39574\" title=\"picture 2F\">",
"      Pigmented seborrheic keratoses face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/42/681\" title=\"picture 3\">",
"      Photodamage scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/14/1248\" title=\"picture 4\">",
"      Photoaging topical tretinoin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15255|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/37/15963\" title=\"table 1\">",
"      Fitzpatrick skin phototypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/22/36204\" title=\"table 2\">",
"      Features of photoaged skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/32/27148\" title=\"table 3\">",
"      Cosmeceuticals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/27/6589\" title=\"table 4\">",
"      Sunscreens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/9/8347\" title=\"table 5\">",
"      Retinoids for photoaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/20/42315\" title=\"table 6\">",
"      Chemical peels",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1610?source=related_link\">",
"      Ablative laser resurfacing for skin rejuvenation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/20/14665?source=related_link\">",
"      Botulinum toxin for cosmetic indications: Treatment of specific sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27049?source=related_link\">",
"      Injectable soft tissue fillers: Overview of clinical use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42089?source=related_link\">",
"      Nonablative skin resurfacing for skin rejuvenation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38282?source=related_link\">",
"      Normal aging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22778?source=related_link\">",
"      Overview of botulinum toxin for cosmetic indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18073?source=related_link\">",
"      Primary prevention of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30968?source=related_link\">",
"      Treatment of actinic keratosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=related_link\">",
"      Vitamin D insufficiency and deficiency in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_54_23401="Toll-like receptors: Roles in disease and therapy";
var content_f22_54_23401=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Toll-like receptors: Roles in disease and therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/54/23401/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/54/23401/contributors\">",
"     Francisco A Bonilla, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/54/23401/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/54/23401/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/54/23401/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/54/23401/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/54/23401/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The toll-like receptors (TLRs) are surface molecules on eukaryotic cells that detect and respond to microbial infection. TLRs derive their name from homology to the Drosophila Toll molecule, an important component of an antifungal defense mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. TLRs constitute a phylogenetically ancient system present in invertebrates and conserved through vertebrate evolution.",
"   </p>",
"   <p>",
"    TLRs belong to a class of molecules known as \"pattern recognition receptors.\" The ligands for these receptors are components of pathogenic microbes and are often called \"pathogen-associated molecular patterns\" (PAMPs).",
"   </p>",
"   <p>",
"    TLRs are frequently referred to as a system of non-specific or \"innate\" immune defense, ie, the response is present and unchanging during the life of the organism and occurs in the same manner with every exposure to the pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/3\">",
"     3",
"    </a>",
"    ]. This is in contrast to specific or \"adaptive\" immunity (present only in vertebrates and mediated by lymphocytes), whereby the immune system response changes during the life of the host. Adaptive immune responses may be more vigorous (or suppressed) with each exposure to a pathogen depending upon encounters with that organism or others, and other conditions prevailing in the host. In vertebrates, although TLRs initiate protective functions that operate independently from adaptive immunity, they also modulate mechanisms having profound impact on the development of specific immune responses.",
"   </p>",
"   <p>",
"    Innate immunity is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16986?source=see_link\">",
"     \"An overview of the innate immune system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/12/16585?source=see_link\">",
"     \"Immunity of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9261997\">",
"    <span class=\"h1\">",
"     STRUCTURE AND FUNCTION OF TLRs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different species have different numbers of distinct TLRs; at least 10 have been discovered in humans (TLR1-10) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/1,2,4\">",
"     1,2,4",
"    </a>",
"    ]. With the exception of TLR2, TLRs initiate signaling by homodimerization. TLR2 forms heterodimers with TLR1 or TLR6. Receptor",
"    <span class=\"nowrap\">",
"     structure/organization,",
"    </span>",
"    ligands and signaling are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef61291 \" href=\"UTD.htm?31/49/32540\">",
"     table 1",
"    </a>",
"    ) and figure (",
"    <a class=\"graphic graphic_figure graphicRef57602 \" href=\"UTD.htm?39/45/40662\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The structure of all of the TLRs is similar. All have an extracellular ligand recognition and binding domain that contains leucine-rich repeats. All have a single transmembrane domain. The cytoplasmic (signaling) domain is homologous to the interleukin-1 receptor and is called a",
"    <span class=\"nowrap\">",
"     Toll/IL-1",
"    </span>",
"    receptor or TIR domain.",
"   </p>",
"   <p>",
"    The final common pathway for TLR signaling involves the transcription factors nuclear factor for the kappa light chain enhancer in B cells (NF-kappa B) and activating protein-1 (AP-1). These transcription factors regulate a multitude of genes, including those encoding important proinflammatory cytokines, such as tumor necrosis factor (TNF), IL-1 beta, IL-6, IL-8, and IL-12. Some TLRs also activate production of type 1 (alpha and beta) interferons by inducing the transcription factors interferon regulatory factors 3 and 7 (IRF3 and IRF7).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CELLULAR AND TISSUE DISTRIBUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;TLRs are differentially expressed on various leukocyte populations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Monocytes and macrophages express all TLRs except TLR3. Myeloid dendritic cells (MDCs) express TLRs 1, 2, 4, 5, 7, and 8, while plasmacytoid dendritic cells (PDCs) express TLRs 7 and 9. The TLRs 2, 4, 6, and 8 are found on mast cells. B cells express TLRs 3, 7, 9, and 10, while T cells express TLRs 3 and 9. A variety of tissue types may express one or more TLRs. As an example, the basolateral surfaces of intestinal epithelial cells express TLR5 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SIGNALING",
"    </span>",
"    &nbsp;&mdash;&nbsp;All TLRs except TLR3 utilize the cytoplasmic proximal signaling intermediate myeloid differentiation primary response protein 88 (MyD88), either by itself (TLRs 5, 7, 8, and 9) or together with the adapter molecule TIR domain-containing adapter protein (TIRAP, TLRs",
"    <span class=\"nowrap\">",
"     1/2,",
"    </span>",
"    <span class=\"nowrap\">",
"     2/6,",
"    </span>",
"    and 4) (",
"    <a class=\"graphic graphic_figure graphicRef57602 \" href=\"UTD.htm?39/45/40662\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/1,2,7\">",
"     1,2,7",
"    </a>",
"    ]. There is a MyD88 independent pathway via the molecule TIR domain-containing adapter inducing IFN beta (TRIF), which is used by TLR3 and TLR4 (the latter via the intermediate TRIF-related adapter molecule, or TRAM).",
"   </p>",
"   <p>",
"    The MyD88 adapter connects through interleukin-1 receptor associated kinases 1 and 4 (IRAK1, IRAK4), tumor necrosis factor receptor associated factor 6 (TRAF6), and transforming growth factor beta activated protein kinase 1 (TAK1) to the mitogen activated protein kinases (MAPKs). This complex kinase cascade culminates in activation of the family of heterodimeric transcription factors known as AP-1. These transcription factors regulate a broad array of genes influencing cell survival, activation, and proliferation.",
"   </p>",
"   <p>",
"    The TAK1 adapter may also lead to activation of the inhibitor of NF-kappa B kinase (IKK) and resultant activation of NF-kappa B. This is another family of heterodimeric transcription factors regulating many genes with important roles in immune responses as well as in the physiology of a broad array of other cell types . These include cytokines, chemokines and growth factors, lymphocyte receptors, adhesion molecules, acute phase reactants, and other transcription factors. TRAF6 may also interact with TRAF-family-member-associated NF-kappa B activator-binding kinase 1 (TBK1), which activates IRF3 and IRF7, leading to production of type 1 interferons.",
"   </p>",
"   <p>",
"    The TRIF adapter through receptor interacting protein 1 (RIP1) connects ultimately to activation of NF-kappa B, and also through TRAF6 to AP-1. TRIF, through TBK1, also activates the transcription factors IRF3 and IRF7.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     REGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the cell surface expression of TLRs and the intracellular consequences of TLR ligation are regulated by a variety of factors. These include exposure to microbial products, other TLR ligands, and cytokines. This regulation is highly complex and still incompletely understood and will not be discussed in depth here. Several reviews are available [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/8-11\">",
"     8-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SPECIFIC TLRS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ligands, cellular expression, signaling molecules utilized, and resultant cellular effects of ligation for each of the TLRs are summarized in tabular form (",
"    <a class=\"graphic graphic_table graphicRef61291 \" href=\"UTD.htm?31/49/32540\">",
"     table 1",
"    </a>",
"    ). Additional information is presented below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     TLR2/1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The heterodimer of TLR2 with TLR1 binds to cell wall components of bacteria and mycobacteria. TLR2 binds triacyl",
"    <span class=\"nowrap\">",
"     lipopeptide/lipoproteins",
"    </span>",
"    and some diacyl lipopeptides [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. It also interacts with porins of Neisseria [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/15\">",
"     15",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     TLR2/1",
"    </span>",
"    is expressed on MDCs and signals via the canonical MyD88 pathway with the TIRAP adapter. TLR2 also exists in a soluble form that can inhibit signaling via the membrane bound receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     TLR2/6",
"    </span>",
"    &nbsp;&mdash;&nbsp;The heterodimer of TLR2 with TLR6 displays a preference for recognizing diacyl lipopeptides, although it can recognize some triacyl lipopeptides [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     TLR2/6",
"    </span>",
"    is expressed on mast cells and it also signals via the canonical MyD88 pathway with the TIRAP adapter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     TLR3",
"    </span>",
"    &nbsp;&mdash;&nbsp;TLR3 binds double stranded RNA (dsRNA), which is produced in the replication of many viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/17\">",
"     17",
"    </a>",
"    ]. TLR3 may also bind to synthetic double stranded RNA, such as polyinosinic-polycytidylic acid (polyI:C) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/18\">",
"     18",
"    </a>",
"    ]. TLR3 is found within endolysosomes (membrane-bound intracellular compartments formed by the fusion of vesicles of internalized viral debris and lysosomes containing degradative enzymes) of B, T, and NK cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/19\">",
"     19",
"    </a>",
"    ]. It signals via a MyD88 independent pathway (TRIF) and induces production of type 1 IFN in addition to inflammatory cytokines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     TLR4",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal ligand for TLR4 is the lipopolysaccharide (LPS) of gram-negative bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/20\">",
"     20",
"    </a>",
"    ]. The interaction of LPS with TLR4 occurs in a complex with LPS binding protein (LBP), CD14, and a molecule called MD-2 (",
"    <a class=\"graphic graphic_figure graphicRef57602 \" href=\"UTD.htm?39/45/40662\">",
"     figure 1",
"    </a>",
"    ). Additional ligands include the fusion protein of respiratory syncytial virus (RSV), heat shock proteins of organisms, such as Chlamydia pneumoniae, and components of the extracellular matrix, such as fibronectin, hyaluronic acid, and heparan sulfate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. TLR4 is expressed on MDCs and mast cells and can signal via MyD88 with TIRAP. It may also induce type 1 IFN through the MyD88 independent pathway via TRAM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     TLR5",
"    </span>",
"    &nbsp;&mdash;&nbsp;TLR5 recognizes bacterial flagellin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/24\">",
"     24",
"    </a>",
"    ]. It is expressed on MDCs and transduces signals via MyD88.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     TLR7 AND 8",
"    </span>",
"    &nbsp;&mdash;&nbsp;TLR7 and TLR8 are very similar in their ligand binding and signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Both bind to single stranded RNA (ssRNA) from viruses, such as influenza and human immunodeficiency virus I (HIV-I). They also recognize imidazoquinolines (synthetic heterocyclic organic molecules), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    , and guanosine analogs, such as loxoribine. TLR7 is expressed on MDCs, PDCs, and B lymphocytes; TLR8 is expressed on MDCs and mast cells. Both signal directly via MyD88.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     TLR9",
"    </span>",
"    &nbsp;&mdash;&nbsp;TLR9 interacts with unmethylated cytosine guanine dinucleotides (CpG) motifs in microbial DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/28\">",
"     28",
"    </a>",
"    ]. TLR9 is expressed within endolysosomes of PDCs, B cells, and T cells, and signals directly via MyD88.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     TLR10",
"    </span>",
"    &nbsp;&mdash;&nbsp;The function of TLR10 is not yet known [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/29\">",
"     29",
"    </a>",
"    ]. It may homodimerize, or heterodimerize with TLR2 or TLR1. It is expressed within endolysosomes of B cells and signals via MyD88.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CELLULAR RESPONSES INDUCED BY TLRs",
"    </span>",
"    &nbsp;&mdash;&nbsp;TLR ligation of mononuclear cells may potentiate the microbicidal activity of phagocytic cells. As an example,",
"    <span class=\"nowrap\">",
"     TLR2/1",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     2/6",
"    </span>",
"    ligation by cell wall components of M. tuberculosis induces nitric oxide-dependent and other bactericidal mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/30\">",
"     30",
"    </a>",
"    ]. The same",
"    <span class=\"nowrap\">",
"     ligand/receptor",
"    </span>",
"    combination may also lead to apoptosis in macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/31\">",
"     31",
"    </a>",
"    ]. This mechanism could potentially limit the spread of microbes that are replicating intracellularly.",
"   </p>",
"   <p>",
"    Cells other than leukocytes also participate in innate immunity, or protection from invasion. Epithelial cells of the intestinal and respiratory tracts and the skin may express various TLRs. Stimulation with microbial products (LPS, etc.) induces production of antimicrobial peptides (defensins) active against a wide variety of different types of pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ligation of TLRs on dendritic cells potentiates their activity as inducers of T cell activation by increasing surface expression of important co-stimulatory molecules, such as CD80 and CD86, and the secretion of stimulatory cytokines, such as IL-12 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Different TLR ligands may lead to somewhat different cytokine responses, or may induce type 1 IFN and lead to activation of qualitatively different types of immune responses (eg, Th1 versus Th2 T cell differentiation) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/2\">",
"     2",
"    </a>",
"    ]. The response to various combinations of TLRs also depends on the relative amounts and types of TLRs on the cell surface, as well as other stimuli, and the developmental program of the target cell.",
"   </p>",
"   <p>",
"    Because pathogens co-evolved with their hosts, we (the host) have acquired sophisticated mechanisms for resistance; in turn, pathogens have developed strategies to circumvent many of them, including TLRs. For example, vaccinia virus encodes molecules with homology to TIR domains and can inhibit signaling via TLR3 and TLR4 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TLRs IN DISEASE PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a large and growing body of literature exploring associations of TLR biology with disease pathogenesis. Some examples are discussed in this section.",
"   </p>",
"   <p>",
"    A rapidly expanding area of research is the epidemiologic study of the many single nucleotide polymorphisms (SNPs) that have been identified in various TLR genes. Some early reports stated that certain variants of TLR2 and TLR4 were associated with impaired signaling after binding their natural ligands [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. SNPs in TLR1 have been associated with candidemia, and SNPS in TLR4, with invasive aspergillosis among recipients of hematopoietic cell transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, subsequent reports have challenged these findings and have stated that some of these polymorphisms do not have functional consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. It is not yet clear which is correct; perhaps the answer depends on the specific stimulus, the response that is measured, or other variables.",
"   </p>",
"   <p>",
"    Studies have attempted to link TLR polymorphisms with particular disease states, such as atherosclerosis and allergy, although the conclusions have been inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/45-53\">",
"     45-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Human immunodeficiency virus (HIV) infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest a correlation between progression of HIV infection and soluble TLR2 levels. One study reported a significant association of lower sTLR2 levels in patients who progressed to AIDS in comparison to non-progressors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/54\">",
"     54",
"    </a>",
"    ]. The level of sTLR2 rose after initiation of antiretroviral therapy. There was no correlation of sTLR2 level and viral load or CD4 count. A lower level of sTLR2 is expected to lead to enhanced signaling via cell-associated TLR2. How this might lead to progression of HIV infection is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Atherosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large body of evidence has accumulated that various infectious agents have epidemiologic links with atherosclerotic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/55\">",
"     55",
"    </a>",
"    ]. These include Chlamydia pneumoniae, H pylori, cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex, and hepatitis B and C [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/56\">",
"     56",
"    </a>",
"    ]. Chronic infection and serum LPS level have been identified as risk factors in a prospective study of the development of atherosclerotic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human atherosclerotic plaques contain endothelial cells and macrophages expressing",
"    <span class=\"nowrap\">",
"     TLR1/2",
"    </span>",
"    and TLR4 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/58\">",
"     58",
"    </a>",
"    ]. Minimally modified low-density lipoprotein is an agonist of TLR4 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/59\">",
"     59",
"    </a>",
"    ]. It binds independently of CD14 and MD-2 and can induce production of chemokines, such as IL-8. Animal data strongly suggest roles for TLRs (particularly TLR4) in recognizing foreign (microbial) and self (extracellular matrix, heat shock proteins) molecules, activating endothelial cells, and recruiting and activating monocytes and macrophages to form inflammatory foci that could lead to the formation of atheromatous plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Allergy and asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have found that exposure to bacterial products has been associated with protection from the development of allergic disease, and TLRs may be integral to the mechanisms involved. However, subsequent work suggests that this relationship may not be so straightforward.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An association between exposure to endotoxin, which forms complexes with TLR4, and protection from allergic sensitization was found in multiple studies. As an example, a report of 61 wheezing infants recorded significantly lower levels of endotoxin in the house dust of those with the highest degree of IgE sensitization to environmental allergens [",
"      <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/60\">",
"       60",
"      </a>",
"      ]. Another study showed that lipoteichoic acid, another component of bacterial cell walls, interacts with TLR2 to downregulate the receptor of IgE (FcEpsilonRI) on mast cells [",
"      <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a different model showed that activation of TLR4 on the surface of pulmonary epithelial cells seemed to promote the development of allergic airway responses and asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/62\">",
"       62",
"      </a>",
"      ]. In a mouse model, naturally occurring combinations of dust mite allergens and LPS were found to trigger epithelial cells through TLR4, leading to eosinophil recruitment and the production of the Th2 cytokines IL-5 and IL-13 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/62\">",
"       62",
"      </a>",
"      ]. Simultaneous inhalation of a TLR4 antagonist completely eliminated the effect. However, the dose of the TLR agonist also plays a role. In another study, low doses of endotoxin acting on TLR4 were observed to enhance Th2 inflammation in a mouse asthma model, whereas high doses induced a Th1 response [",
"      <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, activation of innate immune responses through TLRs appears to have critical impact on the early stages of allergic disease, although the nature of this influence requires further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Primary immunodeficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several known defects of molecules that transduce signals from TLRs. A variety of in vitro methods may be applied to test TLR function. Most measure inflammatory cytokine production (eg, IL-6, TNF) after stimulus with one or more TLR ligands (eg, bacterial lipopolysaccharide, an agonist of TLR4) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56801342\">",
"    <span class=\"h2\">",
"     Testing for TLR function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing of TLR function is becoming available through commercial reference laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/64\">",
"     64",
"    </a>",
"    ]. Tests of TLR function are very sensitive to the condition of the cells. Blood should be sent as soon as possible after collection, especially if it is to be shipped a long distance (ship ambient temperature, protect from heat or cold). If possible, the patient should be clinically well and not actively recovering from any serious illness (ie, well for at least a few weeks prior to testing). A shipping control from an unrelated healthy donor should accompany the specimen. Abnormal tests need to be confirmed by repeat testing. Persistently abnormal tests may be followed up by specific genetic tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5549320\">",
"    <span class=\"h3\">",
"     MyD88 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;All TLRs except TLR3 use the cytoplasmic proximal signaling intermediate MyD88 (myeloid differentiation primary response protein 88), either by itself or together with the adapter molecule",
"    <span class=\"nowrap\">",
"     Toll/IL1R",
"    </span>",
"    domain-containing adapter protein (TIRAP). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Signaling'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    MyD88 deficiency was initially described in nine children suffering from recurrent and severe pyogenic bacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/65\">",
"     65",
"    </a>",
"    ]. These children were susceptible to invasive infections with S. pneumoniae, S. aureus, and P. aeruginosa, but had normal resistance to other common bacteria, viruses, fungi, and parasites. Three children died before the age of one year, while another six were alive at ages 3 to 16 years at the time of publication. Susceptibility to infection improved with age in affected patients, although MyD88 levels did not change, indicating that the function of this adapter molecule becomes redundant as the immune system matures. The defect displayed autosomal recessive inheritance. MyD88 deficiency is clinically indistinguishable from IRAK-4 deficiency, since IRAK4 associates with MyD88 in signal transduction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     IRAK4 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficiency of IRAK4 (MIM 607676) impairs signaling from the TLRs that associate only with the MyD88 adapter. These include",
"    <span class=\"nowrap\">",
"     TLR2/1,",
"    </span>",
"    <span class=\"nowrap\">",
"     2/6,",
"    </span>",
"    and 5, 7, 8, and 9. TLR4 signals through MyD88, but can also make use of the",
"    <span class=\"nowrap\">",
"     TRAM/TRIF",
"    </span>",
"    pathway. TLR3 is unaffected. Signaling by the IL-1 receptor and T cell receptor activation are also impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical and laboratory features of this disorder are indistinguishable from MyD88 deficiency, since IRAK4 associates with MyD88 in signal transduction. Patients with IRAK4 deficiency have recurrent severe infections (cellulitis, arthritis, meningitis, osteomyelitis, organ abscesses, and sepsis) mainly caused by S. aureus, S. pneumoniae and Pseudomonas aeruginosa [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/66,68,69\">",
"     66,68,69",
"    </a>",
"    ]. One survey described 48 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/70\">",
"     70",
"    </a>",
"    ]. As a group, they experienced recurrent bacterial infections, mostly of the upper respiratory tract and skin. None had severe viral, fungal, or parasitic infections. Invasive pneumococcal infections caused the most morbidity and mortality, and were the cause of death in 33 percent. Initial invasive infections occurred before the age of two years in 88 percent.",
"   </p>",
"   <p>",
"    The clinical status of patients with IRAK-4 deficiency seems to improve with age, regardless of therapy, similar to patients with MyD88 defects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/66,71\">",
"     66,71",
"    </a>",
"    ]. In the largest series, no infectious deaths were reported in patients over the age of 8 years and no invasive infections after the age of 14 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum immunoglobulins are normal, specific antibody levels against polysaccharide antigens may be low or normal, and B cell subsets and function in vitro are normal. T cell responses to mitogens and recall antigens are also normal. Peripheral eosinophilia and elevated serum IgE may be observed. Peripheral blood mononuclear cells from patients with IRAK-4 deficiency do not produce TNF when stimulated via IL-1 or IL-18 receptors, or TLRs 2, 3, 4, 5, and 9. Western blot analysis may reveal absence of IRAK-4 protein.",
"   </p>",
"   <p>",
"    The diagnosis also can be made by measuring cytokine production by leukocytes activated by various TLR ligands (TLR function assay, available in at least one commercial laboratory) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/72\">",
"     72",
"    </a>",
"    ]. However, this test is not definitive for IRAK-4 deficiency, since other transduction defects of these pathways will also lead to abnormal results.",
"   </p>",
"   <p>",
"    Antibiotic or other therapy is dictated by specific pathogen sensitivity and the focus of infection. Antibiotic prophylaxis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immune globulin replacement may be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5549596\">",
"    <span class=\"h3\">",
"     UNC93B deficiency and TLR3 mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;UNC93B1 is an endoplasmic reticulum (ER) protein that is involved in the transport of the nucleotide-sensing TLR7 and TLR9 from the ER to endolysosomes. Signaling through TLRs 3, 7, 8, and 9 normally induces production of type 1 interferons following binding to viral RNA. Deficiency of UNC93B1 or TLR3 (MIM #610551 and #613002) leads to susceptibility to herpes simplex (HSV-1) encephalitis due to decreased production of interferons in the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/73-76\">",
"     73-76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1001?source=see_link&amp;anchor=H6#H6\">",
"     \"Herpes simplex virus type 1 encephalitis\", section on 'Host susceptibility'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     NEMO defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;NF-kappa B essential modulator (NEMO), also called the inhibitor of NF-kappa B kinase (IKK) gamma chain, is encoded by a gene on the X chromosome. NEMO is required for the proper function of IKK, which inactivates the inhibitor of NF-kappa B (I-kappa B). In the absence of IKK activity, I kappa-B remains bound to NF-kappa B, holding it in the cytoplasm in an inactive form and preventing its translocation to the nucleus to exert its transcriptional regulatory activities. Thus, in the absence of NEMO, NF-kappa B signaling is blocked, shutting down many pathways, including those originating from all of the TLRs.",
"   </p>",
"   <p>",
"    Mutations that permit partial function of NEMO cause an immunodeficiency in males characterized by extreme susceptibility to all classes of pathogens including opportunistic organisms, and ectodermal dysplasia in a majority (NF-kappa B also transduces signals from receptor systems important for the development of skin and its appendages). NEMO mutations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link&amp;anchor=H19#H19\">",
"     \"Combined immunodeficiencies\", section on 'NEMO and NFKBIA (IKBA) deficiencies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     I-kappa B defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;One patient has been found to have a mutation in the alpha subunit of the I-kappa B complex. This leads to constitutive activity of the inhibitor, and a partial block of NF-kappa B signaling. The phenotype is very similar to NEMO deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link&amp;anchor=H19#H19\">",
"     \"Combined immunodeficiencies\", section on 'NEMO and NFKBIA (IKBA) deficiencies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Common variable immunodeficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defects in the functioning of TLR7 and TLR9, normally prominent on B cells and dendritic cells, have been identified in patients with common variable immunodeficiency. These findings may be important in ultimately understanding the impaired B cell maturation that characterizes this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=see_link\">",
"     \"Pathogenesis of common variable immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     TLR-BASED THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several new therapies in use or development that utilize emerging knowledge of TLR biology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     TLR7 agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;TLR7 agonists have been found to be clinically useful in slowing the growth of malignancies and inhibiting viral replication. However, the precise mechanism of action of these agents remains unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Imiquimod",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    is a synthetic agonist of TLR7 that has been proven very effective as monotherapy for basal cell carcinoma, when applied topically as a 5 percent cream [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. It is also used in the treatment of actinic keratoses and genital warts. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Isatoribine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isatoribine is another synthetic TLR7 agonist. In 12 adults with chronic hepatitis C infection who were otherwise untreated, seven daily injections of isatoribine led to an average 0.76 log10 reduction in blood viral load measured by polymerase chain reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/79\">",
"     79",
"    </a>",
"    ]. The therapy was well tolerated, although the antiviral effect was modest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     TLR9 and CpG DNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Co-administration of oligodeoxynucleotides (ODN) containing CpG motifs during immunization enhances Th1 immune responses in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/80\">",
"     80",
"    </a>",
"    ]. These ODN mimic bacterial DNA sequences and interact with TLR9. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'TLR9'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    ODN are also being studied in human trials. Subcutaneous injection of ODN alone into healthy volunteers leads to readily measurable increases of serum Th1 type cytokine levels (IL-12, IFN alpha) as well as cytokines generally associated with Th2 activation (IL-6) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of an ODN added to a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    (Engerix-B), recipients of the vaccine with added ODN had significantly faster and higher hepatitis B surface antibody responses in comparison to controls who received the vaccine alone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/82\">",
"     82",
"    </a>",
"    ]. The recipients of the vaccine with ODN also had a significantly higher rate of adverse reactions; these were graded as mild to moderate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Cancer therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;CpG ODN are also being studied as agents for cancer therapy. These have been administered in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in a phase I trial in 20 patients with relapsed non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/83\">",
"     83",
"    </a>",
"    ]. The therapy was well tolerated. Increased levels of mRNA for interferon inducible genes were detected in the peripheral blood mononuclear cells of patients after receiving ODN.",
"   </p>",
"   <p>",
"    ODN have also been studied as an adjuvant for a cancer vaccine. Patients with newly diagnosed metastatic colon cancer and elevated serum carcinoembryonic antigen (CEA) levels were given a regimen combining chemotherapy with a cancer vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/84\">",
"     84",
"    </a>",
"    ]. The vaccine was comprised of a CEA-derived peptide with one of three adjuvants: ODN, G-CSF (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    ), or autologous dendritic cells. The vaccines were of apparently equivalent immunogenicity; 8 of 17 (47 percent) patients developed cytotoxic anti-CEA T cell responses, despite having received concomitant immunosuppressive chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Allergen immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coupling of an ODN to an allergen has been evaluated as possible immunotherapy for atopic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/85-87\">",
"     85-87",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one randomized trial, 19 adults allergic to ragweed received subcutaneous injections of a major ragweed pollen allergen (Amb a 1) coupled to an ODN [",
"      <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/85\">",
"       85",
"      </a>",
"      ]. The injections were well tolerated, and the investigators demonstrated in vitro a shift of the peripheral blood T cell cytokine secretion profile from Th2 (\"allergic\") to Th1 (\"non-allergic\").",
"     </li>",
"     <li>",
"      In two separate double-blind, placebo controlled trials of 57 adults [",
"      <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/86\">",
"       86",
"      </a>",
"      ] and 25 adults [",
"      <a class=\"abstract\" href=\"UTD.htm?22/54/23401/abstract/87\">",
"       87",
"      </a>",
"      ] with ragweed allergy, subjects were randomly assigned to treatment using similar preparations of ragweed pollen allergen coupled to ODN, given by subcutaneous injection. In both trials, patients reported clinical benefits for up to two successive ragweed pollen seasons following a course of only six injections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TLRs belong to a class of molecules known as pattern recognition receptors. The ligands for these receptors are components of pathogenic microbes called pathogen-associated molecular patterns (PAMPs). TLRs are part of the innate immune system, although they also modulate mechanisms that impact the development of adaptive immune responses. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TLRs are expressed on leukocytes and various solid tissue cells. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cellular and tissue distribution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The structure of all of the TLRs is similar. Receptor structure, organization, ligands, and signaling are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef61291 \" href=\"UTD.htm?31/49/32540\">",
"       table 1",
"      </a>",
"      ) and figure (",
"      <a class=\"graphic graphic_figure graphicRef57602 \" href=\"UTD.htm?39/45/40662\">",
"       figure 1",
"      </a>",
"      ). The final common pathway for TLR signaling involves transcription factors that regulate a multitude of genes, including those encoding important proinflammatory cytokines. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Signaling'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Specific TLRs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cellular responses induced by TLRs include both increased microbicidal activity and apoptosis of phagocytic cells, production of antimicrobial peptides (defensins), and increased surface expression of important co-stimulatory molecules. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Cellular responses induced by TLRs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of TLRs in inflammatory disease pathogenesis is unclear. Many single nucleotide polymorphisms have been identified in TLR genes, although the results of epidemiologic studies examining their associations with various diseases have been conflicting. TLRs have also been hypothesized to provide possible links between infectious agents and disease in conditions, such as atherosclerosis and allergy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'TLRs in disease pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Defects of molecules that transduce signals from TLRs, including MyD88 and IRAK4, have been implicated in primary immunodeficiency. UNC93B and TLR3 mutations have been identified in patients with selective susceptibility to herpes simplex virus encephalitis. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Primary immunodeficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TLR based therapies in development or in use include the TLR7 agonists",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      and isatoribine. In addition, ODN containing CpG motifs, presumably through binding to TLR9, have been found to augment Th1 immune responses, and have been applied to vaccination, cancer therapy, and immunotherapy for allergic disease. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'TLR-based therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/1\">",
"      Schnare M, Rollinghoff M, Qureshi S. Toll-like receptors: sentinels of host defence against bacterial infection. Int Arch Allergy Immunol 2006; 139:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/2\">",
"      Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun 2009; 388:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/3\">",
"      Gazzinelli RT, Denkers EY. Protozoan encounters with Toll-like receptor signalling pathways: implications for host parasitism. Nat Rev Immunol 2006; 6:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/4\">",
"      Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol 2006; 117:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/5\">",
"      Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002; 168:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/6\">",
"      Gewirtz AT, Navas TA, Lyons S, et al. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001; 167:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/7\">",
"      Beutler BA. TLRs and innate immunity. Blood 2009; 113:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/8\">",
"      Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/9\">",
"      Kawai T, Akira S. TLR signaling. Cell Death Differ 2006; 13:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/10\">",
"      Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/11\">",
"      Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/12\">",
"      Ozinsky A, Underhill DM, Fontenot JD, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A 2000; 97:13766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/13\">",
"      Buwitt-Beckmann U, Heine H, Wiesm&uuml;ller KH, et al. TLR1- and TLR6-independent recognition of bacterial lipopeptides. J Biol Chem 2006; 281:9049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/14\">",
"      Omueti KO, Beyer JM, Johnson CM, et al. Domain exchange between human toll-like receptors 1 and 6 reveals a region required for lipopeptide discrimination. J Biol Chem 2005; 280:36616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/15\">",
"      Massari P, Henneke P, Ho Y, et al. Cutting edge: Immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent. J Immunol 2002; 168:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/16\">",
"      LeBouder E, Rey-Nores JE, Rushmere NK, et al. Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol 2003; 171:6680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/17\">",
"      Schr&ouml;der M, Bowie AG. TLR3 in antiviral immunity: key player or bystander? Trends Immunol 2005; 26:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/18\">",
"      Tanabe M, Kurita-Taniguchi M, Takeuchi K, et al. Mechanism of up-regulation of human Toll-like receptor 3 secondary to infection of measles virus-attenuated strains. Biochem Biophys Res Commun 2003; 311:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/19\">",
"      Pisegna S, Pirozzi G, Piccoli M, et al. p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells. Blood 2004; 104:4157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/20\">",
"      Muroi M, Tanamoto K. Structural regions of MD-2 that determine the agonist-antagonist activity of lipid IVa. J Biol Chem 2006; 281:5484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/21\">",
"      Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/22\">",
"      Sasu S, LaVerda D, Qureshi N, et al. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res 2001; 89:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/23\">",
"      Johnson GB, Brunn GJ, Platt JL. Activation of mammalian Toll-like receptors by endogenous agonists. Crit Rev Immunol 2003; 23:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/24\">",
"      Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/25\">",
"      Heil F, Ahmad-Nejad P, Hemmi H, et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 2003; 33:2987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/26\">",
"      Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/27\">",
"      Lund JM, Alexopoulou L, Sato A, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 2004; 101:5598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/28\">",
"      Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001; 31:3026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/29\">",
"      Hasan U, Chaffois C, Gaillard C, et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol 2005; 174:2942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/30\">",
"      Thoma-Uszynski S, Stenger S, Takeuchi O, et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 2001; 291:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/31\">",
"      Aliprantis AO, Yang RB, Weiss DS, et al. The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J 2000; 19:3325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/32\">",
"      Ayabe T, Ashida T, Kohgo Y, Kono T. The role of Paneth cells and their antimicrobial peptides in innate host defense. Trends Microbiol 2004; 12:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/33\">",
"      Birchler T, Seibl R, B&uuml;chner K, et al. Human Toll-like receptor 2 mediates induction of the antimicrobial peptide human beta-defensin 2 in response to bacterial lipoprotein. Eur J Immunol 2001; 31:3131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/34\">",
"      Lehrer RI, Ganz T. Defensins of vertebrate animals. Curr Opin Immunol 2002; 14:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/35\">",
"      Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/36\">",
"      Bowie A, Kiss-Toth E, Symons JA, et al. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci U S A 2000; 97:10162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/37\">",
"      Harte MT, Haga IR, Maloney G, et al. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med 2003; 197:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/38\">",
"      Bochud PY, Hawn TR, Aderem A. Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. J Immunol 2003; 170:3451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/39\">",
"      Schmitt C, Humeny A, Becker CM, et al. Polymorphisms of TLR4: rapid genotyping and reduced response to lipopolysaccharide of TLR4 mutant alleles. Clin Chem 2002; 48:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/40\">",
"      Plantinga TS, Johnson MD, Scott WK, et al. Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. J Infect Dis 2012; 205:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/41\">",
"      Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008; 359:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/42\">",
"      von Aulock S, Schr&ouml;der NW, Gueinzius K, et al. Heterozygous toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J Infect Dis 2003; 188:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/43\">",
"      van der Graaf C, Kullberg BJ, Joosten L, et al. Functional consequences of the Asp299Gly Toll-like receptor-4 polymorphism. Cytokine 2005; 30:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/44\">",
"      Imahara SD, Jelacic S, Junker CE, O'Keefe GE. The TLR4 +896 polymorphism is not associated with lipopolysaccharide hypo-responsiveness in leukocytes. Genes Immun 2005; 6:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/45\">",
"      Ameziane N, Beillat T, Verpillat P, et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003; 23:e61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/46\">",
"      Edfeldt K, Bennet AM, Eriksson P, et al. Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction. Eur Heart J 2004; 25:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/47\">",
"      Zee RY, Hegener HH, Gould J, Ridker PM. Toll-like receptor 4 Asp299Gly gene polymorphism and risk of atherothrombosis. Stroke 2005; 36:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/48\">",
"      Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/49\">",
"      Kolek MJ, Carlquist JF, Muhlestein JB, et al. Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J 2004; 148:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/50\">",
"      Morange PE, Tiret L, Saut N, et al. TLR4/Asp299Gly, CD14/C-260T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: The PRIME Study. Eur J Hum Genet 2004; 12:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/51\">",
"      Fager&aring;s B&ouml;ttcher M, Hmani-Aifa M, Lindstr&ouml;m A, et al. A TLR4 polymorphism is associated with asthma and reduced lipopolysaccharide-induced interleukin-12(p70) responses in Swedish children. J Allergy Clin Immunol 2004; 114:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/52\">",
"      Adjers K, Karjalainen J, Pessi T, et al. Epistatic effect of TLR4 and IL4 genes on the risk of asthma in females. Int Arch Allergy Immunol 2005; 138:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/53\">",
"      Yang IA, Barton SJ, Rorke S, et al. Toll-like receptor 4 polymorphism and severity of atopy in asthmatics. Genes Immun 2004; 5:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/54\">",
"      Heggelund L, M&uuml;ller F, Lien E, et al. Increased expression of toll-like receptor 2 on monocytes in HIV infection: possible roles in inflammation and viral replication. Clin Infect Dis 2004; 39:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/55\">",
"      Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002; 105:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/56\">",
"      Michelsen KS, Doherty TM, Shah PK, Arditi M. TLR signaling: an emerging bridge from innate immunity to atherogenesis. J Immunol 2004; 173:5901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/57\">",
"      Kiechl S, Egger G, Mayr M, et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001; 103:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/58\">",
"      Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/59\">",
"      Walton KA, Hsieh X, Gharavi N, et al. Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J Biol Chem 2003; 278:29661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/60\">",
"      Gereda JE, Leung DY, Thatayatikom A, et al. Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitisation in infants at high risk of asthma. Lancet 2000; 355:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/61\">",
"      Yoshioka M, Fukuishi N, Iriguchi S, et al. Lipoteichoic acid downregulates FcepsilonRI expression on human mast cells through Toll-like receptor 2. J Allergy Clin Immunol 2007; 120:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/62\">",
"      Hammad H, Chieppa M, Perros F, et al. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med 2009; 15:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/63\">",
"      Dong L, Li H, Wang S, Li Y. Different doses of lipopolysaccharides regulate the lung inflammation of asthmatic mice via TLR4 pathway in alveolar macrophages. J Asthma 2009; 46:229.",
"     </a>",
"    </li>",
"    <li>",
"     Several commercial laboratories offer testing for TLR function. Examples in the United States include ViracorIBT and ARUP.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/65\">",
"      von Bernuth H, Picard C, Jin Z, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008; 321:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/66\">",
"      Picard C, von Bernuth H, Ghandil P, et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore) 2010; 89:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/67\">",
"      McDonald DR, Goldman F, Gomez-Duarte OD, et al. Impaired T-cell receptor activation in IL-1 receptor-associated kinase-4-deficient patients. J Allergy Clin Immunol 2010; 126:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/68\">",
"      Ku CL, Yang K, Bustamante J, et al. Inherited disorders of human Toll-like receptor signaling: immunological implications. Immunol Rev 2005; 203:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/69\">",
"      Picard C, Puel A, Bonnet M, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003; 299:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/70\">",
"      Ku CL, von Bernuth H, Picard C, et al. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med 2007; 204:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/71\">",
"      Bousfiha A, Picard C, Boisson-Dupuis S, et al. Primary immunodeficiencies of protective immunity to primary infections. Clin Immunol 2010; 135:204.",
"     </a>",
"    </li>",
"    <li>",
"     The Toll-like receptor function assay (#0051589). www.aruplab.com (Accessed on February 11, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/73\">",
"      Zhang SY, Jouanguy E, Ugolini S, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007; 317:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/74\">",
"      Casrouge A, Zhang SY, Eidenschenk C, et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 2006; 314:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/75\">",
"      Jouanguy E, Zhang SY, Chapgier A, et al. Human primary immunodeficiencies of type I interferons. Biochimie 2007; 89:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/76\">",
"      Zhang SY, Jouanguy E, Sancho-Shimizu V, et al. Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses. Immunol Rev 2007; 220:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/77\">",
"      Oldfield V, Keating GM, Perry CM. Imiquimod: in superficial basal cell carcinoma. Am J Clin Dermatol 2005; 6:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/78\">",
"      Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005; 152:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/79\">",
"      Horsmans Y, Berg T, Desager JP, et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005; 42:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/80\">",
"      Maletto BA, R&oacute;polo AS, Liscovsky MV, et al. CpG oligodeoxinucleotides functions as an effective adjuvant in aged BALB/c mice. Clin Immunol 2005; 117:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/81\">",
"      Krieg AM, Efler SM, Wittpoth M, et al. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 2004; 27:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/82\">",
"      Cooper CL, Davis HL, Morris ML, et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004; 24:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/83\">",
"      Friedberg JW, Kim H, McCauley M, et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005; 105:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/84\">",
"      Weihrauch MR, Ans&eacute;n S, Jurkiewicz E, et al. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin Cancer Res 2005; 11:5993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/85\">",
"      Simons FE, Shikishima Y, Van Nest G, et al. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 2004; 113:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/86\">",
"      Tulic MK, Fiset PO, Christodoulopoulos P, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004; 113:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23401/abstract/87\">",
"      Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355:1445.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3985 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-118.195.65.248-47B75F185E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_54_23401=[""].join("\n");
var outline_f22_54_23401=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9261997\">",
"      STRUCTURE AND FUNCTION OF TLRs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CELLULAR AND TISSUE DISTRIBUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SIGNALING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      REGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SPECIFIC TLRS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TLR2/1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TLR2/6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TLR3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TLR4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TLR5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TLR7 AND 8",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TLR9",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TLR10",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CELLULAR RESPONSES INDUCED BY TLRs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TLRs IN DISEASE PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Human immunodeficiency virus (HIV) infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Allergy and asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56801342\">",
"      Testing for TLR function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5549320\">",
"      - MyD88 deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - IRAK4 deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5549596\">",
"      - UNC93B deficiency and TLR3 mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - NEMO defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - I-kappa B defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Common variable immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      TLR-BASED THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      TLR7 agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Imiquimod",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Isatoribine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      TLR9 and CpG DNA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Vaccination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Allergen immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3985\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3985|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/45/40662\" title=\"figure 1\">",
"      TLR signaling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3985|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/49/32540\" title=\"table 1\">",
"      Essential features TL receptors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16986?source=related_link\">",
"      An overview of the innate immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=related_link\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1001?source=related_link\">",
"      Herpes simplex virus type 1 encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/12/16585?source=related_link\">",
"      Immunity of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=related_link\">",
"      Pathogenesis of common variable immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_54_23402="Treatment and prevention of Acinetobacter infection";
var content_f22_54_23402=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of Acinetobacter infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/54/23402/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/54/23402/contributors\">",
"     Zeina A Kanafani, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/54/23402/contributors\">",
"     Souha S Kanj, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/54/23402/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/54/23402/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/54/23402/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/54/23402/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/54/23402/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acinetobacter is a gram-negative coccobacillus that has emerged from an organism of questionable pathogenicity to an infectious agent of importance to hospitals worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/1\">",
"     1",
"    </a>",
"    ]. The organism has the ability to accumulate diverse mechanisms of resistance, leading to the emergence of strains that are resistant to all commercially available antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment and prevention of Acinetobacter infection will be reviewed here. The epidemiology, microbiology, and pathogenesis of Acinetobacter infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14103?source=see_link\">",
"     \"Epidemiology, microbiology and pathogenesis of Acinetobacter infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1210354\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF ANTIBIOTIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Antimicrobial resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acinetobacter has the ability to accumulate diverse mechanisms of resistance, which has led to emergence of strains that are resistant to all commercially available antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the 1980s, multidrug resistant strains have become increasingly common causes of nosocomial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. The term &ldquo;multidrug resistance&rdquo; in reference to Acinetobacter does not have a standard definition; it is sometimes used to denote resistance to three or more classes of drugs that would otherwise serve as treatments for Acinetobacter infections (eg, quinolones, cephalosporins, and carbapenems). The term &ldquo;pan-resistance&rdquo; has been used to describe Acinetobacter strains that are resistant to all standard antimicrobial agents tested (except",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 2009 report of surveillance data from more than 100 centers worldwide (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     Meropenem",
"    </a>",
"    Yearly Susceptibility Test Information Collection; MYSTIC), 61 percent of Acinetobacter isolates were resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    and 67 percent were resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/8\">",
"     8",
"    </a>",
"    ]. These results are significantly worse than those published in 2007 from the same reporting system (34 and 40 percent resistance, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/4\">",
"     4",
"    </a>",
"    ]. Carbapenem and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    susceptibility has decreased notably in this short span of time (92 versus 59 percent for tobramycin, and 86 to 92 versus 46 to 52 percent for carbapenems). &nbsp;",
"   </p>",
"   <p>",
"    Carbapenem-resistant strains are emerging worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]; resistance rates have reached 50 to 60 percent in some institutions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Heavy use of third generation cephalosporins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    , and imipenem has contributed to this problem [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/11,13\">",
"     11,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with infection due to resistant strains have higher mortality than patients with infection due to susceptible strains [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/14\">",
"     14",
"    </a>",
"    ]. Independent risk factors for colonization or infection with multidrug-resistant strains of Acinetobacter include previous colonization with methicillin-resistant Staphylococcus aureus (MRSA), beta-lactam use, bedridden status, previous intensive care, presence of a central venous catheter, surgery, mechanical ventilation, hemodialysis, and malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acinetobacter species are capable of accumulating multiple antibiotic resistance genes, leading to the development of multidrug-resistant or pan-resistant strains [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/7,17\">",
"     7,17",
"    </a>",
"    ]. Frequently expressed resistance mechanisms in nosocomial strains of Acinetobacter include beta-lactamases, alterations in cell-wall channels (porins) and efflux pumps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AmpC beta-lactamases are chromosomally encoded cephalosporinases intrinsic to all A. baumannii. Usually, such beta-lactamases have a low level of expression that does not cause clinically appreciable resistance; however, the addition of a promoter insertion sequence ISAba1 next the ampC gene increases beta-lactamase production, causing resistance to cephalosporins [",
"      <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/18\">",
"       18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The most troubling clinical resistance mechanism has been Acinetobacter&rsquo;s acquisition of beta-lactamases, including serine and metallo-beta-lactamases, which confer resistance to carbapenems [",
"      <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/19\">",
"       19",
"      </a>",
"      ]. Acquired extended-spectrum beta-lactamase carriage occurs in Acinetobacter but is not as widespread as in Klebsiella pneumoniae or Escherichia coli [",
"      <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Porin channels in A. baumannii are poorly characterized; it is known that reduced expression or mutations of bacterial porin proteins can hinder passage of beta-lactam antibiotics into the periplasmic space, leading to antibiotic resistance.",
"     </li>",
"     <li>",
"      Overexpression of bacterial efflux pumps can decrease the concentration of beta-lactam antibiotics in the periplasmic space. To cause clinical resistance in Acinetobacter, efflux pumps usually act in association with overexpression of AmpC beta-lactamases or carbapenemases. Efflux pumps can remove beta-lactam antibiotics as well as quinolones, tetracyclines,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"       chloramphenicol",
"      </a>",
"      , disinfectants, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"       tigecycline",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A. baumannii can become resistant to quinolones through mutations in the genes gyrA and parC, and can become resistant to aminoglycosides by expressing aminoglycoside-modifying enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of resistance of Acinetobacter to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    appears to be associated with a mutation in the genes encoding the PmrA and B proteins; additional regulatory factors remain to be determined [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heteroresistance, characterized by resistant subpopulations within a single strain, has been described in Acinetobacter strains [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17495?source=see_link&amp;anchor=H10046302#H10046302\">",
"     \"Overview of antibacterial susceptibility testing\", section on 'Heteroresistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Overview of antibiotic selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections caused by antibiotic-susceptible Acinetobacter isolates may be treated with broad-spectrum cephalosporins, combination",
"    <span class=\"nowrap\">",
"     beta-lactam/beta-lactamase",
"    </span>",
"    inhibitors (eg, a combination including sulbactam), or carbapenems (eg, imipenem or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    , although there are reports of discordant susceptibility to carbapenems) &ndash; either alone or in combination with an antipseudomonal fluoroquinolone or an aminoglycoside [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The duration of treatment is generally similar to that for infections caused by other gram-negative bacilli and depends on the site of infection. Dosing is summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef72436 \" href=\"UTD.htm?37/31/38396\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The beta-lactamase inhibitor sulbactam exhibits in vitro activity against more than 90 percent of Acinetobacter, including carbapenem-resistant strains [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/26\">",
"     26",
"    </a>",
"    ]. In the United States, sulbactam is available in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    and has been used for the treatment of drug-resistant Acinetobacter infections [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Data from observational studies suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    is comparable in efficacy to imipenem [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. However, caution is warranted with the use of ampicillin-sulbactam alone, since it can rapidly lead to the emergence of resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/5\">",
"     5",
"    </a>",
"    ]. Emergence of resistance during therapy has been observed with beta-lactams and cephalosporins [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For infections caused by multidrug-resistant isolates, antibiotic choices may be limited. Polymyxins (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"     polymyxin B",
"    </a>",
"    and polymyxin E &ndash;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    ) are active agents in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/31\">",
"     31",
"    </a>",
"    ]. These drugs are cationic detergents that disrupt bacterial cytoplasmic membranes, causing leakage of cytoplasmic contents [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/32\">",
"     32",
"    </a>",
"    ]. There are no randomized trials addressing their efficacy, largely because they are reserved for use in the setting of highly resistant organisms. Colistin has been used with some success for the treatment of Acinetobacter pneumonia, bacteremia, and meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Susceptibility testing should be performed if colistin is being considered as a therapeutic agent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/35\">",
"     35",
"    </a>",
"    ]. In one study, colistin-resistant strains paradoxically demonstrated enhanced susceptibility to most antibiotics tested and a reduced ability to form biofilm compared with colistin-susceptible strains [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/36\">",
"     36",
"    </a>",
"    ]. Adverse effects associated with systemic colistin include nephrotoxicity (up to 36 percent) and neurotoxicity (relatively uncommon; mostly paresthesias) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23031?source=see_link\">",
"     \"Colistin: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     Tigecycline",
"    </a>",
"    has activity against some multidrug-resistant strains of A. baumannii, although resistance has been reported and clinical experience is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/21,26,38-43\">",
"     21,26,38-43",
"    </a>",
"    ]. Susceptibility testing should be performed if tigecycline is being considered as a therapeutic agent. In a retrospective study of 21 patients with carbapenem-resistant Acinetobacter infections, tigecycline was used as monotherapy in seven patients and as part of a combination therapy in 14 patients. Most patients had surgical site infections followed by ventilator-associated pneumonia. A favorable response was attained in 81 percent of cases; ventilator-associated pneumonia was associated with worse outcome. Notably, clinical response did not predict microbiological response, highlighting the difficulty in eradicating this microorganism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Success has been observed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/36,45,46\">",
"     36,45,46",
"    </a>",
"    ]. Rifampin should not be administered as monotherapy as resistance develops quickly.",
"   </p>",
"   <p>",
"    In the setting of infection due to multidrug-resistant bacteria, treatment with a combination of antibiotics is appropriate. In vitro studies have demonstrated synergistic or additive effects by combining polymyxins with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , imipenem, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/11,45,47\">",
"     11,45,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1211118\">",
"    <span class=\"h1\">",
"     CLINICAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In humans, Acinetobacter can colonize skin, wounds, and the respiratory and gastrointestinal tracts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/48\">",
"     48",
"    </a>",
"    ]. The most frequent clinical manifestations of infection are ventilator-associated pneumonia and bloodstream infections [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/49\">",
"     49",
"    </a>",
"    ]. It may be difficult to distinguish between colonization and true infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition, colonization is a risk factor for subsequent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2008 report from the United States, the National Healthcare Safety Network (NHSN) reviewed the most frequent types of hospital-acquired infection in intensive care units due to gram-negative bacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/51\">",
"     51",
"    </a>",
"    ]. Acinetobacter species, most often A. baumannii, accounted for the following proportion of gram-negative isolates:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ventilator-associated pneumonia isolates &ndash; 8.4 percent",
"     </li>",
"     <li>",
"      Central line-associated bloodstream infection isolates &ndash; 2.2 percent",
"     </li>",
"     <li>",
"      Catheter-associated urinary tract infection isolates &ndash; 1.2 percent",
"     </li>",
"     <li>",
"      Surgical site infection isolates &ndash; 0.6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1211125\">",
"    <span class=\"h2\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acinetobacter pneumonia occurs predominantly in intensive care unit (ICU) patients who require mechanical ventilation and tends to be characterized by a late onset. Patients with pneumonia due to Acinetobacter spend more ventilator days in the ICU before detection of positive cultures than do patients with pneumonia due to other gram-negative bacilli or uninfected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coexisting conditions appear to be a major predictor of outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/6,52,53\">",
"     6,52,53",
"    </a>",
"    ]. One study noted higher mortality among patients with infection due to multidrug-resistant Acinetobacter than among patients infected with infection due to susceptible Acinetobacter strains or uninfected patients; however, when the severity of illness and underlying diseases were considered, the main difference was that patients with multidrug-resistant infection had longer hospital and ICU stays [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1211132\">",
"    <span class=\"h3\">",
"     Nosocomial pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nosocomial Acinetobacter pneumonia is associated with mortality rates of 35 to 70 percent, although attributable mortality is difficult to determine since most patients have concurrent life-threatening conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/34,52,54-56\">",
"     34,52,54-56",
"    </a>",
"    ]. Positive blood cultures and signs of sepsis usually portend a bad prognosis.",
"   </p>",
"   <p>",
"    Most cases of nosocomial Acinetobacter pneumonia occur in previously colonized patients. True Acinetobacter pneumonia must be distinguished from airway colonization in mechanically ventilated patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\", section on 'Quantitative culture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Empiric antibiotic therapy should be selected based on local susceptibility patterns; in general, it should consist of a broad spectrum cephalosporin, a combination",
"    <span class=\"nowrap\">",
"     beta-lactam/beta-lactamase",
"    </span>",
"    inhibitor (eg, a combination including sulbactam), or a carbapenem &ndash; either alone or in combination with an antipseudomonal fluoroquinolone or an aminoglycoside [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/57\">",
"     57",
"    </a>",
"    ]. Carbapenem monotherapy is reasonable in institutions where carbapenem resistance rates are low; there is no evidence for improved outcome with combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Dosing is summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef72436 \" href=\"UTD.htm?37/31/38396\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Once antimicrobial susceptibility data are available, directed therapy may include monotherapy with a carbapenem or beta-lactam, although resistance may emerge during therapy. In the setting of imipenem resistance,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    may be a useful alternative agent, since sulbactam has good activity against Acinetobacter in vitro. In one small observational series,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    -sulbactam appeared to be effective in patients with imipenem-resistant ventilator-associated pneumonia; further study is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration of therapy is similar to that for other causes of nosocomial pneumonia and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Duration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13413526\">",
"    <span class=\"h4\">",
"     Options for resistant organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of resistance to the above agents, therapeutic options are limited, although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    may be an effective alternative. In a meta-analysis of four studies (244 patients) evaluating treatment of ventilator-associated pneumonia due mainly to Acinetobacter baumannii but also Pseudomonas aeruginosa, clinical improvement rates, 28-day mortality, and ICU lengths of stay with intravenous colistin were similar to those observed with a comparator agent (carbapenem or high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/60\">",
"     60",
"    </a>",
"    ]. Among nine studies (178 patients) that did not include a comparator treatment, the pooled clinical response rate for intravenous colistin was 66 percent. However, one small series of 20 cases of nosocomial pneumonia that was not included in the analysis reported a success rate of only 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/33\">",
"     33",
"    </a>",
"    ]. Despite the limitations of the meta-analysis, including heterogeneity of the study design and patient populations evaluated, intravenous colistin remains an effective option for patients with colistin-sensitive Acinetobacter that is resistant to other agents.",
"   </p>",
"   <p>",
"    Nephrotoxicity is the most notorious adverse effect associated with systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    and has been reported in up to 36 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/37\">",
"     37",
"    </a>",
"    ], although in the meta-analysis above, intravenous colistin use was not associated with excess renal dysfunction compared with the other agents evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/60\">",
"     60",
"    </a>",
"    ]. Neurotoxicity is another important side effect but consists mainly of paresthesias and is relatively uncommon. Colistin dosing depends on the available preparation and should be adjusted in patients with impaired renal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23031?source=see_link&amp;anchor=H7#H7\">",
"     \"Colistin: An overview\", section on 'Systemic administration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    may be beneficial in select patients. Among three studies evaluating inhaled colistin as adjunctive therapy to intravenous antibiotics for ventilator-associated pneumonia with drug-resistant gram-negative bacilli, predominantly A. baumannii, the pooled response rate was 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/60\">",
"     60",
"    </a>",
"    ]. Although in one series of 17 patients with Acinetobacter pneumonia, clinical improvement with inhaled colistin without active systemic antibiotics was observed in 57 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/61\">",
"     61",
"    </a>",
"    ], we favor using inhaled colistin in such patients only with intravenous antibiotics. The main adverse effect of inhaled colistin is bronchoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/37\">",
"     37",
"    </a>",
"    ]. Dosing for inhaled colistin is 75 mg or 1 to 3 million units per nebulization every 12 hours. Inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"     polymyxin B",
"    </a>",
"    (500,000 IU twice daily) is an alternative agent; there are reports of successful treatment of multidrug-resistant infections with inhaled and systemic polymyxin B [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/62\">",
"     62",
"    </a>",
"    ], with or without the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (300 mg every eight hours orally or intravenously) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/45,61,62\">",
"     45,61,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23031?source=see_link&amp;anchor=H8#H8\">",
"     \"Colistin: An overview\", section on 'Inhaled administration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     Tigecycline",
"    </a>",
"    is also an acceptable agent in the setting of drug resistance; susceptibility testing should be performed if tigecycline is being considered as a therapeutic agent. In a multicenter study from Argentina, 73 patients with ventilator-associated pneumonia due to Acinetobacter were treated with tigecycline, with a success rate of around 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/63\">",
"     63",
"    </a>",
"    ]. However, tigecycline has been associated with an increased risk of all-cause mortality compared with other agents, most clearly among patients with hospital-acquired pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. In general, tigecycline should not be used in circumstances in which other effective antibiotic choices are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=see_link&amp;anchor=H14#H14\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\", section on 'Tigecycline versus other drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1211139\">",
"    <span class=\"h3\">",
"     Community-acquired pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-acquired Acinetobacter pneumonia is typically characterized by a fulminant illness with an abrupt onset and rapid progression to respiratory failure and hemodynamic instability [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/54,66,67\">",
"     54,66,67",
"    </a>",
"    ]. Septic shock ensues in around one-third of patients. This infection seems to be more common in Southeast Asia than in other regions and has been increasingly reported as a highly fatal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of community-acquired Acinetobacter pneumonia is as outlined in the preceding section for nosocomial Acinetobacter pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1211146\">",
"    <span class=\"h2\">",
"     Bloodstream infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acinetobacter accounts for 1.5 to 2.4 percent of nosocomial bloodstream infections [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/3,69,70\">",
"     3,69,70",
"    </a>",
"    ]. The most frequent sources of Acinetobacter bacteremia are vascular catheters and the respiratory tract [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/27,69,71\">",
"     27,69,71",
"    </a>",
"    ]. Less common sites include wounds and the urinary tract. In one study, approximately 36 percent of Acinetobacter infections were polymicrobial and included skin flora, suggesting that some blood isolates represented contamination from the skin or environment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Septic shock develops in up to one-third of patients with Acinetobacter bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/27,72\">",
"     27,72",
"    </a>",
"    ]; mortality ranges from 20 to 60 percent, although the mortality attributable to bacteremia is difficult to determine in the setting of multiple comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/27,69,71-74\">",
"     27,69,71-74",
"    </a>",
"    ]. Bacteremia associated with Acinetobacter pneumonia is associated with higher mortality than bacteremia associated with catheter infection (39 versus 4 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for Acinetobacter bloodstream infection include intensive care, mechanical ventilation, prior surgery, prior use of broad-spectrum antibiotics, immunosuppression, trauma, burns, malignancy, central venous catheters, invasive procedures, and prolonged hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/69-72,75-77\">",
"     69-72,75-77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of bloodstream infection due to Acinetobacter consists of antibiotic therapy and intravascular catheter removal [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of intravascular catheter-related infections\", section on 'Removal'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Empiric antibiotic therapy should be selected based on local susceptibility patterns; in general, it should consist of a broad spectrum cephalosporin, a combination",
"    <span class=\"nowrap\">",
"     beta-lactam/beta-lactamase",
"    </span>",
"    inhibitor (eg, a combination including sulbactam), or a carbapenem &ndash; either alone or in combination with an antipseudomonal fluoroquinolone or an aminoglycoside [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/57\">",
"     57",
"    </a>",
"    ]. Carbapenem monotherapy is reasonable in institutions where carbapenem resistance rates are low; there is no evidence for improved outcome with combination therapy. Dosing is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef72436 \" href=\"UTD.htm?37/31/38396\">",
"     table 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    Once antimicrobial susceptibility data are available, directed therapy may include monotherapy with a carbapenem or beta-lactam, although resistance may emerge during therapy. In the setting of imipenem resistance,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    may be a useful alternative agent, since sulbactam has good activity against Acinetobacter in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/27,29,70\">",
"     27,29,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of resistance to the above agents, therapeutic options are limited; options include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"     polymyxin B",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    (only for secondary bacteremia). Dosing is outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef72436 \" href=\"UTD.htm?37/31/38396\">",
"     table 1",
"    </a>",
"    ). In one report, treatment with colistin did not reduce mortality in patients with bacteremia due to multidrug-resistant Acinetobacter [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/79\">",
"     79",
"    </a>",
"    ]. These findings highlight the poor outcome of such patients, regardless of whether treatment for bacteremia is initiated.",
"   </p>",
"   <p>",
"    The duration of therapy is 10 to 14 days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of intravascular catheter-related infections\", section on 'Duration of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1211153\">",
"    <span class=\"h3\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acinetobacter spp are a rare cause of infective endocarditis in native and prosthetic heart valves [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/80-83\">",
"     80-83",
"    </a>",
"    ]. In a 1993 review of 171 patients with prosthetic heart valve endocarditis resulting from nosocomial bacteremia, two cases were attributable to Acinetobacter [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/84\">",
"     84",
"    </a>",
"    ]. Acinetobacter endocarditis is typically characterized by acute onset with an aggressive course. Mortality tends to be higher in the setting of native valve endocarditis than prosthetic valve endocarditis, likely because of the low index of suspicion leading to delayed treatment in such cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Empiric antibiotic therapy should be selected based on local susceptibility patterns; in general, it should consist of a broad spectrum cephalosporin, a combination",
"    <span class=\"nowrap\">",
"     beta-lactam/beta-lactamase",
"    </span>",
"    inhibitor (eg, a combination including sulbactam), or a carbapenem &ndash; either alone or in combination with an antipseudomonal fluoroquinolone or an aminoglycoside [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/57\">",
"     57",
"    </a>",
"    ]. Carbapenem monotherapy is reasonable in institutions where carbapenem resistance rates are low; there is no evidence for improved outcome with combination therapy. Dosing is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef72436 \" href=\"UTD.htm?37/31/38396\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Once antimicrobial susceptibility data are available, directed therapy may include monotherapy with a carbapenem or beta-lactam, although resistance may emerge during therapy. In the setting of imipenem resistance,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    may be a useful alternative agent, since sulbactam has good activity against Acinetobacter in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/27,29,70\">",
"     27,29,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of resistance to the above agents, therapeutic options are limited; options include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"     polymyxin B",
"    </a>",
"    . Dosing is outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef72436 \" href=\"UTD.htm?37/31/38396\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Additional issues related to the treatment of endocarditis are outlined separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link\">",
"     \"Antimicrobial therapy of native valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=see_link\">",
"     \"Antimicrobial therapy of prosthetic valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link\">",
"     \"Surgery for native valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3591?source=see_link\">",
"     \"Surgery for prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1211160\">",
"    <span class=\"h2\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acinetobacter is an infrequent cause of nosocomial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/85-87\">",
"     85-87",
"    </a>",
"    ]. Among 95 cases of meningitis following craniotomy, two were due to Acinetobacter spp [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/85\">",
"     85",
"    </a>",
"    ]. Risk factors include neurosurgical procedures, cerebrospinal fluid (CSF) leak, prior antibiotic therapy, and intracranial hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. Nosocomial outbreaks of Acinetobacter meningitis have been reported in association with the intrathecal administration of contaminated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/91\">",
"     91",
"    </a>",
"    ] and with contaminated suctioning equipment in a neurosurgical unit [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/92\">",
"     92",
"    </a>",
"    ]. Mortality ranges from 20 to 30 percent; neurologic deficits in surviving patients can be severe [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/86,90,93\">",
"     86,90,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Community-acquired Acinetobacter meningitis is rare; it primarily occurs in previously healthy individuals in warm climates, and is usually not drug resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with Acinetobacter meningitis present with fever, meningeal signs,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seizures. Cerebral spinal fluid (CSF) typically demonstrates pleocytosis with neutrophilic predominance, elevated protein concentration, and a low CSF-to-serum glucose ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25930?source=see_link\">",
"     \"Diagnosis and treatment of gram-negative bacillary meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Skin contamination with Acinetobacter can be mistaken for true infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/89,95\">",
"     89,95",
"    </a>",
"    ]. In a retrospective analysis of 54 patients with CSF cultures growing Acinetobacter, the organism was considered clinically insignificant in 34 (63 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/89\">",
"     89",
"    </a>",
"    ]. The isolation of Acinetobacter from multiple CSF specimens and the typical clinical and laboratory findings of bacterial meningitis were highly suggestive of true infection.",
"   </p>",
"   <p>",
"    Treatment of meningitis due to Acinetobacter consists of antimicrobial therapy and removal of CNS devices, if present [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/88\">",
"     88",
"    </a>",
"    ]. Empiric antibiotic therapy should be selected based on local susceptibility patterns; in general, it should consist of a broad spectrum cephalosporin, a combination",
"    <span class=\"nowrap\">",
"     beta-lactam/beta-lactamase",
"    </span>",
"    inhibitor (eg, a combination including sulbactam), or a carbapenem &ndash; either alone or in combination with an aminoglycoside [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/30,96,97\">",
"     30,96,97",
"    </a>",
"    ]. Carbapenem monotherapy is reasonable in institutions where carbapenem resistance rates are low; there is no evidence for improved outcome with combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Dosing is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef72436 \" href=\"UTD.htm?37/31/38396\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Once antimicrobial susceptibility data are available, directed therapy may include monotherapy with a carbapenem or beta-lactam, although beta-lactam resistance may emerge during therapy. In the setting of imipenem resistance,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    may be a useful alternative agent, since sulbactam has good activity against Acinetobacter in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/27,29,70,87,98\">",
"     27,29,70,87,98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     Colistin",
"    </a>",
"    may be administered intravenously, which results in moderate penetration of inflamed meninges and spinal fluid levels approximately 25 percent of serum levels [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/33,99\">",
"     33,99",
"    </a>",
"    ]. Colistin can also be administered intraventricularly or intrathecally, usually in conjunction with an active intravenous agent, if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/93,100-103\">",
"     93,100-103",
"    </a>",
"    ]. The dose range of intraventricular or intrathecal colistin therapy has varied widely from 2 to 20 mg (25,000 to 250,000 IU) once daily to 5 to 10 mg (62,500 to 125,000 IU) twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/93\">",
"     93",
"    </a>",
"    ]. Complications of intraventricular and intrathecal colistin include aseptic chemical meningitis or ventriculitis; dose reduction is required as the CSF white blood cell count increases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/93\">",
"     93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25930?source=see_link&amp;anchor=H22#H22\">",
"     \"Diagnosis and treatment of gram-negative bacillary meningitis\", section on 'Intrathecal and intraventricular therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of Acinetobacter meningitis is usually at least three weeks. The response should be assessed clinically and with repeat CSF cultures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1211167\">",
"    <span class=\"h2\">",
"     Skin, soft tissue, and bone infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acinetobacter may contaminate surgical and traumatic wounds, leading to severe soft tissue infection that can also progress to osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/104\">",
"     104",
"    </a>",
"    ]. Surgical wound infections with Acinetobacter are frequently related to the presence of prosthetic material and usually require extensive debridement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/105\">",
"     105",
"    </a>",
"    ]. In rare cases, Acinetobacter has been associated with community-acquired or nosocomial skin infections such as cellulitis and folliculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/105-107\">",
"     105-107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Traumatic wound infections due to multidrug-resistant Acinetobacter complex have been increasingly recognized after war injuries; environmental contamination of field hospitals appears to play an important role in these infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14103?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, microbiology and pathogenesis of Acinetobacter infection\", section on 'Wars and natural disasters'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of Acinetobacter soft tissue infection consists of debridement and antimicrobial therapy guided by susceptibility testing. Appropriate agents include a broad spectrum cephalosporin, a combination",
"    <span class=\"nowrap\">",
"     beta-lactam/beta-lactamase",
"    </span>",
"    inhibitor (eg, a combination including sulbactam), or a carbapenem [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/57\">",
"     57",
"    </a>",
"    ]. Dosing is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef72436 \" href=\"UTD.htm?37/31/38396\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Once antimicrobial susceptibility data are available, directed therapy may include monotherapy with a carbapenem or beta-lactam, though beta-lactam resistance may emerge during therapy. In the setting of imipenem resistance,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    may be a useful alternative agent, since sulbactam has good activity against Acinetobacter in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of resistance to the above agents, therapeutic options are limited; options include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"     polymyxin B",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    . Dosing is outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef72436 \" href=\"UTD.htm?37/31/38396\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The usual duration of therapy for skin and soft tissue infections is 10 to 14 days or until local signs of infection have resolved. Patients with osteomyelitis should be treated for 4 to 6 weeks following surgical debridement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1211174\">",
"    <span class=\"h2\">",
"     Urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urinary tract can become colonized readily with Acinetobacter, particularly in the setting of indwelling urinary catheters; the incidence of infection is low [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/3,109\">",
"     3,109",
"    </a>",
"    ]. In a review of 5000 urinary tract infections in medical intensive care units in the United States, 1.6 percent was due to Acinetobacter; 95 percent of these infections were associated with urinary catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/3\">",
"     3",
"    </a>",
"    ]. Community-acquired urinary tract infection can occur but is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/110,111\">",
"     110,111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of other signs or symptoms of infection, isolation of Acinetobacter may be attributed to colonization. Treatment for infection should be initiated if a positive culture is accompanied by pyuria and systemic signs or symptoms in the absence of another source of infection.",
"   </p>",
"   <p>",
"    Treatment consists of catheter removal and antimicrobial therapy guided by susceptibility testing. Appropriate agents include a broad spectrum cephalosporin, a combination",
"    <span class=\"nowrap\">",
"     beta-lactam/beta-lactamase",
"    </span>",
"    inhibitor (eg, a combination including sulbactam), a carbapenem, an antipseudomonal fluoroquinolone, or an aminoglycoside. In the setting of drug resistance,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    are acceptable alternative agents. However, tigecycline has poor excretion in the urinary tract. Given this, along with the observed increased risk of mortality with tigecycline use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/64,65\">",
"     64,65",
"    </a>",
"    ], this agent should only be used when no other options are available. Dosing is outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef72436 \" href=\"UTD.htm?37/31/38396\">",
"     table 1",
"    </a>",
"    ). The duration of therapy is for 10 to 14 days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=see_link&amp;anchor=H7#H7\">",
"     \"Urinary tract infection associated with urethral catheters\", section on 'Urinary tract infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1211181\">",
"    <span class=\"h2\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acinetobacter can cause colonization or infection of the eye. Colonization has been observed in contact lens wearers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/112\">",
"     112",
"    </a>",
"    ]. Infection can include corneal ulcers, endophthalmitis, periorbital cellulitis, and infection after penetrating trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/113-118\">",
"     113-118",
"    </a>",
"    ]. In one series including 750 cases of corneal ulcers, Acinetobacter was the third most common cause, accounting for 7 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/115\">",
"     115",
"    </a>",
"    ]. Most infections occurred postoperatively, usually following cataract surgery or other ocular surgeries. Treatment consists of topical or subconjunctival ophthalmic antibiotic preparations, guided by susceptibility results. The duration of treatment is generally similar to that for infections caused by other gram-negative bacilli and depends on the site of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=see_link\">",
"     \"Bacterial endophthalmitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link\">",
"     \"Orbital cellulitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acinetobacter can cause nosocomial sinusitis in patients admitted to the intensive care unit; mechanical ventilation is the most important predisposing factor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. Acinetobacter sinusitis has been associated with the development of pneumonia, as the infected sinuses serve as reservoirs for dissemination to the lower respiratory tract [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/119\">",
"     119",
"    </a>",
"    ]. Treatment of Acinetobacter sinusitis consists of nasal tube removal and sinus drainage and lavage. The approach to antimicrobial therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=see_link&amp;anchor=H11974598#H11974598\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Treatment\", section on 'Antimicrobials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acinetobacter peritonitis has been described in patients undergoing peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/121-123\">",
"     121-123",
"    </a>",
"    ]. The most common manifestations are abdominal pain and a cloudy dialysate. The management of peritonitis in patients undergoing peritoneal dialysis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=see_link\">",
"     \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREVENTION AND CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals for control of multidrug-resistant Acinetobacter are early recognition, aggressive control of spread, and preventing establishment of endemic strains. Multidrug-resistant Acinetobacter remains largely susceptible to disinfectants and antiseptics; occasional reports of failure are more likely to represent failure of personnel to follow cleaning procedures than disinfectant resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Control is most successful when a common source is identified and eliminated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/1,125\">",
"     1,125",
"    </a>",
"    ]. Aggressive and monitored cleaning of environmental reservoirs (using ultraviolet markers of cleaning efficacy) is also important [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/125\">",
"     125",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     Hydrogen peroxide",
"    </a>",
"    vapor was found to be an effective decontamination method [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/126\">",
"     126",
"    </a>",
"    ]. When neither common sources nor environmental reservoirs are identified, control depends on active surveillance, contact isolation, health care worker compliance with hand hygiene, and aseptic care of vascular catheters and endotracheal tubes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/54/23402/abstract/125,127\">",
"     125,127",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1214596\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acinetobacter species are capable of accumulating multiple antibiotic resistance genes, leading to the development of multidrug-resistant strains (resistance to three or more classes of drugs that would otherwise be effective antibiotics for Acinetobacter infections) or pan-resistant strains (resistance to all standard antimicrobial agents tested except",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"       colistin",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Antimicrobial resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In humans, Acinetobacter can colonize skin, wounds, and the respiratory and gastrointestinal tracts. The most frequent clinical manifestations of infection are ventilator-associated pneumonia and bloodstream infections. Less frequent manifestations include meningitis, skin and soft tissue infections, and urinary tract infections. (See",
"      <a class=\"local\" href=\"#H1211118\">",
"       'Clinical approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Empiric antibiotic therapy should be selected based on local susceptibility patterns. In general, infections may be treated with broad spectrum cephalosporins, combination",
"      <span class=\"nowrap\">",
"       beta-lactam/beta-lactamase",
"      </span>",
"      inhibitors (eg, a combination including sulbactam), or carbapenems &ndash; either alone or in combination with an antipseudomonal fluoroquinolone or an aminoglycoside. Dosing is summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef72436 \" href=\"UTD.htm?37/31/38396\">",
"       table 1",
"      </a>",
"      ). Once susceptibility data are available, directed monotherapy may be administered. The duration of treatment is generally similar to that for infections caused by other gram-negative bacilli and depends on the site of infection. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Overview of antibiotic selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For infections caused by multidrug-resistant isolates, antibiotic choices may be limited. Options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"       polymyxin B",
"      </a>",
"      , polymyxin E (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"       colistin",
"      </a>",
"      ) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"       tigecycline",
"      </a>",
"      . Inhaled colistin may be added to systemic therapy in selected patients for treatment of Acinetobacter pneumonia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Overview of antibiotic selection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1211132\">",
"       'Nosocomial pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals for control of multidrug-resistant Acinetobacter are early recognition, aggressive control of spread, and preventing establishment of endemic strains. Control depends on identification of common sources and environmental reservoirs. If this is not possible, attention to active surveillance, contact isolation, health care worker compliance with hand hygiene, and aseptic care of vascular catheters and endotracheal tubes are needed. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prevention and control'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/1\">",
"      Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/2\">",
"      Lolans K, Rice TW, Munoz-Price LS, Quinn JP. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 2006; 50:2941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/3\">",
"      Gaynes R, Edwards JR, National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/4\">",
"      Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis 2007; 57:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/5\">",
"      Tatman-Otkun M, G&uuml;rcan S, Ozer B, Shokrylanbaran N. Annual trends in antibiotic resistance of nosocomial Acinetobacter baumannii strains and the effect of synergistic antibiotic combinations. New Microbiol 2004; 27:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/6\">",
"      Sunenshine RH, Wright MO, Maragakis LL, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007; 13:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/7\">",
"      Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43 Suppl 2:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/8\">",
"      Rhomberg PR, Jones RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 2009; 65:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/9\">",
"      Pournaras S, Markogiannakis A, Ikonomidis A, et al. Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit. J Antimicrob Chemother 2006; 57:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/10\">",
"      Playford EG, Craig JC, Iredell JR. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect 2007; 65:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/11\">",
"      Manikal VM, Landman D, Saurina G, et al. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000; 31:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/12\">",
"      Peleg AY, Franklin C, Bell JM, Spelman DW. Emergence of carbapenem resistance in Acinetobacter baumannii recovered from blood cultures in Australia. Infect Control Hosp Epidemiol 2006; 27:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/13\">",
"      Corbella X, Montero A, Pujol M, et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 2000; 38:4086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/14\">",
"      Lee NY, Lee HC, Ko NY, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2007; 28:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/15\">",
"      Tacconelli E, Cataldo MA, De Pascale G, et al. Prediction models to identify hospitalized patients at risk of being colonized or infected with multidrug-resistant Acinetobacter baumannii calcoaceticus complex. J Antimicrob Chemother 2008; 62:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/16\">",
"      Dizbay M, Tunccan OG, Sezer BE, Hizel K. Nosocomial imipenem-resistant Acinetobacter baumannii infections: epidemiology and risk factors. Scand J Infect Dis 2010; 42:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/17\">",
"      Hsueh PR, Teng LJ, Chen CY, et al. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis 2002; 8:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/18\">",
"      Mugnier P, Poirel L, Pitout M, Nordmann P. Carbapenem-resistant and OXA-23-producing Acinetobacter baumannii isolates in the United Arab Emirates. Clin Microbiol Infect 2008; 14:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/19\">",
"      Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43 Suppl 2:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/20\">",
"      Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005; 352:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/21\">",
"      Peleg AY, Adams J, Paterson DL. Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/22\">",
"      Adams MD, Nickel GC, Bajaksouzian S, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 2009; 53:3628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/23\">",
"      Superti SV, Martins Dde S, Caier&atilde;o J, et al. Indications of carbapenem resistance evolution through heteroresistance as an intermediate stage in Acinetobacter baumannii after carbapenem administration. Rev Inst Med Trop Sao Paulo 2009; 51:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/24\">",
"      Bergogne-B&eacute;r&eacute;zin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/25\">",
"      Lesho E, Wortmann G, Moran K, Craft D. Fatal Acinetobacter baumannii infection with discordant carbapenem susceptibility. Clin Infect Dis 2005; 41:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/26\">",
"      Henwood CJ, Gatward T, Warner M, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/27\">",
"      Cisneros JM, Reyes MJ, Pach&oacute;n J, et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996; 22:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/28\">",
"      Smolyakov R, Borer A, Riesenberg K, et al. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. J Hosp Infect 2003; 54:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/29\">",
"      Jellison TK, Mckinnon PS, Rybak MJ. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. Pharmacotherapy 2001; 21:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/30\">",
"      N&uacute;&ntilde;ez ML, Mart&iacute;nez-Toldos MC, Bru M, et al. Appearance of resistance to meropenem during the treatment of a patient with meningitis by Acinetobacter. Scand J Infect Dis 1998; 30:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/31\">",
"      Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006; 43 Suppl 2:S89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/32\">",
"      Horton J, Pankey GA. Polymyxin B, colistin, and sodium colistimethate. Med Clin North Am 1982; 66:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/33\">",
"      Levin AS, Barone AA, Pen&ccedil;o J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/34\">",
"      Garnacho-Montero J, Ortiz-Leyba C, Jim&eacute;nez-Jim&eacute;nez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/35\">",
"      Due&ntilde;as D&iacute;ez AI, Bratos P&eacute;rez MA, Eiros Bouza JM, et al. Susceptibility of the Acinetobacter calcoaceticus-A. baumannii complex to imipenem, meropenem, sulbactam and colistin. Int J Antimicrob Agents 2004; 23:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/36\">",
"      Li J, Nation RL, Owen RJ, et al. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 2007; 45:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/37\">",
"      Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006; 10:R27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/38\">",
"      Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007; 59:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/39\">",
"      Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J Infect 2007; 55:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/40\">",
"      Seifert H, Stefanik D, Wisplinghoff H. Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother 2006; 58:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/41\">",
"      Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008; 62:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/42\">",
"      Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 59:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/43\">",
"      Anthony KB, Fishman NO, Linkin DR, et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/44\">",
"      Metan G, Alp E, Yildiz O, et al. Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections. J Chemother 2010; 22:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/45\">",
"      Motaouakkil S, Charra B, Hachimi A, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006; 53:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/46\">",
"      Bassetti M, Repetto E, Righi E, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008; 61:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/47\">",
"      Saballs M, Pujol M, Tubau F, et al. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2006; 58:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/48\">",
"      Albrecht MC, Albrecht MA, Griffith ME, et al. Impact of Acinetobacter infection on the mortality of burn patients. J Am Coll Surg 2006; 203:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/49\">",
"      Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008; 358:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/50\">",
"      Struelens MJ, Carlier E, Maes N, et al. Nosocomial colonization and infection with multiresistant Acinetobacter baumannii: outbreak delineation using DNA macrorestriction analysis and PCR-fingerprinting. J Hosp Infect 1993; 25:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/51\">",
"      Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/52\">",
"      Garnacho-Montero J, Ortiz-Leyba C, Fern&aacute;ndez-Hinojosa E, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005; 31:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/53\">",
"      Garnacho J, Sole-Violan J, Sa-Borges M, et al. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 2003; 31:2478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/54\">",
"      Leung WS, Chu CM, Tsang KY, et al. Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome. Chest 2006; 129:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/55\">",
"      Fagon JY, Chastre J, Domart Y, et al. Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis 1996; 23:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/56\">",
"      Fagon JY, Chastre J, Hance AJ, et al. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993; 94:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/57\">",
"      American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/58\">",
"      Bernabeu-Wittel M, Pichardo C, Garc&iacute;a-Curiel A, et al. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin Microbiol Infect 2005; 11:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/59\">",
"      Wood GC, Hanes SD, Croce MA, et al. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002; 34:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/60\">",
"      Florescu DF, Qiu F, McCartan MA, et al. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012; 54:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/61\">",
"      Kwa AL, Loh C, Low JG, et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005; 41:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/62\">",
"      Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis 2007; 58:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/63\">",
"      Curcio D, Fern&aacute;ndez F, Vergara J, et al. Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline. J Chemother 2009; 21:58.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. file://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (Accessed on July 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/65\">",
"      Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/66\">",
"      Anstey NM, Currie BJ, Hassell M, et al. Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii, with carriage in the throat in at-risk groups. J Clin Microbiol 2002; 40:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/67\">",
"      Chen MZ, Hsueh PR, Lee LN, et al. Severe community-acquired pneumonia due to Acinetobacter baumannii. Chest 2001; 120:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/68\">",
"      Ong CW, Lye DC, Khoo KL, et al. Severe community-acquired Acinetobacter baumannii pneumonia: an emerging highly lethal infectious disease in the Asia-Pacific. Respirology 2009; 14:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/69\">",
"      Wisplinghoff H, Edmond MB, Pfaller MA, et al. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis 2000; 31:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/70\">",
"      Cisneros JM, Rodr&iacute;guez-Ba&ntilde;o J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect 2002; 8:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/71\">",
"      Chen HP, Chen TL, Lai CH, et al. Predictors of mortality in Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 2005; 38:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/72\">",
"      Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 1995; 74:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/73\">",
"      Grupper M, Sprecher H, Mashiach T, Finkelstein R. Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol 2007; 28:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/74\">",
"      Lee YT, Kuo SC, Yang SP, et al. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis 2012; 55:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/75\">",
"      Garc&iacute;a-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, et al. Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis 2001; 33:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/76\">",
"      G&oacute;mez J, Simarro E, Ba&ntilde;os V, et al. Six-year prospective study of risk and prognostic factors in patients with nosocomial sepsis caused by Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 1999; 18:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/77\">",
"      Tilley PA, Roberts FJ. Bacteremia with Acinetobacter species: risk factors and prognosis in different clinical settings. Clin Infect Dis 1994; 18:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/78\">",
"      Hanna H, Afif C, Alakech B, et al. Central venous catheter-related bacteremia due to gram-negative bacilli: significance of catheter removal in preventing relapse. Infect Control Hosp Epidemiol 2004; 25:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/79\">",
"      Lim SK, Lee SO, Choi SH, et al. The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections. J Korean Med Sci 2011; 26:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/80\">",
"      Gradon JD, Chapnick EK, Lutwick LI. Infective endocarditis of a native valve due to Acinetobacter: case report and review. Clin Infect Dis 1992; 14:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/81\">",
"      Valero C, Fari&ntilde;as MC, Garc&iacute;a Palomo D, et al. Endocarditis due to Acinetobacter lwoffi on native mitral valve. Int J Cardiol 1999; 69:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/82\">",
"      Rizos I, Tsiodras S, Papathanasiou S, et al. Prosthetic valve endocarditis due to Acinetobacter spp: a rare case and literature review. Am J Med Sci 2007; 333:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/83\">",
"      Malik AS. Acinetobacter endocarditis in children: a case report and review of the literature. Infection 1995; 23:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/84\">",
"      Fang G, Keys TF, Gentry LO, et al. Prosthetic valve endocarditis resulting from nosocomial bacteremia. A prospective, multicenter study. Ann Intern Med 1993; 119:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/85\">",
"      Korinek AM, Baugnon T, Golmard JL, et al. Risk factors for adult nosocomial meningitis after craniotomy: role of antibiotic prophylaxis. Neurosurgery 2006; 59:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/86\">",
"      Chen SF, Chang WN, Lu CH, et al. Adult Acinetobacter meningitis and its comparison with non-Acinetobacter gram-negative bacterial meningitis. Acta Neurol Taiwan 2005; 14:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/87\">",
"      Levin AS, Levy CE, Manrique AE, et al. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents 2003; 21:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/88\">",
"      Rodr&iacute;guez Guardado A, Maradona JA, Asensi V, et al. [Postsurgical meningitis caused by Acinetobacter baumannii: study of 22 cases and review of the literature]. Rev Clin Esp 2001; 201:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/89\">",
"      Chen HP, Lai CH, Chan YJ, et al. Clinical significance of Acinetobacter species isolated from cerebrospinal fluid. Scand J Infect Dis 2005; 37:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/90\">",
"      Siegman-Igra Y, Bar-Yosef S, Gorea A, Avram J. Nosocomial acinetobacter meningitis secondary to invasive procedures: report of 25 cases and review. Clin Infect Dis 1993; 17:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/91\">",
"      Kelkar R, Gordon SM, Giri N, et al. Epidemic iatrogenic Acinetobacter spp. meningitis following administration of intrathecal methotrexate. J Hosp Infect 1989; 14:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/92\">",
"      Wroblewska MM, Dijkshoorn L, Marchel H, et al. Outbreak of nosocomial meningitis caused by Acinetobacter baumannii in neurosurgical patients. J Hosp Infect 2004; 57:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/93\">",
"      Ng J, Gosbell IB, Kelly JA, et al. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J Antimicrob Chemother 2006; 58:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/94\">",
"      Chang WN, Lu CH, Huang CR, Chuang YC. Community-acquired Acinetobacter meningitis in adults. Infection 2000; 28:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/95\">",
"      Gusten WM, Hansen EA, Cunha BA. Acinetobacter baumannii pseudomeningitis. Heart Lung 2002; 31:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/96\">",
"      Nguyen MH, Harris SP, Muder RR, Pasculle AW. Antibiotic-resistant Acinetobacter meningitis in neurosurgical patients. Neurosurgery 1994; 35:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/97\">",
"      Chang WN, Chuang YC, Lu CH. Acinetobacter meningitis: four nosocomial cases. J Formos Med Assoc 1999; 98:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/98\">",
"      Kendirli T, Ayd&iacute;n HI, Hac&iacute;hamdiolu D, et al. Meningitis with multidrug-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. J Hosp Infect 2004; 56:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/99\">",
"      Jim&eacute;nez-Mej&iacute;as ME, Pichardo-Guerrero C, M&aacute;rquez-Rivas FJ, et al. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 2002; 21:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/100\">",
"      Al Shirawi N, Memish ZA, Cherfan A, Al Shimemeri A. Post-neurosurgical meningitis due to multidrug-resistant Acinetobacter baumanii treated with intrathecal colistin: case report and review of the literature. J Chemother 2006; 18:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/101\">",
"      Benifla M, Zucker G, Cohen A, Alkan M. Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E. J Antimicrob Chemother 2004; 54:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/102\">",
"      Katragkou A, Roilides E. Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin. J Clin Microbiol 2005; 43:4916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/103\">",
"      Fernandez-Viladrich P, Corbella X, Corral L, et al. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin Infect Dis 1999; 28:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/104\">",
"      Davis KA, Moran KA, McAllister CK, Gray PJ. Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis 2005; 11:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/105\">",
"      Glew RH, Moellering RC Jr, Kunz LJ. Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies. Medicine (Baltimore) 1977; 56:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/106\">",
"      Chiang WC, Su CP, Hsu CY, et al. Community-acquired bacteremic cellulitis caused by Acinetobacter baumannii. J Formos Med Assoc 2003; 102:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/107\">",
"      Bachmeyer C, Landgraf N, Cordier F, et al. Acinetobacter baumanii folliculitis in a patient with AIDS. Clin Exp Dermatol 2005; 30:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/108\">",
"      Song JY, Kee SY, Hwang IS, et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 60:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/109\">",
"      Turnidge J, Bell J, Biedenbach DJ, Jones RN. Pathogen occurrence and antimicrobial resistance trends among urinary tract infection isolates in the Asia-Western Pacific Region: report from the SENTRY Antimicrobial Surveillance Program, 1998-1999. Int J Antimicrob Agents 2002; 20:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/110\">",
"      Hoffmann S, Mabeck CE, Vejlsgaard R. Bacteriuria caused by Acinetobacter calcoaceticus biovars in a normal population and in general practice. J Clin Microbiol 1982; 16:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/111\">",
"      Lau SM, Peng MY, Chang FY. Resistance rates to commonly used antimicrobials among pathogens of both bacteremic and non-bacteremic community-acquired urinary tract infection. J Microbiol Immunol Infect 2004; 37:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/112\">",
"      Corrigan KM, Harmis NY, Willcox MD. Association of acinetobacter species with contact lens-induced adverse responses. Cornea 2001; 20:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/113\">",
"      Wang AG, Wu CC, Liu JH. Bacterial corneal ulcer: a multivariate study. Ophthalmologica 1998; 212:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/114\">",
"      Gopal L, Ramaswamy AA, Madhavan HN, et al. Postoperative endophthalmitis caused by sequestered Acinetobacter calcoaceticus. Am J Ophthalmol 2000; 129:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/115\">",
"      Mahajan VM. Postoperative ocular infections: an analysis of laboratory data on 750 cases. Ann Ophthalmol 1984; 16:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/116\">",
"      Mark DB, Gaynon MW. Trauma-induced endophthalmitis caused by Acinetobacter anitratus. Br J Ophthalmol 1983; 67:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/117\">",
"      Miller J. Acinetobacter as a causative agent in preseptal cellulitis. Optometry 2005; 76:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/118\">",
"      Mathews D, Mathews JP, Kwartz J, Inkster C. Preseptal cellulitis caused by Acinetobacter lwoffi. Indian J Ophthalmol 2005; 53:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/119\">",
"      Bert F, Lambert-Zechovsky N. Sinusitis in mechanically ventilated patients and its role in the pathogenesis of nosocomial pneumonia. Eur J Clin Microbiol Infect Dis 1996; 15:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/120\">",
"      Pneumatikos I, Konstantonis D, Tsagaris I, et al. Prevention of nosocomial maxillary sinusitis in the ICU: the effects of topically applied alpha-adrenergic agonists and corticosteroids. Intensive Care Med 2006; 32:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/121\">",
"      Dandecha P, Sangthawan P. Peritonitis in acute peritoneal dialysis in a university hospital. J Med Assoc Thai 2002; 85:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/122\">",
"      Galvao C, Swartz R, Rocher L, et al. Acinetobacter peritonitis during chronic peritoneal dialysis. Am J Kidney Dis 1989; 14:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/123\">",
"      Valdez JM, Asperilla MO, Smego RA Jr. Acinetobacter peritonitis in patients receiving continuous ambulatory peritoneal dialysis. South Med J 1991; 84:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/124\">",
"      Hartstein AI, Rashad AL, Liebler JM, et al. Multiple intensive care unit outbreak of Acinetobacter calcoaceticus subspecies anitratus respiratory infection and colonization associated with contaminated, reusable ventilator circuits and resuscitation bags. Am J Med 1988; 85:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/125\">",
"      Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol 2003; 24:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/126\">",
"      Otter JA, Yezli S, Schouten MA, et al. Hydrogen peroxide vapor decontamination of an intensive care unit to remove environmental reservoirs of multidrug-resistant gram-negative rods during an outbreak. Am J Infect Control 2010; 38:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/54/23402/abstract/127\">",
"      Urban C, Segal-Maurer S, Rahal JJ. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 2003; 36:1268.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3150 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-C1C910ED83-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_54_23402=[""].join("\n");
var outline_f22_54_23402=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1214596\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1210354\">",
"      PRINCIPLES OF ANTIBIOTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Antimicrobial resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Overview of antibiotic selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1211118\">",
"      CLINICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1211125\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1211132\">",
"      - Nosocomial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13413526\">",
"      Options for resistant organisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1211139\">",
"      - Community-acquired pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1211146\">",
"      Bloodstream infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1211153\">",
"      - Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1211160\">",
"      Meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1211167\">",
"      Skin, soft tissue, and bone infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1211174\">",
"      Urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1211181\">",
"      Other infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREVENTION AND CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1214596\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3150\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3150|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/31/38396\" title=\"table 1\">",
"      Systemic antibiotics for Acinetobacter infections in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=related_link\">",
"      Antibiotic studies for the treatment of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=related_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=related_link\">",
"      Antimicrobial therapy of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=related_link\">",
"      Bacterial endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=related_link\">",
"      Clinical presentation and diagnosis of ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23031?source=related_link\">",
"      Colistin: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25930?source=related_link\">",
"      Diagnosis and treatment of gram-negative bacillary meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14103?source=related_link\">",
"      Epidemiology, microbiology and pathogenesis of Acinetobacter infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=related_link\">",
"      Microbiology and therapy of peritonitis in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=related_link\">",
"      Orbital cellulitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17495?source=related_link\">",
"      Overview of antibacterial susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=related_link\">",
"      Surgery for native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3591?source=related_link\">",
"      Surgery for prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=related_link\">",
"      Treatment of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=related_link\">",
"      Urinary tract infection associated with urethral catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_54_23403="Colic management";
var content_f22_54_23403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Overview of the management of colic",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Ask about symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acknowledge the importance of the problem",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Try to see the family during the baby's crying time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Listen to the crying",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Try to calm the baby",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Examine the baby",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gently dismantle the pain hypothesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discuss the effects of stress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Affirm the baby's good health and great promise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tell parents there is light at the end of the tunnel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Offer tips on soothing the baby (See table \"Suggested colic strategies\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Individualize your advice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absolve guilt",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recommend time-out",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discuss individual differences",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Be there when the parents need you",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_54_23403=[""].join("\n");
var outline_f22_54_23403=null;
var title_f22_54_23404="Disadv prostate ca treat";
var content_f22_54_23404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F77851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F77851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The disadvantages of the main treatment options for early prostate cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       External beam radiation therapy (EBRT)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Significant risk of impotence (difficulty having an erection)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Best outcomes require special type of EBRT, called 3-D conformal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Low risk of rectal symptoms after treatment completed (eg, needing to rush to the bathroom frequently to have a bowel movement)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Not possible to know for sure if cancer has spread to the lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Up to half of patients have some temporary bladder or bowel symptoms during treatment (eg, needing to rush to the bathroom frequently, rectal bleeding/pain)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Brachytherapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Significant risk of impotence (difficulty having an erection)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Success of treatment to control cancer depends somewhat on physician's careful placement of radiation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Low risk of later rectal symptoms (eg, needing to rush to the bathroom frequently to have a bowel movement)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Not possible to know for sure if cancer has spread to the lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Treatment not appropriate if tumor has spread outside the covering of the prostate (called the prostate capsule)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Up to half of men have some temporary bladder or bowel symptoms with treatment (leaking urine, rushing to the bathroom frequently)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Radical prostatectomy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Significant risk of impotence (difficulty having an erection)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       There is a risk of complications related to surgery (pain, bleeding, infection, injury of nearby organs)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The risk of complications depends on the skill and experience of the surgeon, to some extent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Low risk of incontinence (leaking urine) after recovering from surgery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Active surveillance (\"watch and wait\")",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tumor may grow or spread, making it impossible to cure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Treatment when cancer is larger or more advanced may have more side effects than if treatment is done sooner",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Living with untreated cancer may cause you to worry",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Vogelzang NJ, Scardino PT, Shipley WU, et al. Comprehensive textbook of genitourinary oncology, 3rd Edition. Lippincott Williams &amp; Wilkins 2005. Copyright &copy;2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_54_23404=[""].join("\n");
var outline_f22_54_23404=null;
var title_f22_54_23405="Rapid overview adrenal crisis in children and adolescents";
var content_f22_54_23405=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rapid overview: Adrenal crisis in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Signs and symptoms that may indicate adrenal crisis:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Hypotension or shock, particularly if disproportionate to apparent underlying illness.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull; Serum electrolyte abnormalities:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Hyponatremia with or without hyperkalemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Metabolic acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Vomiting and diarrhea, sometimes with severe abdominal pain or unexplained fever, weight loss and anorexia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Consider the diagnosis in:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;",
"        <em>",
"         Any patient with known disorders of adrenal insufficiency",
"        </em>",
"        (eg, congenital adrenal hyperplasia), especially if exposed to stress (illness).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Other patients presenting with the above signs, especially with",
"        <em>",
"         hyperpigmentation or vitiligo",
"        </em>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;",
"        <em>",
"         Critically ill patients with septic shock",
"        </em>",
"        , who are unresponsive to fluid resuscitation and inotropic medications (in this case, adrenal crisis can be caused by bilateral adrenal hemorrhage).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Patients on or withdrawing from",
"        <em>",
"         chronic treatment with corticosteroids",
"        </em>",
"        , especially if exposed to stress.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Patients with",
"        <em>",
"         other autoimmune endocrine deficiencies",
"        </em>",
"        , such as type 1 diabetes mellitus, hypothyroidism, or gonadal failure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;",
"        <em>",
"         Neonates with the above symptoms and signs",
"        </em>",
"        should prompt consideration of the diagnosis of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, or (very rarely) other causes of adrenal insufficiency.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - In the United States, 21-hydroxylase deficiency is part of the newborn screen in all states, so most affected infants will be diagnosed prior to presentation with adrenal crisis. Adrenal crisis usually presents between the first and fourth week of life. Affected females will have ambiguous genitalia; males usually have no obvious genital abnormalities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - The presentation of adrenal crisis in an infant may mimic that of pyloric stenosis. However, infants with pyloric stenosis typically have hypokalemic alkalosis rather than the hyperkalemic acidosis that is typical of adrenal crisis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Evaluation:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; If adrenal crisis is suspected, then patients should be treated empirically with stress doses of corticosteroids, as outlined below.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Baseline blood samples should be drawn for subsequent testing for electrolytes, glucose, cortisol and other adrenal steroids, ACTH, and renin, prior to the administration of corticosteroids. Treatment should not be delayed pending results.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;",
"        <em>",
"         Fluids:",
"        </em>",
"        give bolus of 5 percent Dextrose with 0.9 percent saline, without potassium (D5NS), 20 mg/kg over one hour.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;",
"        <em>",
"         Stress corticosteroids:",
"        </em>",
"        administer hydrocortisone succinate (SoluCortef) as a bolus at the following doses:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Infants and toddlers, 0 to 3 years old: 25 mg IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Children 3 to 12 years: 50 mg IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Children and adolescents 12 years and older: 100 mg IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Continue corticosteroids at the same dose given as a constant rate or as four divided doses over the following 24 hours.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;",
"        <em>",
"         Electrolytes:",
"        </em>",
"        if hyperkalemia is present, perform EKG to evaluate:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - EKG changes consistent with hyperkalemia: initially a tall peaked T wave with shortened QT interval, followed by progressive lengthening of the PR interval and QRS duration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - If these changes are present, treat with insulin and glucose infusion, with or without other measures to treat hyperkalemia (See \"Clinical manifestations and treatment of hyperkalemia\").",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Monitor and treat other electrolyte abnormalities and fluid balance.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_54_23405=[""].join("\n");
var outline_f22_54_23405=null;
var title_f22_54_23406="Glossary LBP terms";
var content_f22_54_23406=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Glossary of lower back pain terms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Acupuncture",
"       </td>",
"       <td>",
"        An intervention consisting of the insertion of needles at specific acupuncture points.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Artificial disc replacement",
"       </td>",
"       <td>",
"        Replacement of a degenerated vertebral disc with an artificial (prosthetic) disc.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Back school",
"       </td>",
"       <td>",
"        An intervention consisting of an education and a skills program, including exercise therapy, in which all lessons are given to groups of patients and supervised by a paramedical therapist or medical specialist.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Biofeedback",
"       </td>",
"       <td>",
"        The use of auditory and visual signals reflecting muscle tension or activity in order to inhibit or reduce the muscle activity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Brief educational interventions",
"       </td>",
"       <td>",
"        Individualized assessment and education about low back pain problems without supervised exercise therapy or other specific interventions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Chemonucleolysis",
"       </td>",
"       <td>",
"        Treatment of herniated discs with intradiscal injections of an enzyme extracted from papaya (chymopapain). Chymopapain acts by digesting the jelly-like inner portion of the disc known as the nucleus pulposus, while at the same time, leaving the outer portion, the annulus fibrosis, essentially intact. Collagenase (which may be less likely to induce an allergic reaction) has also been used.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Cognitive behavioral therapy",
"       </td>",
"       <td>",
"        An intervention that involves working with cognitions to change emotions, thoughts, and behaviors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Discectomy",
"       </td>",
"       <td>",
"        Removal of all or parts of an intervertebral disc in order to relieve pressure on adjacent nerve roots.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Epidural steroid injection",
"       </td>",
"       <td>",
"        An intervention that involves the administration of steroids in the space between the dura and the spine via a catheter. Epidural injections can be performed by the translaminar approach (via the interlaminar space in the spine), the transforaminal approach (through the neuroforamen ventral to the nerve root), or the caudal approach (through the sacral hiatus at the sacral canal).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Exercise therapy",
"       </td>",
"       <td>",
"        A supervised exercise program or formal home exercise regimen, ranging from programs aimed at general physical fitness or aerobic exercise to programs aimed at muscle strengthening, flexibility, stretching, or different combinations of these elements.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Facet joint injection",
"       </td>",
"       <td>",
"        Injection of a glucocorticoid into the facet joints in order to reduce inflammation and/or swelling.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Functional restoration (also referred to as work hardening or work conditioning)",
"       </td>",
"       <td>",
"        An intervention that involves simulated or actual work tests in a supervised environment in order to enhance job performance skills and improve strength, endurance, flexibility, and cardiovascular fitness in injured workers.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Fusion surgery",
"       </td>",
"       <td>",
"        A surgical procedure that unites (fuses) two or more vertebra together. The goal behind fusion surgery is to restrict spinal motion in order to relieve symptoms. A variety of spinal fusion techniques are practiced. All involve the placement of a bone graft between the vertebrae. In addition, fusion can be performed with or without the use of supplemental hardware (instrumentation) such as plates, screws, or cages that serve as an internal splint while the bone graft heals.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Interdisciplinary therapy (also referred to as multidisciplinary therapy)",
"       </td>",
"       <td>",
"        An intervention that combines and coordinates physical, vocational, and behavioral components and is provided by multiple health care professionals with different clinical backgrounds. The intensity and content of interdisciplinary therapy varies widely.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Interferential therapy",
"       </td>",
"       <td>",
"        The superficial application of a medium frequency alternating current modulated to produce low frequencies up to 150 Hz.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Intradiscal glucocorticoid injection",
"       </td>",
"       <td>",
"        Injection of a glucocorticoid directly into a lumbar disc in order to reduce swelling and inflammation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Intradiscal electrothermal therapy (IDET)",
"       </td>",
"       <td>",
"        An intervention involving the placement of an electrode into the intervertebral disc in patients with presumed discogenic back pain. The catheter is slowly heated and kept at a predetermined temperature for a predetermined time in order to coagulate and shrink adjacent tissues.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Laminectomy",
"       </td>",
"       <td>",
"        Removal of the vertebral lamina in order to relieve pressure on the spinal cord or nerve roots.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Local injections",
"       </td>",
"       <td>",
"        Injections into the soft tissues surrounding the back with a local anesthetic, sometimes with a glucocorticoid. A variety of target sites have been proposed, including tender points and various anatomic sites.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Low-level laser therapy",
"       </td>",
"       <td>",
"        The superficial application of lasers at wavelengths between 632 and 904 nm. Optimal treatment parameters (wavelength, dosage, dose-intensity) are uncertain.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Massage",
"       </td>",
"       <td>",
"        Soft tissue manipulation using the hands or a mechanical device through a variety of specific methods.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Medial branch block",
"       </td>",
"       <td>",
"        Injection of a local anesthetic (with or without a glucocorticoid) into the area of the nerve innervating the facet joint. Medial branch blocks may be used diagnostically (to determine whether the facet joint is the source of back pain) or therapeutically.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Percutaneous electrical nerve stimulation (PENS)",
"       </td>",
"       <td>",
"        An intervention involving the insertion of acupuncture-like needles and applying low-level electrical stimulation. It differs from electroacupuncture in that the insertion points target dermatomal levels for local pathology, rather than acupuncture points.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Percutaneous intradiscal radiofrequency thermocoagulation (PIRFT)",
"       </td>",
"       <td>",
"        An intervention similar to IDET, this intervention involves insertion of an electrode or catheter into the intervertebral disc. Unlike IDET, the electrode or catheter itself does not become hot. Instead, heat is generated in surrounding tissues by an alternating radiofrequency current.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Progressive relaxation",
"       </td>",
"       <td>",
"        A technique that involves the deliberate tensing and relaxation of muscles, in order to facilitate the recognition and release of muscle tension.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Provocative discography",
"       </td>",
"       <td>",
"        A procedure involving injection of radiographic contrast material into the nucleus of an intervertebral disc, which may elicit pain. It is most commonly performed in patients with chronic low back pain in order to help identify those who are more likely to benefit from interventional procedures intended to treat 'discogenic' back pain.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Radiofrequency denervation",
"       </td>",
"       <td>",
"        Destruction of nerves using heat generated by a radiofrequency current. It involves the placement of a catheter or electrode near or in the target nerve. Once the position of the catheter is confirmed by fluoroscopy, a radiofrequency current is applied in order to heat and coagulate adjacent tissues, including the target nerve.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Sacroiliac joint injection",
"       </td>",
"       <td>",
"        Injection of glucocorticoid into the area near the sacroiliac joint, in order to reduce inflammation and/or swelling.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Shortwave diathermy",
"       </td>",
"       <td>",
"        Therapeutic elevation of the temperature of deep tissues by application of shortwave electromagnetic radiation with a frequency range from 10 to 100 MHz.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Spinal manipulation",
"       </td>",
"       <td>",
"        Manual therapy in which loads are applied to the spine using short or long lever methods. High velocity thrusts are applied to a spinal joint beyond its restricted range of movement. Spinal mobilization, or low-velocity, passive movements within or at the limit of joint range, is often used in conjunction with spinal manipulation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Transcutaneous electrical nerve stimulation (TENS)",
"       </td>",
"       <td>",
"        Use of a small battery-operated device to provide continuous electrical impulses via surface electrodes, with the goal of providing symptomatic relief by modifying pain perception.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Yoga",
"       </td>",
"       <td>",
"        An intervention distinguished from traditional exercise therapy by the utilization of specific body positions, breathing techniques, and emphasis on mental focus. Many styles of yoga are practiced, each emphasizing different postures and techniques.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_54_23406=[""].join("\n");
var outline_f22_54_23406=null;
var title_f22_54_23407="Rounded atelectasis RLL CT";
var content_f22_54_23407=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rounded atelectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rounded atelectasis in the right lower lobe. The lesion has a curvilinear connection to the right hilus, a so-called comet tail. Adjacent pleural thickening is present, which is characteristic of rounded atelectasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_54_23407=[""].join("\n");
var outline_f22_54_23407=null;
